S1-01: Radioiodine Therapy of Hyperthyroidism

**Seyed Rasoul Zakavi**

Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

Hyperthyroidism is a form of thyrotoxicosis due to inappropriately high synthesis and secretion of thyroid hormones by the thyroid. Prevalence of hyperthyroidism is about 1% of general population in different parts of the world and the most common causes include Grave\'s disease, multinodular goiter or toxic adenoma. Radio-iodine therapy (RIT) with I-131 is the preferred method of treatment in toxic nodular goiter (single or multinodular) all around the world. It is also considered as effective and acceptable method of treatment in patients with Grave\'s disease. Treatment of Grave\'s disease may vary in different parts of the world. While RIT is used more commonly as first treatment modality in USA, surgery or antithyroid drugs (ATD) are chosen as the first treatment in other countries. Anyhow recurrence is very common after ATD therapy and RIT is usually considered for treatment of these patients in the course of therapy. Radio.iodine therapy is contraindicated in pregnancy, lactation and when there is high suspicion of thyroid cancer. Presence of Grave\'s ophthalmopathy and inability to comply with radiation safety recommendations are other factors that are considered in choosing optimal treatment method. In patients with highly elevated T4 and T3 levels, older age and severe symptoms of hyperthyroidism, pretreated with beta-blockers and antithyroid drugs are usually performed before radio-iodine therapy. While Beta-blockers have no effect on success of RIT and may be continued safely, discontinuation of ATD is necessary before RIT. In a recent clinical trial, we showed that 24-48 h of methimazole (MMI) discontinuation before RIT is as effective as longer term discontinuation. Although RIT has been used for more than 50 years, there is no consensus on the optimal dose of radio-iodine for treatment of hyperthyroidism. It is recommended that sufficient radiation should be administered in a single dose. Generally two approaches have been used for this purpose. One approach uses a fixed dose of I-131 for treatment of all patients. The other approach tries to calculate the delivered dose to the thyroid. Accurate determination of thyroid radiation dose requires measurement of effective half life of I-131 which is impractical as a routine clinical test. However postulating an average effective half life of I-131, an acceptable estimate of radiation dose to thyroid is achievable by measurement of thyroid weight and RAIU. Each of fixed or calculated methods of RIT may be further categorized to low or high dose subgroups. In a recent meta-analysis on toxic nodular goiter, we showed that calculated dose may be preferable to fixed dose method and could treat patients with lesser amount of I-131. Radiation safety precautions also should be fully explained to the patient to prevent unnecessary radiation of family and friends as well as to prevent radioactive contamination. It is equally important to prevent irrational fear of radiation.

Multiple aspects of radio-iodine therapy of hyperthyroidism will be discussed in this presentation.
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S1-02: Magnesium Deficiency in Benign Thyroid Disorders

**Roy Moncayo, Viktoria Plaschke, Martina Leitner, Stephanie Pfab, Lorenza Scarpa**

Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria

In a series of observational studies we have looked at the persistence of symptoms in patients that were receiving pharmacologically adequate treatment for thyroid disease. The most common symptoms were fatigue and exhaustibility followed by muscle cramps, muscle aches, irregular heartbeat, nervousness, perspiration, irritability, depressive mood, poor concentration, and poor memory. Due to the lack of correlation to thyroid treatment these clinical entities could be misinterpreted as being psychosomatic. We have found a common denominator behind the "so-called" thyroid disease complex of symptoms, namely magnesium deficiency. Magnesium deficiency was related to psychological stressors, physical stressors due to alterations in the musculoskeletal system, to infection, to the post.partum period and to early pregnancy after IVF. The definition of low magnesium levels was based on the serum values found in control subjects who did not present any of these events or symptoms. The mean normal magnesium levels were 0.95 ± 0.08 mmol. A visible ultrasound sign of magnesium deficiency is that of increased thyroid perfusion. This alteration can disappear after magnesium supplementation using organic magnesium salts. We prescribe pure magnesium citrate 1.4 mmol 3--4 times/day. In some cases where thickened vessels are seen, coenzyme Q10 at a dose of 3 × 30mg/week can be given. Magnesium supplementation requires patient compliance since it can take up to 9--12 months to show full recovery of symptoms, including also cognitive changes. A longer period of time is needed to achieve reversal of the morphological changes of the thyroid as seen in ultrasound. Parallel to this, thyroid antibody titers can decrease and elevated thyrotropin levels can return to normal. We conclude that patients with suspected thyroid disease should also have a determination of serum magnesium levels. Levels lower than 0.9 mmol/require supplementation as outlined here. Taking care of the causes that lead to hypomagnesaemia such as musculoskeletal changes and psychological stress will eliminate the false diagnosis of psychosomatic disease and clearly improve the QOL of the patients. Life situations that negatively influence these stressors can produce changes of QOL without being directly related to thyroid function. Limiting treatment of hypothyroidism only to thyroid hormone administration is not enough.
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S1-03: Prevalence of Normal Thyrotropin Levels in European Patients with Thyroid Autonomy Detected by Thyroid Scintigraphy

**Giorgio Treglia, Pierpaolo Trimboli, Frederik Anton Verburg, Luca Giovanella**

Nuclear Medicine and Thyroid Center, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland

**Purpose:** International guidelines diverge significantly about the usefulness of thyroid scintigraphy (TS) in patients with nodular goiter. Particularly its role in detecting/excluding autonomously functioning thyroid nodules (AFTN) in patients with normal serum thyrotropin (TSH) is widely debated. Therefore we assessed the prevalence of normal TSH values among patients with AFTN detected by TS performed in our center. Furthermore we carried out a meta-analysis of the literature to evaluate the usefulness of TS in European patients with AFTN and normal TSH values.

**Materials and Methods:** We included patients with AFTN detected by TS and enrolled at our Center. Pooled prevalence of AFTN with normal TSH values was calculated. Furthermore a comprehensive literature search of European studies published from 2000 up to 2014 on AFTN detected by TS was performed and a meta-analysis on the prevalence of patients with AFTN and normal TSH values was carried out.

**Results**: 110 patients with AFTN enrolled at our center and 2662 European patients with AFTN described by six articles were selected for the meta-analysis. Prevalence of patients with AFTN and normal TSH was 35% in our Center. Pooled prevalence of AFTN detected by TS with normal TSH was 45% (95% confidence interval: 27--64%) on a per patient based analysis.

**Conclusion**: Serum TSH measurement is not an effective screening test to diagnose AFTN, at least in Europe, as a significant proportion of patients with AFTN detected by TS had a normal TSH value. TS remains the only technique that permits the diagnosis of thyroid autonomy which does not require invasive procedures.
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S1-04: Efficacy of Fixed High Dose (30 mCi) Iodine.131 Therapy for Solitary Toxic Thyroid Nodule

**Khalid Bashir Makhdomi**

Aga Khan University Hospital, Nairobi, Kenya

**Objective:** To determine the effectiveness of a fixed high dose (30 mCi) Iodine-131 therapy for treatment of solitary toxic thyroid nodules.

**Material and Methods:** Twenty seven consecutive patients, presenting with hyperthyroidism, whose 99mTcO4 thyroid scan revealed solitary toxic thyroid nodules, and who had undergone high dose (30 mCi) Iodine-131 therapy, with follow-up of a minimum 1 year, were recruited for this retrospective study. The therapies had been done at our institution from January 2008 to December 2012.

The Technetium Thyroid uptake pre-treatment was noted for all patients. The biochemical status, freeT4 and thyrotropin, at the end of 1-year was noted.

**Results:** The Technetium thyroid uptake ranged from 3.7% to 9.8%, with a mean of 5.9%. Twenty two (81.5%) of the patients were biochemically euthyroid at the end of 1-year. Three patients (11.1%) had documented hypothyroidism between 7 and 10 months after the therapy and were on thyroxine supplementation. Two patients (7.4%) had continued to stay biochemically hyperthyroid at the end of 1-year. Both were on anti.thyroid medications, and both eventually had surgeries.

**Conclusions:** Empirical, fixed high dose (30 mCi) Iodine-131 therapy for solitary toxic thyroid nodules produces very good cure rates with very modest incidence of hypothyrodism, and should hence be considered as an effective option for management.
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S1-05: Effectiveness of Excluding Thyroid Cancer in Patients Referred to Radioiodine Therapy for Benign Thyroid Diseases: A 9-Year Follow-up Cohort Study

**Maria H. Listewnik, Maria Chosia, Hanna Piwowarska-Bilska Krystyna Jasiakiewicz, Barbara Zaborek, Piotr Zorga, Bozena Birkenfeld**

Department of Nuclear Medicine, Pomeranian Medical University, Szczecin, Poland

**Introduction:** Radioiodine (RAI) treatment is one of the methods used to cure hyperthyroidism. Nuclear medicine physicians treating patients with radioiodine have to keep in mind that an overlooked malignant lesion may pose a risk of complications for the patient. The aim of the study was to create a framework for assessing the effectiveness of RAI treatment procedure in terms of avoiding a thyroid cancer occurrence in the follow-up examination.

**Methods:** The study consisted of two stages: the aim of the initial stage was to determine the best procedure of excluding thyroid cancer prior to radioiodine treatment for benign thyroid diseases, whereas the final stage was aimed at establishing the best follow-up method for patients who have undergone radioiodine treatment. The endpoint was defined as a diagnosis of thyroid cancer after radioiodine treatment for benign thyroid diseases. The initial group comprised 5213 subjects referred to ^131^I treatment for benign thyroid diseases in 2000--2008. To exclude thyroid malignancy, patients were qualified for fine needle aspiration biopsy (FNAB) on the basis of clinical examination, thyroid gland scintigraphy and ultrasonography. Altogether, 816 patients were qualified for FNAB at the nuclear medicine department prior to radioiodine treatment. The final group consisted of 4314 subjects who were treated with radioiodine for benign thyroid diseases in 2000--2008 and were followed up for 0--108 months (median 13 month) after RAI treatment.

**Results:** Thyroid malignancy or suspicion of a malignant lesion in the initial group was found in 16 (1. 96%) subjects (4--papillary cancer, 2--suspicion of papillary cancer, 5--follicular tumor, 2--suspicion of follicular tumor, 1--Hürthle cell tumour, 1--further histological investigation required, 1--insular thyroid cancer). Suspicious FNAB results were found in 12 out of 4314 subjects of the final group. In 3 cases FNAB revealed lymph node metastases due to other cancer (lung cancer); papillary thyroid cancer was confirmed in 2 (0,05%) patients after 39 and 57 months from RAI therapy respectively; benign thyroid lesions were found in 3 patients; the diagnosis was not confirmed in 4 patients with suspicion of malignant lesions.

**Conclusions:** (1) The diagnostic procedure presented above should be implemented to exclude thyroid malignancy before RAI treatment for benign thyroid diseases. (2) RAI treatment is a safe procedure and the risk of thyroid cancer is insignificant.
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S1-06: Management of Paediatric Thyroid Carcinoma

**Monica A. Rossleigh**

Department of Nuclear Medicine and PET, Prince of Wales and Sydney Children\'s Hospitals, Sydney, Australia

Ten percent of all thyroid cancer occurs in patients under 21 years of age but it accounts for less than 1% of all cancers under 10 years of age. The majority are well differentiated (WDTC)-papillary 90%; follicular 10%. Medullary cancer is uncommon in children but can occur and may be familial (MEN2). There is an increasing female incidence with age and this commences at menarche. The majority are I-131 avid and often highly TSH sensitive. Thyroid nodules in children are of concern as they have a higher rate of malignancy than in adults. The long term prognosis of WDTC in children is excellent with a long term survival of 97%. However, paediatric WDTC often presents at a more advanced stage than adults. Pulmonary metastases occur in 9--30% of children with WDTC. The disease can be persistent or recurrent. Progression free survival in children is 65--70% at 5 years. The main stay of treatment is total thyroidectomy ± central neck lymph node dissection, TSH suppression and I-131 therapy. The use of rhTSH (Thyrogen) in children appears safe. It avoids the often debilitating effects of hypothyroidism, which includes impaired school performance. The expected long lifespan of paediatric and adolescent patients creates a therapeutic challenge of achieving the maximum benefit of I-131 therapy to prevent disease related morbidity and achieve disease free survival versus avoiding the complications of therapy over decades.
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S1-07: Radioiodine Therapy of Juvenile Differentiated Thyroid Cancer

**Jasna Mihailovic**

Department of Nuclear Medicine, Oncology Institute of Vojvodina, Sremska Kamenica, Serbia

Juvenile differentiated thyroid carcinoma (DTC) is a rare neoplasm, accounting for 0.5--3% of all childhood malignancies. It appears in 2--10% in patients aged ≤20 years. Incidence in pre-pubertal period is 1--7% in adolescent period. In Serbia, according to the Serbian Cancer Registry 42 newly diagnosed DTC patients aged ≥19 years were reported during the period 1999--2010, with a 3.7:1 female-to-male ratio. Juvenile DTC has aggressive clinical appearance showing cervical nodal involvement in most of the cases, often associated with distant metastatic disease. Nevertheless, comparing with adults, the overall mortality rate in children is not increased. Guideline for juvenile DTC treatment has not been published yet. Thyroid cancer in children and adolescents is usually treated empirically. In some institutions, I-131 activity is adjusted by body weight (1.85--7.4 MBq/kg) or by age (1/3 of the adult activity is administered to a 5-year-old; 1/2 of the adult activity in a 10-year-old; and 5/6 of the adult activity in a 15-year-old) or surface area. The German procedure guidelines for radioiodine therapy in pediatric DTC patients suggest adjusted ablation activity according to the 24-h thyroid bed uptake body weight: \<5% uptake would receive 50 MBq/kg; 5--10% uptake would receive 25 MBq/kg; and 10--20% uptake would receive 15 MBq/kg. Radioiodine ablation which is established on different patient body characteristics (weight, surface area, thyroid bed radioiodine uptake) seems to be an adequate strategy to fixed dosing or to flexible dosing based on age. In children, some physicians use fixed activities 1.1--11.0 GBq, while others use 131I activities adjusted activity to body weight (37.0--92.5 MBq/kg). In patients with extensive lung metastases, one must consider possible high-absorbed dose in lungs and consequently recommend lower radioiodine activity. Dosimetry is another option which enables 131I treatment on a calculated patient-specific basis. The main advantage of dosimetric approach is that optimal doses are estimated to give the highest probability for efficient tumor eradication. In our institution, we analyzed the juvenile DTC and detected recurrent disease in 22% of patients with a median time to recurrence of 52 months. The probability of recurrence was 16.7% at 5 years, 22.3% at 10 years, and 33.3% at 15 and 23 years after the initial treatment. The significant prognostic factors of the recurrent disease, are the type of initial treatment (extent of primary surgery and administration radioiodine treatment), patient\'s age at diagnosis, and tumor multifocality. Lower risk for recurrence was detected in a group of patients who underwent TT and radioiodine ablation versus patients who received different kind of treatment.
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S1-08: Read the Small Letters of the Guidelines for Ablation Therapy and Apply Them to the Patients. Size Does not Always Matter

**Savvas Frangos**

Department of Nuclear Medicine, Bank of Cyprus Oncology Centre, Nicosia, Cyprus

There are many guidelines and recommendations suggesting ablation therapy in differentiated thyroid carcinoma (DTC). Most of them are concentrating on the size of the tumor. This presentation will be focused on the details of the guidelines and recommendations. We will find that at least one set of recommendations suggests the need of ablation to a large part of the patients with DTC smaller than 1 cm. We will examine the following guidelines and recommendations: EANM, NCCN and ATA. Moreover, the ETA and SNMMI recommendations will also be taken into consideration. The presentation will be supported by data on patient and treatment characteristics from a large cohort of patients treated on two tertiary referral centers within the European Union, more specifically Cyprus and Greece.
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Abstracts - Scientific Session 2: Thyroid Diseases II: S2-01 Oncological Therapy of Radioiodine Negative Thyroid Cancer

**Markus Raderer**

Department of Oncology, Medical University of Vienna, Vienna, Austria

Patients with metastatic thyroid cancer becoming refractory to radioiodine therapy are relatively rare, but present a special challenge to clinical oncologists.

Early attampts at using chemotherapy, mostly the anthracyclince doxorubicin, were rated as relatively toxic without inducing relevant remissions (response rates 0--37%), although retrospective analyses have shown that patients responding to chemotherapy had a better survival than non.responders. (11 years vs. 4 years). Recent attempts using chemotherapy in the setting of elevated TSH, however, have given promising preliminary results, with 6/14 patients having objective remission and a further 7 patients disease stabilisation, with the progression free survival being 17 months after therapy with epirubicin and doxorubicin. In addition, novel drug combinations using oxalipatin and gemcitabine have shown 57% objective responses with the survival at 2 years being 80% in patients with a priori severely reduced performance status.

The detection of various kinases being operative in thyroid cancer has led to therapeutic attempts using various thyrosine kinase inhibitors (TKIs), including a randomized study comparing sorafenib at a dose of 2 × 400 mg daily with placebo. All patients had to have documented progression according to RECIST.criteria within 14 months prior to inclusion in the trial along with measurable disease and documented refractoriness according to pre-defined criteria. Median progression free survival was significantly prolonged by the application of sorafenib (10.8 months vs. 5.8 months in the placebo arm), though objective remissions were exceedingly rare. In addition, the majority of patients required dose reductions or interruption of therapy, and diarrhea (68%) and hand-foot-syndrome (76%) were common. Taken together, sorafenib was able to prolong PFS in patients with documented progression, but was accompanied by relevant side effects. In view of this, it should be used only in patients requiring therapy due to symptomatic disease.
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S2-02: The Anti-Vascular Endothelial Growth Factor Receptor Agent Lenvatinib: A New Promising Molecule for Progressive Radioiodine-Refractory Differentiated Thyroid Cancer

**Christian Pirich**

University Hospital Salzburg, Salzburg, Austria

Cure can be achieved in the majority of patients with differentiated thyroid cancer. New therapeutic strategies involving multikinase inhibitors have been developed for the subset of patients with worse prognosis who mostly exhibit radioactive iodine (131I)-refractory locally advanced or metastatic differentiated thyroid cancer. Recently, recommendations have been published for the definition and the management of iodine refractory patients. Lenvatinib, an oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, fibroblast growth factor receptors 1 through 4, platelet.derived growth factor receptor- α, RET, and KIT, demonstrated efficacy in a recently published phase 3, placebo-controlled randomized clinical trial in patients with radioactive iodine (131I)-refractory locally advanced or metastatic differentiated thyroid cancer by prolonging progression-free survival (placebo group: 3.6 months, levatinib 18.3 months). Lenvatinib adds to the armamentarium of targeted therapies for patients with radioiodine (131I)-refractory locally advanced or metastatic differentiated thyroid cancer by showing superior clinical response rates in this patient group. Close patient monitoring and expertise are needed to handle the spectrum of adverse effects which are common to this type of drugs.
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S2-03: The Efficacy of Radioactive Iodine Therapy for Insular Thyroid Carcinomas

**Emerita Andres-Barrenechea, Emelyn Gail Caverte**

Department of Nuclear Medicine and PET, St. Luke\'s Medical Center, Quezon City, Philippines

**Objective:** Insular carcinoma of the thyroid (ITCA) is an uncommon pathologic entity and many of the tumors have been documented only in case reports in the literature. Thus the exact incidence remains unknown. Thus our main objective was to determine the efficacy of I-131 for insular thyroid carcinoma, as there are no guidelines because of the rarity of the disease.

**Materials and Methods:** In this age of theranostics, one must be certain that this type of TCA is I-131 sensitive. Thus for our patient who is a 54-year-old male, a pre-therapy total body scan was done showing multiple bone, lung and soft tissue metastases. He had no complaints except for the severe left shoulder pain.

The TSH was elevated at 12.79 uIU/ml and the serum thyroglobulin was markedly elevated at 1286 ng/ml. Because of the bone involvement including the parietal area, left gleno-humeral, joint, ribs, vertebra and pelvis as well as the lungs, 200 mCi of I-131 was given orally. Upon discharge thyroid hormone suppression was prescribed.

**Results:** After 3 months, a repeat TBS showed marked interval decrease of the lesions, roughly 70% including total ablation of thyroid remnants, skull lesions and mostly of the lung metastases. There was likewise marked lowering of the thyroglobulin level to 150 ng/ml.

**Discussion:** Insular thyroid cancer is a relatively new subtype of TCA and the criteria for diagnosis among pathologists are not uniform. Approximately the incidence is 3% of primary TCA. Concomitant well-differentiated TCA (WDTCA) was noted in ITCA and anaplastic Ca (ATCA), strengthening the postulate that WDTCA can dedifferentiate into either of these subtypes. In fact most of the history shows long.standing goiter. The patients with ITCA are usually younger than those with ATCA and survival is longer with ITCA. Hence in one study it was concluded that insular TCA has an intermediate position between WDTCA and ATCA with regard to both histologic features and biologic aggressiveness. The positive p53 overexpression is seen in anaplastic and show worse survival than those without as in insularTCA. Insular thyroid carcinoma (ITC), is the most studied group under the poorly differentiated thyroid carcinoma (PDTC), is a rare malignancy characterized with diffuse island like pattern (insulae). These tumors display differentiated epithelial function with aggressive behavior with high rates of regional and distant metastases particularly in the lungs and bones like seen in our patient. The follicular epithelial component of these neoplastic cells, arranged in an insular pattern, has the distinct potential to concentrate radioiodine. This allows postoperative radioiodine imaging and the potential for adjuvant radioiodine therapy. Although literatures regarding this rare disease have been scarce, most of the cases featured have patients undergo RAI and L-thyroxine treatment. The low incidence of this disease occurring makes it difficult for a standard guideline to be followed. Most authors agree that primary treatment should be total thyroidectomy with neck node dissection if needed. Evidence of the potential for PDTC to uptake I-131, considering RAI therapy in all postoperative patients who underwent a complete resection is prudent. About 80% to 85% of patients have demonstrated that these tumors displayed radioavidity. However, no studies have shown statistically that I-131 prolongs 5-year survival.

**Conclusion:** Although the efficacy of I-131 in ITC has not been clearly and thoroughly studied, our case showed that I-131 therapy is efficacious.
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S2-04: Somatostatin Receptor Therapy of Radioiodine-Negative Thyroid Cancer Patients - Project HORIZON-2020

**Margarida Rodrigues**

Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria

The treatment options for patients with ^131^I-negative thyroid cancer, that is, ^131^I-refractory differentiated thyroid cancer (DTC) and medullary thyroid cancer (MTC) are limited. Proof-of-principle for peptide receptor radionuclide therapy (PRRT) in ^131^I-negative thyroid cancer has been derived with several radiolabelled somatostatin (SST) receptor (R) binding peptide analogues, based on octreotide and lanreotide derivatives. The project HORIZON-2020 aims to establish the use of radiolabelled SST analogues in the diagnosis and therapy of ^131^I-negative thyroid cancer within an international expert group and to carry out preclinical research on the technological refinement of this therapeutic approach in ^131^I-negative DTC and MTC. A prospective, multicenter Phase II therapy study with open-label design in patients with metastatic ^131^I-negative, SSTR-positive thyroid cancer including differentiated and medullary subtypes will be performed. Specific objectives are to evaluate the diagnostic efficacy of SSTR.targeted diagnosis by ^68^Ga-DOTATOC PET/CT, identify by tumour dose estimation those patients who might benefit from PRRT with ^90^Y/^177^Lu-DOTATOC, assess the efficacy of PRRT with ^90^Y/^177^Lu-DOTATOC alone or in combination with other treatment modalities such as sorafenib in DTC patients or vandetanib in MTC patients, evaluate in ^131^I-negative and SSTR subtype 2 negative MTC patients new cholecystokinin-2-receptor (CCK2R) targeting peptide derivatives for diagnosis and treatment, assess the in vitro-in vivo relationship of SSTR subtype/ CCK2R expression on isolated thyroid cancer cells to stratify patients for alternative targeting treatment options based on peptides with improved binding, and assess the genetic pattern of ^131^I-negative thyroid cancer by large scale analyses. Based on obtained data, clinical guideline for ^131^I-negative thyroid cancer patients will be presented at various European academic societies.
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S2-05: Proteasome Inhibitor Therapy with Bortezomib of Dedifferentiated, Radioiodine Negative and Somatostatin Receptor Negative Thyroid Cancer

**Margarida Rodrigues, Daniel Putzer, Sabine Buxbaum, Wolfgang Eisterer, Irene Virgolini**

Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria

**Objective:** Despite a multimodal therapeutic approach, dedifferentiated thyroid cancer still accounts for a high number of thyroid cancer associated deaths. We evaluate the response of dedifferentiated thyroid cancer patients to bortezomib therapy.

**Materials and Methods:** Eight patients with progredient, metastasized, radioiodine negative and somatostatin receptor negative thyroid cancer were investigated. Patients received bortezomib with a standard dose of 1.3 mg/m^2^ body surface given intravenously on day 1, 4, 8 and 11, undergoing 3 therapeutic cycles, with 10 days between each cycle. ^18^F-FDG-PET and control of thyreoglobulin levels were performed before, 6 weeks after and 6 months after therapy. Quantitative evaluation of PET scans was performed by calculation of SUV of clearly defined tumor lesions.

**Results:** Treatment was tolerated well by all patients; adverse events included polyneuropathy (2 patients) and leukopenia (WHO grade I, 3 patients; grade II, 1 patient). Three patients showed decrease of thyreoglobulin levels and SUV in posttherapeutic follow-up investigations. Two patients showed a mixed response with decreasing SUV only 6 months after treatment and a slightly increasing thyreoglobulin level. However, clinical situation improved markedly after treatment. Three patients had progressive disease in the posttherapeutic follow-up.

**Conclusions:** The proteasome inhibitor bortezomib is a promising therapeutic approach for otherwise untreatable radioiodine negative thyroid cancer patients with rather low toxicity in comparison to other available targeted drugs. Clinical benefit was seen after therapy with bortezomib in 63% of our patients. These encouraging results provide rationale for further investigation on the usage of proteasome inhibitors for the development of a specific therapeutic regime in the treatment of dedifferentiated thyroid cancer.
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S2-06: Peptide Receptor Radionuclide Therapy of Metastatic, Progressive, Treatment-refractory Medullary Thyroid Cancer Using 177Lu and 90Y.labeled Octreotide Analogs

**Ameya D. Puranik, Harshad R. Kulkarni, Aviral Singh, Richard P. Baum**

Theranostics Center of Molecular Imaging (PET/CT) and Molecular Radiotherapy, Zentralklinik Bad Berka, Bad Berka, Germany

**Introduction:** Medullary thyroid carcinoma (MTC) represents about 3--16% of thyroid cancer. Distant metastases are present in 13% of patients at initial diagnosis and portend a poor prognosis with a 10-year survival rate of only 40%. Somatostatin receptors type 2 (SSTR2) are expressed with moderate (sometimes strong) intensity in most MTC, making it a promising therapeutic target, particularly in advanced cases where all treatment options are futile. Hence, this study was aimed at assessing the efficacy (response and survival) of PRRT in patients with treatment.refractory metastatic medullary thyroid cancer.

**Materials and Methods:** We retrospectively analyzed a consecutive cohort of 28 patients (14 males and 14 females, mean age 47.9 years, age range 26-72 years) with histopathologically proven recurrent medullary thyroid cancer with widespread distant metastases, who were referred for PRRT between 2004 and 2012 to our center. All patients had undergone primary surgery and were heavily pretreated for progressive metastases by external beam radiotherapy, chemotherapy or treatment with kinase inhibitors, respectively. SSTR expression was confirmed before PRRT by ^68^Ga-DOTATOC PET/ CT. Patients received up to 5 PRRT cycles using Y-90 or Lu-177 labeled DOTATATE or DOTATOC. The primary end point was treatment response assessed on follow up by ^68^Ga-DOTATOC PET/CT and ^18^F FDG PET/CT (and in addition morphological imaging modalities); survival statistics were a secondary end point. Comprehensive relevant clinical information was gathered from our extensive PRRT database (310 items per patient) and external medical records and during long-term follow-up at our center (until death).

**Results:** Based on molecular imaging - using EORTC criteria - 17/28 (60.7%) patients showed stable disease (SD), 5/28 (17.7%) showed a partial response (PR), while 6/28 (21.4%) of patients suffered from disease progression (PD). Thus 22/28 (79%) patients showed no progression which is a significant success considering the baseline disease status before PRRT. Median survival in patients with SD was 36 months and 72 months in patients with PR, respectively. Median survival for patients with PD was only 24 months. There were only minor hematological and no serious renal adverse effects.

**Conclusions:** PRRT is effective for the treatment of metastatic, progressive medullary thyroid cancer with proven SSTR expression (confirmed by ^68^Ga-DOTATOC PET/CT) - even after all other therapeutic options have been exhausted - as demonstrated by a marked survival benefit for patients responding to PRRT (SD or PR status which is achieved in 79%).
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S2-07: Risk of Disease Recurrence in Patients with Differentiated Thyroid Carcinoma with Postoperative Thyroglobulin \<1 ng/mL

**Sofia Vaz, Ines P. Carvalho, Rita Sousa, Margarida Vieira, Angelo Silva, Deolinda Madureira, Susana Esteves, Edward Limbert, Teresa C. Ferreira, Lucilia Salgado**

Department of Nuclear Medicine, Portuguese Institute of Oncology, Lisbon Center, Lisbon, Portugal

**Objective:** Recent publications address the issue of managing patients (pts) without Iodine-131 therapy (RAI) if they have postoperative thyroglobulin (Tg) \<1 ng/mL. The main objective of our study was to compare and identify factors that influence the occurrence of regional (N1) and distant (M1) metastases in pts with postoperative Tg \<1 ng/mL, managed with or without RAI, after thyroid surgery. Furthermore we aimed to determine the disease free survival (DFS) and overall survival (OS) of these pts.

**Materials and Methods:** We conducted a single.center cohort study with retrospective data collection in pts with differentiated thyroid cancer (DTC), that did the first therapy between 2000 and 2009. Inclusion criteria were pts older than 18 years, without other cancers, with postoperative Tg \<1 ng/mL (measured until 6 month after surgery), without positive anti.thyroglobulin antibodies and with follow-up \>2 years. Information about age, tumor size, histology, vascular invasion, TNM staging and follow-up was obtained from clinical records. It was considered N1 when there was histologically confirmation and M1 when there were imagiological abnormalities. Pts were also classified according to the recurrence risk of disease based on the American (ATA) and the European (ETA) Thyroid Association Guidelines from 2009 to 2006, respectively. For statistical analyses ANOVA, Fisher test and Kaplan--Meier method were used. From an overall group of 2356 pts, only 372 fulfilled the inclusion criteria and were considered for analysis. There were 308 (83%) female, with a median age of 48 years (19--89). The median Tg was 0.5 ng/mL (0.2--0.9) with TSH that ranged from 0 to 100 µIU/mL. RAI was given to 314 pts (84.4%). The median follow-up was 6.6 years (2--14,5).

**Results:** Disease recurrence was found in 15 pts (4%): 8 N1 and 7 M1 (6 of whom also had N1). Fourteen of these pts had performed RAI after thyroid surgery; 1 pt with N1 recurrence did not. Considering the N1 versus M1 recurrences, we found that it occurred a median of 2.9 (0.2--8.2) versus 6.1 (3.8--10.6) years after the first surgery, the mean number of administered RAI were 1.4 (1--2) versus 3.1 (1--6) treatments and the mean total administered activity was 6.6 GBq (4.2--9.3\] versus 13.6 GBq (4.8--33.3\], respectively. When comparing pts with M1, N1 or those without recurrence during follow-up, we verified the following distribution according to initial staging: mean age (years) -- 55, 45 and 48; mean tumor size (cm) -- 4.9, 2.6 and 2.4; aggressive histology (%) -- 42.9, 12.5 and 9.5; vascular invasion (%) -- 57.1, 25 and 18.8; T4 (%) -- 42.9, 37.5 and 25.5; N1 (%) -- 28.5, 50 and 17.4 and M1 (%) -- 14.3, 0 and 0.8. The factors significantly associated with recurrence (either N1 or M1) were tumor size (*P* \< 0.009) and N1 at staging (*P* = 0.038). Aggressive histology (*P* = 0.060) and vascular invasion (*P* = 0.088) showed a trend for association, but without statistical significance probably due to small number of recurrences. We did not find statistical relevance when testing the association of recurrence with age, T and M at staging.

Considering classification of the pts according to ETA guidelines, there was no recurrence in very low risk group, but there were 1.8% in low risk (2 N1 and 1 M1) and 7.5% in high risk group (6 N1 and 6 M1). Using ATA guidelines there were 1.6% recurrence in low (2 N1 and 1 M1), 6% in intermediate (3 N1 and 2 M1) and 6.8% in high risk (3 N1 and 4 M1). The 5-year DFS was 96% (95% IC: 94--98%) and 5-year OS was 99% (IC: 98--100%). Eight pts (2.2%) died 7.2 years (3.2--8.8) after the first surgery, 2 had M1, 1 of whom had disease related death.

**Conclusion:** In pts with Tg \<1 ng/mL the risk of recurrence of disease was very low (N1 --2.2% and M1-1.9%). In our study the factors with significant association with recurrence were tumor size and the existence of N1 at staging. In spite of the fact that the majority of recurrences occurred in pts submitted to RAI, the small number of recurrences does not allow any definite conclusion. The general 5 years DFS and OS was very good.
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S2-08: Recombinant Thyrotropin in the Management of Differentiated Thyroid Carcinoma: What Has Been Achieved and Where Do We Go From Here

**Partha S. Choudhury**

Rajiv Gandhi Cancer Institute and Research Centre Delhi, New Delhi, India

After total or near total thyroidectomy the role of first therapeutic dose of radioactive iodine is many folds. The most common amongst this is the destroying of the post-surgical remnant, identifying and subsequent treatment of previously unknown disease facilitating initial staging, acting as adjuvant therapy and treatment of metastatic disease, if known. The response to the treatment can be measured by choosing different clinical end points like a negative whole body I^131^ scan suggesting effective remnant ablation, lowered recurrence rates suggesting effective adjuvant treatment, response to metastatic disease or stable disease suggesting effective palliation. Risk stratification is an important parameter in deciding the radio-iodine treatment dose and the patient\'s follow-up schedule. This is generally achieved with the review of available parameters in the first few weeks post.surgery which includes detailed histopathological report, completeness of resection from the surgical notes, post-operative thyroglobulin and ultrasonography of the neck. These are the clinical variables used to quantify the risk of recurrence.

Although the standard risk stratification at the time of initial therapy never change, the effectiveness of the therapy changes the risk estimates: high risk patient with good response to radio-iodine and low risk patient with inadequate response can modify the risk assessment over time. Patient preparation for radio-iodine treatment is crucial for the effectiveness of therapy. There are actually no controlled studies as to what is an adequate TSH level for proper patient preparation. An arbitrary level of \>30 has been taken as a cut off value in uncontrolled studies. The TSH response can be achieved by either withdrawal of thyroxine for 4--5 weeks or the use of recombinant (r) TSH. In this presentation our approach to radio-iodine treatment of a patient of differentiated thyroid cancer, both ablation of residual tissue and treatment of metastatic disease, will be discussed and the role of r-TSH in facilitating early treatment post-surgery, its impact on the quality of life will be emphasized upon.
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S2-09: Radioiodine Ablation with Recombinant Thyrotropin in Differentiated Thyroid Cancer - SKM Experience

**Yasir Majeed, Saima Riaz, Humayun Bashir, Aamna Hassan, M. Khalid Nawaz**

Department of Nuclear Medicine, Shaukat Khanum Memorial Cancer Hospital and Research Center, Lahore, Pakistan

**Objective:** Retrospective review of differentiated thyroid carcinoma (DTC) patients treated with recombinant human thyrotropin (rhTSH) stimulated radioiodine therapy (RAI).

**Materials and Method:** Using hospital information system (HIS) a total of 43 patients were identified from July 2003 to December 2014. Demographic data and following information was retrieved: TSH at the time of RAI therapy, thyroid remnant size, therapeutic dose of RAI, outcome of ablation assessed by whole body scan acquired 6 to 12 months into follow-up.

**Results:** Our cohort of 43 patients included 30 (68.9%) females. Papillary thyroid carcinoma 36 (83.7%), Follicular thyroid carcinoma 7 (16.3%). The remnant size was assessed in three categories.

Category 1: Remnant size up to 2 cm. 17 (39.5%) patients with TSH in the range of 3.9--10.8, (4 were euthyroid, 13 insufficient hypothyroidism).

Category 2: Remnant size 2--3 cm. 14 (32.6%) patients with TSH in the range of 2.5--8.3. (4 in euthyroid stage, 10 insufficient hypothyroid stage).

Category 3: Remnant size \>3 cm. Four (9.3%) patients with TSH in the range of 2.4--3.3. (2 were euthyroid, 2 insufficiently hyperthyroid).

Five patients had an irresectable disease (11.6%) with TSH in the range of 1.05--21.3. (i.e. 3 in euthyroid stage, 2 insufficiently hypothyroid). In 3 patients remnant size was not available in records. In total, 16 patients were euthyroid at the time of ablations while 27 patients were insufficiently hypothyroid. Overall mean TSH was 6.4 (range 1.05--21.3). In 40/43 patients response to therapy was available. Thirty.four patients had complete ablation after one dose of radioactive iodine while 6 patients had to be given more than one dose of RAI. Two patients were treated with less than 100 mCi. Forty patients were treated with dose of 100--150 mCi while one patient was treated with the dose of \>150 mCi. All patients had sufficient thyroid tissue destruction with rhTSH simulated RAI as evidenced by an appropriate elevation in off thyroxine TSH levels checked within 12 months post therapy. This was also seen in nonsurgical candidates with intact thyroid. There was no statistically significant correlation between the size of the remnant or the successes of ablation. However, significant correlation was found between TSH and remnant size (*P* = 0.013).

**Conclusion:** Recombinant TSH assisted RAI therapy is an effective method of thyroid ablation irrespective of the remnant size.
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S2-10: 131I Single-Photon Emission Computed Tomography-Computed Tomography Scintigraphy in the Management of Patients with Differentiated Thyroid Carcinoma

**Sonya Sergieva**

Department of Nuclear Medicine, Sofia Cancer Center, Sofia, Bulgaria

Clinical application of 131I whole-body scintigraphy followed by target single-photon emission computed tomography-computed tomography (SPECT.CT) study and Tg assessment in differentiated thyroid carcinoma (DTC) has been published in a lot of papers as a "gold standard" for monitoring of patients after radioiodine therapy. This new hybrid modality provide perfect registration of functional (SPECT) and anatomical (CT) images. CT part of the study is used for attenuation correction of SPECT images for improvement of image quality and visualization of lesions \<10 mm. SPECT-CT diagnostic technique depicts precise topography and morphological characteristics at the site of abnormal tracer activity. Additional anatomical information from SPECT-CT improved the certainty and accuracy of ^131^I whole-body scans. Fusion images enable precise morphological characterization and right topography of unclear planar findings. One of the advantages of iodine SPECT-CT in the neck region is to differentiate equivocal foci as thyroid remnant, enlarged cervical lymph nodes or physiological uptake in the region of esophagus or salivary glands. SPECT-CT is a very useful modality in non-iodine avid disease due to lack or subsequent loss of ^131^I uptake possibility and increased Tg. This has been reported to occur more frequently in Hurthle cell thyroid cancer, in some papillary subtypes (tall cell) and poorly differentiated (insular) thyroid cancer or in DTC after several courses of performed ^131^I treatment. The possibility or negativity for disease as determined by posttherapeutic SPECT-CT correlated more closely to success or failure of radioiodine treatment or to abandon additional ^131^I application. Negative ^131^I SPECT-CT data significantly impacts clinical management in a lot of number of patients. Proposed changes in management include indications and the volume of lymph node dissection in cervical lymphadenopathy, to select patients for external been radiotherapy in non-operable cases for correct radiotherapy planning of the target volume in bone oseolytic lesions, mediastinal and cervical metastatic lymph nodes or to carry out chemotherapy.

Single-photon emission computed tomography.CT studies are very useful in follow-up of patients with clinical data for disease progression but with negative Tg because of positive TAT in order to continue ^131^I therapy. In conclusion SPECT-CT studies have been reported to change clinical management in significant number of patients with DTC. Proposed changes in the management include indication and the volume of surgery intervention, the need to give ot withhold ^131^I treatment in DTC patients, to select cases for external been radiotherapy or chemotherapy.

**Address for correspondence:**

Dr. Sonya Sergieva, Sofia Cancer Center, Sofia, Bulgaria. E-mail: <sonya.sergieva@yahoo.com>

Abstracts - Scientific Session 3: Radiopharmacy: S3-01 Radiopeptides Targeting G-Protein Coupled Receptors in Cancer: From Bench to Bed

**Helmut R. Maecke**

Department of Nuclear Medicine, University Hospital Freiburg, Freiburg, Germany

In the development of targeted imaging and therapy agents the most important challenge and prerequisite is to identify and validate the molecular targets of any disease. They should be specific, relevant, easily accessible and highly expressed. In addition they should have no or at least very low expression in normal tissue. Among the many drug targets is the large family of G.protein coupled receptors (GPCRs). It is the most important family of marketed drugs and the basic accomplishments. By researchers were recognized by the award of the recent Nobel price in chemistry. GPCRs also play a role in cancer. Several of these receptors are massively overexpressed in different human tumors such as neuroendocrine tumors (overexpresstion of the somatostatin receptor family), prostate and breast tumors (bombesin receptor family), brain tumors (NK1 receptor) etc. This allows to develop probes for imaging and potentially targeted therapy (theranostics). Natural ligands targeting GPCRs are often peptides. They need to be modified for metabolic stability, modified for labeling with radiometals (conjugation of bifunctional chelators) or radiohalogens (prosthetic groups). Preserved biological integrity after modification and labeling needs to be assured, long retention times in the tumor is important, e.g., conferred by internalisation. Radiometal labeling in particular needs to be reasonably fast and the radiometal complexes have to show high stability with regard to radiometal release. These prerequisites will be discussed for somatostatin receptor based radiopeptides in particular. For a succesfull clinical application preclinical imaging and biodistribution in adequate animal models are mandatory. New tracers for positron emission tomography (PET) and single photon emission computed tomography (SPECT) will be presented for neuroendocrine tumors and prostate cancer.

How (coordination) chemistry affects pharmacology will be an important focus of this lecture. Another important aspect will be to discuss the different properties of agonistic radioligands which cause signaling and internalisation (transfer of the receptor ligand complex into the cell) and antagonists which block the action of agonists and are not internalised but may recognise more receptor binding sites. Finally early and extented human use studies will be presented for the 2 tumor entities mentioned above. It will be demonstrated how improved peptide and chelate chemistry improves diagnostic accuracy and therapeutic outcome in tumor treatment.
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S3-02: Targeted Molecular Imaging and Therapy of Chemokine Receptor-4 Expression in Cancer Patients

**Hans-Juergen P. Wester, Ken Herrmann, Margret Schottelius, Katrin Philipp-Abbrederis, Theresa Osl, Andreas Poschenrieder, Andreas Buck, Horst Kessler, Richard B. Baum, Carlos Gerngross, Michael Lassmann, Herrmann Einsele, Stefan Knop, Markus Schwaiger, Ulrich Keller**

Technical University of Munich, Munich, Germany

The C-X-C chemokine receptor type 4 (CXCR4) is a GPcR that mediates recruitment of cells by interaction with its endogenous ligand CXCL12 (SDF-1ä). Engagement of CXCR4 triggers various intracellular signal transduction pathways, ultimately resulting in chemotaxis, proliferation, and cell survival. The CXCR4/CXCL12 axis is a major determinant for retaining and recruiting hematopoietic stem cells into the bone marrow niche. In cancer, high CXCR4 expression is often associated with tumor dissemination and poor prognosis. There is experimental evidence that cancer cells are recruited to putative protective niches, from where relapse is thought to occur. We recently developed evaluated in this study the novel CXCR4 ligand \[68Ga\] Pentixafor for mapping CXCR4 expression density in mice xenografted with human CXCR4 + SCLC, B-cell lymphoma and multiple myeloma (MM) cell lines, and in patients with advanced hematologic malignancies, including B- and T-cell non-Hodgkin lymphoma, MM, and various solid tumors by means of PET. \[68Ga\] Pentixafor-PET provided images with excellent specificity and contrast in several lymphoproliferative cancer entities and selected solid tumors. In a cohort of 14 patients with advanced MM, \[68Ga\] Pentixafor-PET/CT/MRI scans revealed MM manifestations in 10/14 patients, whereas only 9/14 standard \[18F\] fluorodeoxyglucose-PET/CT scans were rated visually positive. Assessment of blood counts and standard CD34 + flow cytometry did not reveal significant blood count changes associated with tracer application. \[68Ga\] Pentixafor-PET/CT showed also high-medium uptake in patients with SCLC, adrenal carcinoma, mammary cancer and CUPs. In addition to these imaging marker, a therapeutic probe capable for labeling with Lu/Y/Bi and other (radio) metal has been developed. First studies in patients with MM demonstrated high uptake and long retention of these probes over a period of 2 weeks with a metabolic response of 34--50% within two weeks after application of e.g., 15 GBq 177Lu-pentixather (optimized dose by individual dosimetry). Our findings identify the CXCR4 PET tracer pentixafor as a novel tool for *in vivo* imaging of hematologic neoplasms. In addition, pentixafor not only seems to be a biomarker suitable for identifying patients who could be treated with CXCR4-directed drugs, but also represents a valuable lead structure for targeted therapy by means of Pentixather and radionuclide therapy of the cancer cell and its protecting niche.
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S3-03: Preclinical Application of 47Sc-Folate - Pilot Study in Tumor-Bearing Mice

**Cristina Müller, Katharina Domnanich, Klaudia Siwowska, Ulli Köster, Andreas Türler, Roger Schibli, Nicholas van der Meulen**

Center for Radiopharmaceutical Sciences, Paul Scherrer Institute, Villigen-PSI, Switzerland

**Objective:** The aim of this study was to produce and investigate 47Sc (T1/2 = 3.35 d, Eβ-av = 162 keV, Eγ = 159 keV) for β-radionuclide therapy and for SPECT imaging using a novel DOTA-folate conjugate with improved tissue distribution properties.

**Materials and Methods:** 47Sc was produced via the 46Ca (n, γ) 47Ca 47Sc nuclear reaction from a 46 Catarget which was irradiated in a high.flux nuclear reactor at ILL. After shipment of the target material to PSI, 47Sc was separated from the Ca using chromatographic methods which were previously established at our laboratory. 47Sc was then used for radiolabeling of an albumin-binding folate conjugate and investigated *in vitro* using folate receptor (FR)-positive KB tumor cells. A pilot therapy study was conducted with mice bearing KB-tumor xenografts. Treatment of mice was carried out by injection of 47Sc-folate (10 MBq) whereas control mice received only saline. Additional tumor-bearing mice were used for SPECT-imaging studies.

**Results:** 47Sc was separated from Ca twice a week and used for radiolabeling, yielding 47Sc-folate of a high radiochemical purity (\>96%). 47Sc-folate showed FR-specific binding to KB tumor cells *in vitro* and was able to reduce cell viability to about 40% and 10% of controls, respectively, if the cells were exposed to high activities (10 MBq/mL and 20 MBq/mL, respectively). A significant tumor growth delay and, as a consequence, an increased median survival time (38.5 d) were observed in treated mice compared to untreated controls (25 d). The SPECT/CT scans confirmed high uptake of 47Sc-folate in KB-tumors and indicated excellent features of 47Sc for imaging purposes.

**Conclusions:** In these preclinical studies the excellent characteristics of 47Sc were demonstrated for therapeutic applications and the option of using it for SPECT. These findings, along with our previous results obtained with the PET radionuclide 44Sc, show great promise for the future application of the 44/47Sc matched pair concept in nuclear medicine.
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S3-04: Prostate-Specific Membrane Antigen Targeting Iron Oxide Nanoparticles for Positron Emission Tomography/ Magnetic Resonance Dual Modal Imaging

**Jae Min Jeong**

Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea

Development of nanoparticles with multi-modal imaging capability requires incorporation of various moieties such as PEG chains, bifunctional chelating agents, fluorescence dyes, and specific targeting ligand, which is a very complicate procesure. We have published a simple and convenient one pot method for preparation of multifuncitional nanoparticles (NP) by encapsulation with specific amphiphiles.\[1\] In the present study, we tried to develop iron oxide (IO) PET/MR dual-modality NP for targeting PSMA using the encapsulation method. Amphiphiles were synthesized by conjugating stearylamine with SCN-Bn-DOTA or Glu-Urea-Lys (GUL). These were suspended into 1 mL of 8% Tween 60 solution and the mixture was sonicated for 30 min. IO solution in 100 µL chloroform was added to the mixture and vortexed, heated (80°C) and sonicated. The solution was purified by Sephacryl S500 and concentrated using Amicon centrifuge filter. The particle size of resulting DOTA-IO-GUL NP was measured by DLS and TEM imaging. The size of NP DOTA-IO-GUL was 11.01 ± 1.541 nm by DLS and confirmed by TEM. The prepared NP was labeled with 68Ga in 1.0 M NaOAc buffer (pH = 5.6). Labeling efficiency of 68Ga-DOTA-IO-GUL was \>99%. T2 weighted MRI and PET images were obtained using PSMA positive tumor (22Rv1) xenografted mice. We confirmed that DOTA-IO-GUL was selectively taken up to PSMA positive tumor (22Rv1) at 1 hr post-injection of 68Ga-DOTA-IO-GUL through the tail vein. by MRI and PET.
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S3-05: Cyclic Minigastrin Radiolabelled with Lu-177: Preclinical Evaluation of a Kit Formulation for Clinical Use

**Christine Rangger, Dariusz Pawlak, Lajos Balogh, Zita Postenyi, Renata Mikolajczak, Elisabeth von Guggenberg**

Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria

**Aim:** Due to the non-availability of specific radiopharmaceuticals targeted diagnosis and therapy with radiolabelled minigastrin analogues specifically binding to the cholecystokinin-2-receptor (CCK2R) still show very limited clinical use in nuclear medicine. This particular target is highly overexpressed in different human cancers such as medullary thyroid cancer and small cell lung cancer. Within an international collaboration of the International Atomic Energy Agency (IAEA) different kit formulations for the radiolabelling with Lu-177 of two cyclic minigastrin analogues, namely cyclo \[γ-D-Glu-Ala-Tyr-D-Lys\]-Trp-Met-Asp-Phe-NH~2~ (cyclo-Met-MG) and cyclo \[γ-D-Glu- Ala-Tyr-D-Lys\]-Trp-Nle-Asp-Phe-NH~2~ (cyclo-Nle-MG), have been developed. The kit formulations have been evaluated preclinically including stability studies and cell uptake studies in cell lines expressing the human CCK2R.

**Materials and Methods:** The cyclic minigastrin analogues, DOTA-cyclo-Met-MG and DOTA-cyclo-Nle-MG were provided through the IAEA. In first wet labelling experiments the radiolabelling parameters for the labelling with Lu-177 were optimized. Reaction conditions were adapted to keep Met-oxidation as low as possible and quality control was performed by radio-HPLC and ITLC-SG. Optimized ready-to-use kit formulations were elaborated allowing radiolabelling by straightforward addition of the radiometal and incubation in a heating block with controlled temperature. The stability of the radiolabelled peptides prepared from kit formulations was studied up to 2 days after preparation (p.p.) and the receptor specific cell uptake was confirmed in A431 human epidermoid carcinoma cells stably transfected with the human CCK2R.\[1\]

**Results:** Radiolabelling with Lu-177 was evaluated using different buffers for pH adjustment. The one vial kit formulation selected for DOTA-peptides was composed of ascorbic acid, L.Met and gentisic acid and pH adjusted to pH 4--4.5. Peptide losses due to sterile filtration during kit preparation as determined by HPLC analysis before and after sterile filtration resulted to be below 5%. ^177^Lu-DOTA-cyclo-Nle-MG (50--100 GBq/µmol) was prepared from kit formulations with quantitative yield resulting in high RCP \>98% (incubation at 80°C for 25 min). The stability in solution resulted to be very good with RCP \>98% 4 h p.p. declining to \>96% at 1 and 2 days p.p. For ^177^Lu-DOTA-cyclo-Met-MG (\>50 GBq/µmol) the incubation time was reduced to 15 min to avoid Met-oxidation resulting in RCP \>93%, with \<1% free Lu-177 and \>5% Met-oxidized peptide. The stability in solution remained stable up 1 day p.p. (RCP \>91%), but due to increasing Met-oxidation dropped to 81% at 2 days p.p. Cell uptake studies in A431-CCK2R cells showed high retained receptor specific cell internalization. The percentage of the internalized activity from the total activity added resulted to be \>24% for ^177^Lu-DOTA-cyclo-Nle-MG. The Met-containing peptide ^177^Lu-DOTA-cyclo-Met-MG showed a somewhat lower uptake of \>21% which could be explained by a partial Met-oxidation during cell incubation (\~30%) - as determined by radio-HPLC analysis of the radioligand solution at the end of the experiment - leading to loss of receptor affinity.

**Conclusions:** The presented kit formulation allows the easy and straightforward preparation of ^177^Lu-labelled cyclic minigastrin analogues in the clinical setting. From the results obtained so far DOTA-cyclo-Nle-MG seem most promising for clinical use. The substitution of Met with Nle in the peptide sequence prevents Met-related oxidative processes during radiolabelling and metabolic processes in vivo. In this way a loss of receptor leading to impaired receptor targeting during diagnostic and therapeutic applications can be avoided. Biodistribution studies in xenografted nude mice as well as dosimetric/therapeutic studies in animals are currently in progress and will be also presented.
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S3-06: 18F-Labelled F3 Derivatives Targeting Cancer and Tumour Endothelial Cells

**Phoebe Y.H. Lam, Katherine A. Vallis**

University of Oxford, Oxford Institute for Radiation Oncology, Oxford, United Kingdom

**Objective:** The nucleolin receptor (NR) has been found to over.express on tumour cell membranes and angiogenic blood vessels.\[1\] The peptide F3 binds specifically to the NR, and tumour targeting F3 derivatives for diagnostic and therapeutic purposes have previously been reported, including 111In-DTPA-F3 (previous work in our group), with rapid renal clearance observed in vivo.\[2\] We aim to develop the first 18F-labelled F3 derivative with favourable pharmacokinetics for tumour PET imaging.

**Materials and Methods:** Site-specifically PEGylated F3 derivatives were radiolabelled with \[^18^F\] AlF~3~. Binding affinities and cellular distribution of the compounds were assessed on tumour (H2N) and tumour epithelial (2H-11) cells, and specific uptake via the NR was demonstrated by SiRNA knockdown of nucleolin on both cell lines. Immunohistochemistry was performed with anti-nucleolin antibody on frozen tumour sections. Partition coefficients and stability of the radiotracer were assessed before performing biodistribution studies on tumour bearing mice.

**Results:** Site-specific synthesis of NODA-PEG-F3 and NODA-PEG-cys-F3 were achieved in 4 steps each with \>60% overall yields. Fluorine-18 radiolabelling at 100°C in 20 min resulted in ^18^F-NODA-PEG-F3 and ^18^F-NODA-PEG- cys - F3 of \~85% RCY as a homogenous species. The binding affinities of ^18^F-NODA-PEG-F3 (Kd = 46-4 ± 2.7 nM) and ^18^F-NODA-PEG-cys-F3 (Kd = 49.2 ± 4.1 nM) were in the same range as F3 (Kd = 11.0 ± 3.5 nM) and 111In-DTPA-F3 (Kd = 27.0 ± 2.4 nM). SiRNA knockdown of nucleolin resulted in a binding affinity reduction of 50.60%, confirming cell surface binding via the NR. Both ^18^F-NODA-PEG-F3 (LogD = --3.10 ± 0.08) and ^18^F-NODA-PEG-cys-F3 (LogD = --3.11 ± 0.12) were found to be more lipophilic than 111In-DTPA-F3 (LogD = --3.48 ± 0.26), and are stable in plasma serum for up to 2 h. Immunohistochemistry confirmed the presence of cell surface NR in xenografted tumours, and biodistribution revealed enhanced *in vivo* accumulation of ^18^F-NODA-PEG-F3.

**Conclusions:** ^18^F-NODA-PEG-F3 and ^18^F-NODAPEG-cys-F3 are hereby reported as the first 18F-labelled F3 derivatives known to date. Both compounds were obtained in a site.specific, high yielding and efficient manner, and bind to surface NR in the low nanomolar range. Increased lipophilicity by PEGylation improved *in vivo* retention. ^18^F-NODA-PEG-F3 is currently undergoing further development as a PET tracer.
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S3-07: Validation of a Cassette Based Fully Automated Synthesis of 177Lu-PSMA617

**Clemens Decristoforo, Dominik Summer, Alexander Wurzer, Roland Haubner, Irene Virgolini, Elisabeth von Guggenberg**

Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria

**Introduction:** Prostate specific membrane antigen (PSMA) is an extracellular target overexpressed in prostate cancer. PET tracers based on Glu-NH-CO-NH-Lys as PSMA targeting sequence, in particular 68Ga-PSMA-HBED-CC has shown excellent imaging properties in prostate cancer patients with advantages over ^18^F-choline. Recently a DOTA-version of this PSMA inhibitor with an optimized linker moiety (PSMA617) has been and showed highly promising properties when labelled with Lu-177 for therapeutic application, in particular exhibiting high accumulation in prostate cancer lesions and low kidney retention. We here report on the validation of synthesis of ^177^Lu-DOTA-PSMA 617 on a fully automated cassette based system in a GMP compliant environment for clinical application.

**Materials and Methods:** Preliminary radiolabelling tests were performed and the procedure was adopted for an automated synthesis module based on single use casettes (PharmTracer, Eckert and Ziegler). Reaction was performed in an sodium ascorbate buffer pH 4.5, 20 min heating at 95°C and precursor amounts were varied from 40 to 100 MBq 177Lu/µg precursor with activities between 4 and 13 GBQ ^177^Lu- The reaction solution was purified using a C-18 reversed phase cartridge (SEPPAK) and sterile filtered. The product was analysed by Reversed Phase HPLC using an isocratic TFA/Acetonitrile/water gradient and TLC (ammonacetate/methanol, ITLC-SG). Additionally precursor amount half life, appearance, pH, ethanol content, sterility and endotoxins and stability were tested and master batches produced.

**Results:** Almost quantitative (\>90%) yields were achieved using ≤70 MBq ^177^Lu/µg precursor using the same cassettes as for somatostatin analogues, when using more ^177^Lu/µg precursor yields dropped significantly. The final product revealed 1 single peak on HPLC, analytical methods including TLC and HPLC similar to ^177^Lu-Somatostatin analogues could be employed. The product was radiochemically stable for more than 24 h. The final preparation complied with pharmaceutical standards including high radiochemical purity and fulfilling quality parameters for parenteral preparations.

**Conclusion:** The synthesis of ^177^Lu-PSMA 617 was successfully established on a GMP compliant automated module and allows transfer for clinical application. Synthesis parameters were very comparable to those used for radiolabelling Somatostatin analogues. The amount of precursor used should be carefully chosen in view of the injected activity required for therapeutic patient studies.

**Address for correspondence:**
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Abstracts - Scientific Session 4: Medical Physics/Radiation Protection: S4-01 Molecular Imaging - Part 1

**Bernd Pichler**

Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University of Tübingen, Tubingen, Germany

Abstract not available.

S4-02: Molecular Imaging - Part 2.

**Thomas Beyer**

Center for Medical Physics and Biomedical Engineering, Medical University Vienna, Vienna, Austria

Abstract not available.

S4-03: Image Segmentation for Personalized

Dosimetry in Radionuclide Therapy: A Semi.Automatic Workflow Matching a Reference Phantom to the Individual Patient Anatomy

**Matthias Blaickner, Harshad Kulkarni, Stefan Wiessalla, Christiane Schuchard, Richard Baum**

Department of Health and Environment, Biomedical Systems, Austrian Institute of Technology, Vienna, Austria

The aim of this work is the development of a computational workflow to process PET/CT or SPECT/CT data for the purpose of individualized dosimetry calculations in radionuclide therapy. Segmentation is achieved by deforming a predefined subdivision surfaces (SubD) reference phantom in order to locally match the individual patient anatomy. After loading the co-registered PET/ CT or SPECT/CT data of the patient the non-uniform morphing works by means of following steps: (1) entire SubD reference phantom gets manually superimposed with the patient imaging data with the aid of rotation, translation as well as linear scaling and thus results in an alignment of the torso boundaries. (2) The torso boundaries stay fixed whereas the organ of interest gets manually superimposed and the surrounding organs are adaptively transformed by lattice modification. Any organ can be chosen to adaptively transform or to stay fixed. (3) The superimposed organ of interest of the SubD reference phantom acts as initial surface which converges at organ boundaries of the patient imaging data by means of a 3D gradient vector flow active contour. (4) Fine adjustment of the surrounding organs is performed using a signed distance field and lattice modification. Above workflow results in a SubD phantom that locally matches the individual patient anatomy. No further segmentation is necessary since every point in space is affiliated with an organ or tissue. The morphed phantom can be discretized in any voxels size and thus be used for a voxel wise dosimetry, e.g. by a convolution of the accumulated activity with respective dose kernels. The resulting visual depiction of the dose distribution and the associated dose-volume histograms then base on a fully segmented phantom that matches the individual patient\'s anatomy. The computational approach enables individualized dosimetry in radionuclide therapy combined with fast segmentation, thus sparing the clinical staff the tedious work of manual delineation and subsequently ruling out inter-observer errors.

**Address for correspondence:**
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S4-04: Lu-177 BPAMD for Treatment of Skeletal Metastases in Prostate Cancer: First Dosimetric Results

**Christiane Schuchardt, Stefan Wiessalla, Harshad Kulkarni, Frank Rösch, Richard P. Baum**

Theranostics Center for Molecular Radiotherapy and Molecular Imaging (PET/CT), Zentralklinik Bad Berka, Bad Berka, Germany

**Aim:** Lu-177 BPAMD (4-{\[bis-(phosphonomethyl)) carbamoyl\] methyl}-7, 10-bis (carboxymethyl)-1, 4, 7, 10-tetraazacyclododec-1-yl acetic acid) is a promising agent for the treatment of skeletal metastases in prostate cancer. The aim of our study was to determine the organ and tumor kinetics and to estimate the mean absorbed dose to normal organs and tumor lesions.

**Materials and Methods:** 18 patients (aged 68 ± 10 years) suffering from carcinoma of prostate with skeletal metastases were treated with activities of 3.5--7.1 GBq Lu-177 BPAMD. On the basis of conjugated planar whole-body scintigraphies 0.5 h, 3 h, 24 h, 48 h and 72 h p.i. the time-dependent whole-body, organ and tumor activities were determined and dosimetric calculations performed according to the MIRD scheme using OLINDA/ EXM software. To describe the kinetics we used the following parameters: mean half-life (hours) and uptake (%IA, fraction of injected activity), which were calculated using the fit of the time-dependent activity curve to a mono- or bi-exponential function. Blood samples were drawn in 13 patients to estimate the absorbed dose to the red marrow.

**Results:** The whole body (WB) uptake showed a bi-exponential decrease, the second half-life was 65 ± 17 h and varied from 24% to 46% IA at 20h p.i. The resulting mean absorbed WB dose was 0.07 ± 0.03 mGy/MBq. A rapid decline was found for the renal uptake, followed by a mono.exponential function after 20 h p.i. and a half-life of 56 ± 14 h. The maximum kidney uptake was 9% IA. The uptake of the bone lesions showed a first increase until 3 h p.i. followed by a slow decrease with a very long half-life of 54--160 h (identical to the physical half-life of Lu-177). The blood kinetics were fitted to a tri.exponential function with low variation, the longest half-life was 23h. The following organ absorbed doses were calculated: Whole body: 0.04--0.13 mGy/MBq, kidneys: 0.11--0.63 mGy/MBq; skeletal metastases: 2.4--209 mGy/MBq. The resulting dose to the red marrow was 0.04--0.1mGy/MBq. We found a high inter-patient variability when comparing the dosimetric results of all patients. Contrary, the intra-patient variability was very low concerning one patient receiving 3 cycles of therapy.

**Conclusions:** We found a fast washout of Lu-177 BPAMD in whole body and normal organs as well as a fast blood clearance. In opposite, the skeletal lesions showed a slow wash-out and a long half-life. Therefore, Lu-177 BPAMD has optimal characteristics for therapy of bone metastases in prostate cancer.

**Address for correspondence:**

Dr. Christiane Schuchardt, Theranostics center for molecular radiotherapy and molecular imaging (PET/CT), Zentralklinik Bad Berka GmbH, Bad Berka, Germany. E-mail: <christiane.schuchardt@zentralklinik.de>

S4-05: Biodistribution and Dosimetry of Lu-177 Prostate-Specific Membrane Antigen for Therapy of Metastatic Prostate Cancer: First Results

**Christiane Schuchardt, Stefan Wiessalla, Harshad Kulkarni, Mostafa Shahinfar, Hans-Jürgen Wester, Richard P. Baum**

Theranostics Center for Molecular Radiotherapy and Molecular Imaging (PET/CT), Zentralklinik Bad Berka, Bad Berka, Germany

**Aim:** The prostate specific membrane antigen (PSMA) is in prostate cancer cells significant over expressed compared to normal prostate tissue. Aim of our study was to determine the kinetics and dosimetry in the radionuclide therapy of metastasized prostate cancer using the novel with Lu-177 labeled tracer PSMA.

**Methods:** Included were 15 patients with metastasized prostate cancer (aged 73 ± 8 years), the high PSMA expression was verified before by Ga-68 PSMA PET/ CT. The administered activity was 3.6--8.6 GBq Lu-177 PSMA. Based on 5 conjugated planar whole-body scans, the time-dependent whole-body and tumor activities were determined, and dosimetric calculations performed according to the MIRD scheme using OLINDA/EXM software. To describe the kinetics, we used the following parameters: mean half-life (hours) and uptake (%IA, fraction of injected activity), which were calculated using the fit of the time-dependent activity curve to a mono- or bi-exponential function. Blood samples were drawn to determine the blood kinetics and to estimate the absorbed dose to red marrow.

**Results:** An intense uptake in the tumor lesions as well as a significant renal uptake was found for all patients. The whole body uptake showed an exponential decline with a half-life of 12--91 h. The maximum renal uptake was 12% IA and showed a fast wash-out with half-lives of 19--82 h. The uptake of lymph node and bone lesions followed an exponential decline with half-lives of 14--149 h. The following organ. and tumor doses were calculated: Whole body 0.03 ± 0.02 mGy/MBq; kidneys 0.6 ± 0.4 mGy/MBq; tumor lesions 10 ± 17mGy/MBq (maximum 78 mGy/MBq). The results of the blood sampling showed a fast clearance from blood with half-lives up to 42 h.

**Conclusions:** These first results show that because of the high tumor uptake, the fast renal wash-out and the fast blood clearance, peptide receptor.mediated radionuclide therapy (PRLT) using Lu-177 PSMA is a new promising treatment option for metastasized, Mormon-refractory progressive prostate cancer.

**Address for correspondence:**

Dr. Christiane Schuchardt, Theranostics center for molecular radiotherapy and molecular imaging (PET/CT), Zentralklinik Bad Berka GmbH, Bad Berka, Germany. E-mail: <christiane.schuchardt@zentralklinik.de>

S4-06: Peptide Receptor Radionuclide Therapy Using Lu-177 HA DOTATATE and Lu-177 DOTATOC in the Same Patient: Comparison of Biokinetics and Dosimetry

**Christiane Schuchardt, Stefan Wiessalla, Harshad Kulkarni, Mostafa Shahinfar, Hans-Jürgen Wester, Richard P. Baum**

Theranostics Center for Molecular Radiotherapy and Molecular Imaging (PET/CT), Zentralklinik Bad Berka, Bad Berka, Germany

**Aim:** Peptide receptor radionuclide therapy with radiolabelled octreotide analogues is effective in patients with somatostatin receptor (SSTR) positive tumours. The aim of this retrospective study was to compare the biodistribution and mean absorbed doses to normal organs and tumors using the Lu-177 labelled somatostatin analogues DOTATOC and high affinity DOTATATE (HA-DOTATATE) in the same patient.

**Methods:** We examined 4 patients (P1-P4) with metastasized neuroendocrine tumours with high SSTR expression as verified by Ga.68 SSTR PET/CT. The patients received 6.4--7.5 GBq Lu-177 DOTATOC and in the subsequent cycle 7.1--7.4 GBq HA DOTATATE. The time-dependent whole-body, organ and tumor activities were determined based on conjugated planar whole-body scintigraphies acquired 0.5 h, 3 h, 20 h, 44 h and 68 h p.i. and dosimetric calculations (MIRD scheme) were performed using OLINDA software. To describe the kinetics, we used the following parameters: mean effective half-life (hours) and uptake (%IA, fraction of injected activity), which were calculated using the fit of the time-dependent activity curve to a mono- or bi-exponential function.

**Results:** The whole body uptake was higher for HA-DOTATATE: P1 49/23% IA, P2 49/20% IA, P3 32/15% IA, P4 39/14% IA (HA DOTATATE/ DOTATOC at 20 h p.i.). Mean effective whole body half-lives were comparable in 2 patients (P1 61 h, P4 41 h), whereas HA DOTATATE showed longer half-lives in the remaining 2 patients (P2 64/55 h, P3 50/42 h). The resulting mean absorbed whole body doses were: P1 0.09/0.05 mGy/MBq, P2 0.07/0.03 mGy/MBq, P3 0.04/0.02 mGy/MBq, P4 0.04/0.02 mGy/MBq. Similar to whole body, also the renal uptake was higher for HA DOTATATE: P1 4/2% IA, P2 4/2% IA, P3 3/2% IA and P4 6/2% IA (HA DOTATATE/DOTATOC at 20 h p.i.). In consequence, also the mean absorbed dose to the kidneys was higher for HA-DOTATATE P1 1.3/0.6 mGy/MBq, P2 1.1/0.5 mGy/MBq, P3 1.9/0.5 mGy/ MBq, P4 1/0.4 mGy/MBq.For tumor lesions (liver, bone and lymph node metastases), no significant difference concerning the uptakes, half-lifes and mean absorbed doses were found.

**Conclusions:** These first results demonstrate the higher affinity of HA-DOTATATE to SSTR 3 and 5 (as compared to DOTATOC) results in comparatively higher uptakes in normal organs. No significant differences were found between the 2 peptides concerning the measured tumor doses. These preliminary results have to be verified in further studies with a higher amount of patients and better statistics.
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S4-07: Dose Escalation Study with 188Re-Zoledronic Acid in Patients with Painful Bone Metastases

**Tatiana Kochetova, Valeriy Krylov, Lev Volosnev**

Medical Radiological Research Center, Obninsk, Russian Federation

^188^Re-Zoledronic acid is new potential bone seeking radiopharmaceutical which combine advantages of generator produced 188Re and zoledronic acid with its high affinity to bone lesions. The main aim of this study was to evaluate the maximum tolerated activity of ^188^Re-Zoledronic acid in breast cancer or prostate cancer patients with multiple bone metastases. Twenty-one patients received a single injection of the radiopharmaceutical in various dosage. The first three was in receipt of 35 MBq/kg, after 8 week follow up with blood count and chemistry measurement without any toxicity the second three received 45 MBq/kg. Then another follow up with no remarkable side effects was passed and the following group was treated with 55 MBq/kg of the investigational drug. In order to rich significance of the results, the lust group was enlarged up to 15 patients. Any adverse event grade IV or prolonged grade III related to ^188^Re-Zoledronic acid considered to be unacceptable. Despite the administrated activity was up to 5.8 MBq (every syringe was measured with dose calibrator before and after injection) the treatment was well tolerated without any serious symptomatic complications even in ones with wide spread bone metastases who previously received multiple courses of chemotherapy. After treatment and follow up, most of the patients were remained under the supervision, some of them later received chemotherapy, external beam therapy or repeated courses of radionuclide therapy with 153Sm.EDTMP in standard regimen without any outstanding reactions. To asses effectiveness, larger investigations are necessary, but low activities seems to be effective as well with may be shorter duration of pain palliation. So that ^188^Re-Zoledronic acid can be used in different dosage depending to clinical case and treatment plan.
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S4-08: Applications of Positron EmissionTomography/Computed Tomography in External Beam Radiation Therapy Dose Planning

**Kalevi Kairemo**

Department of Molecular Radiotherapy and Nuclear Medicine, Docrates Cancer Center, Helsinki, Finland

F-Fluorodeoxyglucose/positron emission tomography (FDG-PET) and PET/CT add information to the staging of patients with many solid cancers, such as lung cancer, head and neck cancer, GI cancers, lymphomas, melanoma, sarcomas etc., Other PET tracers can be used e.g., for staging of brain, prostate and breast cancers. External beam radiation therapy (EBRT) is an essential treatment modality in many of these malignancies. In practice, molecular imaging based on PET/(SPECT) is the only modality in defining biological target volume (BTV) for EBRT. However, it is not yet widely used and there are no prospective randomized studies available. Retrospectively, the EBRT response has been analyzed in a preliminary when dose planning was based on BTV target definition by comparing clinical and biochemical results of dose planning modulated therapy in group of 14 prostate cancer patients with PET/ CT and conventional dose planning VMAT (RapidArc) (Kairemo *et al*., Curr Radiopharm, in press). Patients with PET/CT dose planning VMAT had less incidence of biochemical relapse, clinical manifestation of diseases and longer statistically significant duration of disease free period and biochemical stability as compared to patients treated conventional dose planning VMAT. Now, we apply this routinely in the daily praxis: besides FCH, we have experience of using ^18^F-FACBC.PET and combinations with Na^18^F-PET. PET based EBRT applications to dominant intraprostatic lesions require still further development. Hypoxia is a key player in the resistance to EBRT in many cancers. Dose definition and planning should be based on combined information from FDG and hypoxia tracer PET/CT studies. Preliminary results exist in head and neck cancer. PET/CT should be part of EBRT development, because existing preliminary results are very encouraging.
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Abstracts - Scientific Session 5: Prostate Cancer/Bone Pain Palliation: S5-01 Therapy of Prostate Cancer - an Overview

**Wolfgang Horninger**

Department of Urology, Medical University of Innsbruck, Innsbruck, Austria
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S5-02: Theranostics of Prostate Cancer (PRLT) Using Ga-68 and Lu-177 Labeled Prostate-Specific Membrane Antigen Small Molecule - A New Horizon for Nuclear Medicine

**Richard P. Baum, Harshad Kulkarni, Christiane Schuchardt, Aviral Singh, M. Weineisen, Margret Schottelius, Hans-Jürgen Wester**

Theranostics Center for Molecular Radiotherapy and Molecular Imaging (PET/CT), Zentralklinik Bad Berka, Bad Berka, Germany

Prostate specific membrane antigen (PSMA) overexpression in prostate cancer makes it an ideal target for diagnosis as well as therapy (THERANOSTICS). Ga-68 PSMA-HBED-CC is a sensitive and specific PET tracer for the detection of prostate cancer recurrence and metastases. Peptide radioligand therapy (PRLT) with Lu-177 labeled PSMA small molecules was performed in 53 metastasized castrate.resistant prostate cancer patients, administering a total of 106 cycles. Ga-68 PSMA PET/CT was used for patient selection and follow-up. The mean administered activity of Lu-177 PSMA per cycle was 5.7 ± 0.8 GBq, median 5.8. Post-therapy response could be assessed until now in 27 patients. Intense PSMA expression, demonstrated by pre-therapy Ga-68 PSMA-HBED-CC PET/CT, was also noted on post-therapy Lu-177 PSMA planar and SPECT/ CT images. According to molecular imaging criteria, partial remission was noted in 11 and stable disease in 5 patients, while morphological response (according to RECIST) was observed in 6 patients, and stable disease in 13 patients. The disease continued to progress in 8 patients. All symptomatic patients reported significant improvement in pain and quality of life after therapy. Dosimetric evaluation according to MIRD scheme exhibited rapid clearance from blood with half-life up to 42 h. The treatment was well tolerated by all patients without any significant adverse effects or alterations in any of the laboratory parameters or renal function (as determined by Tc-99m MAG3/TER). There were absolutely no side effects reported, especially there was no evidence of salivary toxicity (dry mouth). Organ- and tumor doses were as follows: Whole body 0.02 ± 0.01 mGy/MBq; kidneys 0.35 ± 0--14 mGy/MBq; tumor lesions 0.14.19.8 mGy/MBq. The maximum tumor dose reached in one cycle was 300 Gy.

**Conclusion:** Peptide radioligand therapy utilizing Lu-177 DOTAGA PSMA small molecules is feasible, safe and effective. The high tumor uptake makes it a potent treatment in end-stage disease (killing tumor and not only improving symptoms). There was excellent tolerability in all patients treated, i.e., no hematological, salivary or renal toxicity with fast renal washout and blood clearance. Ga-68 PSMA PET/CT plays an important role in THERANOSTICS - selection of patients as well as follow-up/assessment of therapy response after radionuclide therapy. Future perspectives which should be examined include improving the treatment potency and safety by means of hyperfractionation, increase of treatment activity/dose, improved kidney protection by PMPA, use of radiosensitizers, different radionuclides and combination of therapies.
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S5-03: 68Ga-Prostate-Specific Membrane Antigen: Positron Emission Tomography/ Computed Tomography: Paradigm Shift in the Management of Prostate Cancer

**Mike Sathekge**

Department of Nuclear Medicine, University of Pretoria and Steve Biko Academic Hospital, Pretoria, South Africa

Abstract not available.

S5-04: The Role of Positron Emission Tomography Imaging with 68Ga- Prostate.Specific Membrane Antigen and 18F-Choline in Recurrent Prostate Cancer Patients

**Franceso Ceci**

Service of Nuclear Medicine, Policlinico S. Orsola-Malpighi, University of Bologna, Italy

**Aim:** During the last decade, choline.positron emission tomography/computed tomography (PET/CT), labelled either with 11C or 18F proved to be a better diagnostic tool to restage prostate cancer (PCa) patients during biochemical relapse when compared to conventional imaging. Choline PET/CT has proved to have a significant impact on therapeutic management of recurrent PCa. Detection rate of Choline PET/CT is related to PSA-level and PSA-kinetics. However, choline PET/CT showed a lack of sensitivity and suboptimal specificity at low PSA-levels. Recently, new receptor based radiotracers binding with high affinity to prostate specific membrane antigen (PSMA), a cell surface protein with a significantly increased expression in PCa cells, have been proposed for PET imaging. 68Ga-labelled PSMA ligand HBED.CC PET/ CT (68Ga-PSMA.PET/CT) has been shown to detect PCa relapses and metastases with high tumour to non-tumour contrast by binding to the extracellular domain of PSMA, followed by internalization. Furthermore, in preliminary studies, 68Ga-PSMA-PET/CT demonstrated higher detection rate and higher tumour to background ratio compared to choline PET/CT. The aim of the presentation is to evaluate the role of PET imaging with 68Ga-PSMA and 18F-Choline in prostate cancer patients, presenting biochemical or clinical recurrence after primary therapies. In particular, it will exposed the influence of anti-androgen therapy on PET/CT detection rate in both radiotracers.
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S5-05: Gamma Imaging in Patients Following 223Ra/XOFIGO

**Kalevi Kairemo**

Department of Molecular Radiotherapy and Nuclear Medicine, Docrates Cancer Center, Helsinki, Finland

Radium-223-dichloride (^223^RaCl~2~) is a new bone-seeking calcium analogue alpha-emitter, which has obtained marketing authorization for the treatment skeletal metastases of hormone-refractory prostate cancer. The current treatment regimen is based on six consecutive fixed doses of ^223^RaCl~2~ at 4 week intervals and the administered activity dose -- 50 kBq/kg/cycle - is based on patient weight. In a new European legislation, including radionuclide therapy, dose planning will be a new prerequisite of radionuclide therapies (EC Directive 2013/59/Euratom). A method will be presented for relative dose calculation and target evaluation based on gamma imaging with therapeutic ^223^RaCl~2~ doses. Two patients were analyzed using semiquantitative serial gamma imaging to estimate dosimetry in tumors and see possible pharmacokinetic differences in the treatment cycles. Selected patients were imaged using NaF-PET/CT after the first cycle for early response evaluation. The lesions were rather well visualized in gamma scintigraphy in spite of low gamma activity (\<1.1% gamma radiation) at 0, 7 and 28 days using 30--60 min acquisition times. Both our patients analyzed in serial gamma imagings, had two lesions in the gamma imaging field, the mean counts of the relative uptake varied from 27.8 to 36.5 (pt 1), and from 68.8 to 82.2 (pt 2). The half-lives varied from 1.8 d to 3.6 d during the 6 cycles (pt 1), and from 1.6 d to 2.4 d (pt 2), respectively. In the lesion half-lives calculated from the imaging the maximum difference between the treatment cycles in the same lesion was 2-fold. Of these patients, pt 1 demonstrated a serum PSA response, whereas there was no PSA response in pt 2. Our recommendation based on statistical simulation analysis, is serial measurement at days 0--8 at least 3 times, this improve the accuracy significantly to study the lesion activities, half-lives or calculated relative absorbed radiation doses as calculated from the imaging. In our NaF-PET/CT material lesion number, SUVmax, and total metabolic volume were used for analysis, but differences after first cycle were minor. For example, in five patients with \>50% skeletal involvement, the PERCIST change varied from -- 13.1% to 17.1%. In summary, our results, although preliminary, suggest that dose planning and calculations should be included as a part of this treatment modality because lesion behavior is individual. On the other hand, from the relative absorbed radiation doses based on gamma imaging, the response cannot be predicted because with very similar relative doses, not all patients respond. Our very preliminary data does not suggest either that early response could be predicted from skeletal nuclear (osteoblastic activity related) PET imaging.
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S5-06: Gallium 68 Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography Scans in Recurrent Prostate Cancer

**Ishita Sen, Vineet Pant, Abhinav Singhal, Sanjay Gogoi**

Fortis Memorial Research Institute, New Delhi, India

**Introduction:** The diagnosis of recurrence in prostate cancer is based mainly on prostate.specific antigen (PSA) level above a threshold or on PSA kinetic value. Once the diagnosis of biochemical recurrence is established, the key question remains whether the rise in PSA is reflective of local or distant disease in order to plan the most appropriate treatment. Generally initial negative nodes and negative seminal vesicle invasion, PSA doubling time (PSA~dt~) more than6 months, and Gleason score \<7 are related to a higher risk of local relapse, while PSA doubling time (PSA~dt~) less than 6 months, positive lymph nodes, seminal vesicle invasion, and Gleason score more than 6 are related to systemic relapse.

**Aim:** The aim of this study was to study the distribution of metastatic sites as detected by Glu-NH-CO-NH-Lys-(Ahx)-\[~68~Ga (HBED-CC)\] (~68~Ga-PSMA) scans and to assess whether the intensity of uptake and presence of local and distant recurrent disease correlated with the aggressiveness of the initial tumour and the PSA doubling times.

**Materials and Methods:** 35 patients with biopsy proven prostate cancer and rising prostate.specific antigen (PSA) levels were subjected to ~68~Ga-PSMA positron emission tomography (PET)/CT. Quantitative assessment of tracer uptake was performed 90 minutes post- injection by analysis of maximum standardized uptake values (SUVmax).

**Results:** PSMA PET CT scans were able to detect at least one site of disease in 11 out of the 14 patients with a PSA doubling time of more than 6 months yielding a detection rate of 78.5% with four patients showing evidence of systemic metastatic disease. PSMA PET CT scans was able to detect sites of disease in all the patients with a PSA doubling time of less than 6 months (detection rate of 100%) with 18 of the 21 patients showing evidence of systemic metastases. The intensity of uptake also correlated with the initial Gleasons score with higher SUV Max seen in the patients with a higher Gleasons score and in those with systemic metastases.

**Conclusion:** Ga 68 PSMA PET CT scans detect sites of recurrent prostate cancer with a high sensitivity especially in the group of patients showing a rapidly increasing PSA level. The presence of systemic disease can not always be predicted by the PSA doubling time and the initial staging of disease with the PSMA PET CT showing sites of unanticipated systemic metastases even in patients with a slow PSA rise. The intensity of uptake of Ga 68 PSMA also correlates with the Gleasons score of the tumour likely suggesting a higher uptake of Ga 68 PSMA in the more aggressive tumours.
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S5-07: The Relation Between Bone Pain Response and Skeletal Metastases in Cancer Patients Receiving 153Samarium-EDTMP Therapy

**Mai Elzahry, Helmut Sinzinger, Mohamed Gaber, Waleed Diab**

Department of Nuclear Medicine, South Valley University, Qena, Egypt

Pain is the commonest clinical manifestation of bone metastases .Its treatment is palliative in nature, the major aim not being complete eradication, but rather relief. Radioactive isotopes represent an appealing alternative to conventional treatment modalities. Among the various radioisotopes available, we obtained extensive clinical experience with 153Sm-EDTMP.

**Objective:** To elaborate if there is a relation between bone pain response and gender, type of cancer, patients age, number and extent of the bone lesions and number of 153 Sm-EDTMP therapeutic doses in patients who underwent 153Sm-EDTMP therapy for painful metastatic bone lesions of prostate and breast.

**Materials and Methods:** 110 patients were included in this analysis, 63 (57.3%) males (age range; 52--89 year) and 47 (42.7%) females \[age range: 35--84 year\], their diagnoses were prostate and breast cancer, respectively. Conventional whole body Tc-99m MDP bone scan (to confirm bone metastases), relevant blood counts, detailed assessment of pain symptoms, analgesic consumption were obtained from all patients before receiving 153Sm-EDTMP therapy. 153Sm-EDTMP administration was performed according to the Vienna protocol developed at the Department of Nuclear Medicine, Vienna, Austria.

**Results:** Indicate that patients who showed regression or stabilization in scintigraphy, a very good pain response to the repeated doses of therapy was observed, while in the patients showed progression in scintigraphy, the response was moderate (83.4%) in breast cancer and 92.4% in prostate cancer. Regarding the patients who received only a single dose of the therapy, we noticed a good pain response (100%, 73.3%) among breast and prostate cancer patients who had \>10 bone lesions detected by scintigraphy, with a reasonable response (75%, 66.6%) among the patients who had \<10 lesions, respectively.

**Conclusion:** 153Sm-EDTMP provided a complete pain palliation in about 60% of patients with painful metastatic dissemination, a partial one in about 30% and no response only in \<10%. 153Sm-EDTMP therapy. induced pain response is not related to the type of cancer, gender, patients age and the number of therapeutic doses, however, pain response shows significant relation to the extent of bone lesions. This explains a high response rate (100%) in patients who showed scintigraphic regression, repeated doses of 153Sm-EDTMP offer a significant palliative benefit to cancer patients with metastatic bone pain.
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S5-08: Diagnosis and Follow-up of Recurring and Metastatic Prostate Cancer by Ga-68 Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography

**Harshad Kulkarni, Hans-Jürgen Wester, Richard P. Baum**

Theranostics Center for Molecular Radiotherapy and Molecular Imaging (PET/CT), Bad Berka, Germany

**Aim:** The aim of our study was to examine the role of Ga-68 PSMA-HBED-CC PET/CT in prostate cancer patients presenting with rising prostate specific antigen (PSA).

**Methods:** 86 prostate cancer patients (mean age 61 ± 8, range 48--86 years) presenting with rising PSA (mean PSA 10.1 ng/ml, range 0.2--245) underwent contrast-enhanced Ga-68 PSMA PET/CT. It was performed again in 14 patients with metastatic prostate cancer for follow-up after 2 cycles of peptide radioligand therapy (PRLT) using Lu-177 PSMA ligand. PET/CT was assessed visually and semiquantitatively (SUVmax) by a nuclear medicine physician and a radiologist with 10 years experience respectively.

**Results:** Local residual/recurrent disease was observed in 16 patients, pelvic lymph node metastases in 2 patients, and initial bone marrow metastases (negative on CT) in 3 patients. Multiple PSMA.positive metastases were observed in 25 patients; 14 with high uptake underwent radioligand therapy with Lu-177 labeled PSMA ligand. The detection rate of Ga-68 PSMA was 84.8% (73/86). Molecular response assessment after Lu-177 PSMA radioligand therapy demonstrated partial remission in 8 patients, stable disease in 4 and progressive disease in 2 patients. There was a strong correlation between change in SUVmax and change in serum PSA level (*r* = 0.84).

**Conclusions:** Ga-68 PSMA-HBED-CC PET/CT is a sensitive and specific modality for the detection of prostate cancer recurrences and metastases. It is highly promising for the effective stratification of metastatic prostate cancer patients undergoing therapy with Lu-177 labeled PSMA ligands (Theranostics), for patient selection as well as for assessment of therapy response by molecular imaging criteria, and also correlates well with biochemical response as determined by serial PSA measurements.
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Abstracts - Scientific Session 6: Radiosynovectomy: S6-01 Radiosynovectomy - State of the Art 2015, Part 1

**Gynter Mödder, Renate Mödder-Reese**

Nuramed German Centre for Radiosynovectomy, Koln, Germany

Radiosynoviorthesis (RSO) is a proven important instrument for local treatment of chronic inflammatory joint diseases in the context of medical and orthopaedic efforts. By local application of radioactive agents an attempt is made to influence the painful destructive synovial process favourably as an alternative to surgical synovectomy. In Germany RSO nowadays is performed in about 70.000 joints per year, as much as radioiodine therapy in thyroid diseases. Basically RSO is indicated for the local treatment of almost all kinds of chronic synovitis. The main indications for RSO are:

Rheumatoid arthritisSeronegative spondarthropathy (i.e. reactive arthritis, psoriatic arthritis)Haemarthrosis in haemophiliacRecurrent joint effusions (i.e., after arthroscopy)Pigmented villonodular synovitis (PVNS)Osteoarthritis (Activated arthrosis)After joint prosthesis: persistent effusions, polyethylene diseaseUndifferentiated arthritis (where the arthritis is characterized by synovitis, synovial thickening or effusion).

The most common and approved radiopharmaceuticals used for RSO are following β-emitters:

\[~90~Y\] yttrium-citrate or -silicate (\[~90~Y\] colloid), only used for RSO of knee joints\[~186~Re\] rhenium sulphide (\[~186~Re\] colloid), used for RSO of middle sized joints\[~169~Er\] erbium citrate (\[~169~Er\] colloid, used for RSO of small joints.

The radioactive particles in colloidal form are taken up by phagocytosis in synovial macrophages with homogenous distribution on the surface of synovium. β-radiation leads to coagulation necrosis, sclerosis and fibrosis of the synovial tissue including vessels and pain receptors, resulting in reducing effusion, swelling and pain of the joint. Cartilage has no nerves and vessels and cannot inflict pain and because of having no ability for phagocytosis this tissue is no target for the radiation effects. Patients should be submitted after ineffective conservative local and/or systemic (rheumatic diseases) treatment. Also after surgical interventions RSO might improve the complaints of the patient, that is, after total knee replacement or effusions after arthroscopy. Side effects are very rare, and good efficacy of RSO is about 70--80% for years by only one treatment. In some more difficult cases fractionated RSO may lead to success. Diagnostic studies prior to RSO: (1) Ultrasound study (obligatory prior to RSO to rule out a Baker\'s cyst). (2) Multiphase scintigraphy with ~99m~Tc-MDP is the best diagnostic tool for detecting synovitis (soft tissue scintigraphy) and bone involvement (bone scintigraphy). Performance of RSO: Apart from the knee all joints have to be punctured by fluoroscopy and often by arthrography. After RSO distribution scintigram confirms the appropriate intra.articular distribution of the radiopharmaceutical. Only after use of Erbium-169 no scintigram is available. Immobilization of the treated joints by a splint is required for 48 hours avoiding necrosis and leakage. The first follow-up care is recommended about 6 months after RSO or earlier, of course, when problems (reactive inflammation, suspect of infection, swelling of Baker\'s cyst) occur.

**Results:** Response rates reported in abundant literature range from about 60% to \>80% for all joints, often with greater success for rheumatoid diseases than for osteoarthritis. Most of the studies relating to RSO during the last 40 years do not fulfil the criteria of modern evidence based medicine, but recently a number of well designed trials have been carried out evaluating the efficacy of RSO. RSO provides better results in rheumatoid arthritis than in osteoarthritis, depending on stage of joint damage. Deformed or unstable joints might fail treatment and therefore surgical interventions should be considered. Close cooperation with orthopaedists and rheumatologists is necessary to consider RSO in each patient to ensure optimal medical care.
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S6-02: Radiosynovectomy - State of the Art 2015, Part 2

**Knut Liepe**

Department of Nuclear Medicine, Klinikum Frankfurt, Frankfurt, Germany

**Aim:** Radiosynovectomy is a useful therapeutic option that involves radiopharmaceutical injections into joints, especially to treat rheumatoid arthritis. A problem for comparison of radiosynovectomy response is the lack of a gold standard for estimation the effect. Most papers used a subjective score by patient, which is uncertain. Therapeutic effects between 60 to 90% are described in the literature.

Objective scoring, e.g., using the results of two phase bone scintigraphy, is a good option in this topic. Liepe *et al*.\[1\] published data of bone scans before and after radiosynovectomy in 136 patients and 424 joints. The success of RSO was evaluated after 12 months by patients' estimation and comparison of the pre- and post-therapeutic uptake in blood pool phase.\[2\] The subjectively estimated success rates for the small, medium-sized, and large joints were 89% (215/242), 86% (112/130), and 79% (41/52), and for RA and OA 89% (280/313) and 79% (88/111), respectively. The scintigraphically determined response rates for small and medium.sized joints were 81% (86/106) and 69% (35/51), respectively. There was a mismatch between patients\' assessment and scintigraphic assessments in 18% (28/157) with 6 false.negative and 22 false-positive estimations using scintigraphy as the standard of reference. In another publication using a subjective score, Liepe *et al*.\[3\] showed an excellent or good response in 57% of treated knees, 63% of shoulders, 60% of wrists, 64% of ankles, 54% of thumb bases, 55% of MCP\'s. 54% of PIP\'s, 53% of DIP\'s and 54% of MTP\'s. Side effects associated to the RSO that is, swelling or transient increase of pain were recorded in 15% of the patients that resolved within 1 month. No patient had any skin alteration after treatment. An important point for an exact indication for the treatment is an optimal pre-therapeutic diagnostic (case history, palpation of the joints and two phase scintigraphy). All rheumatic patients should have a local scan of the fingers (3 min) and a fast whole body scan (20 cm/min). If the patient described pain in the ankle, than perform a lateral scan of the ankle (3 min) and in cases with pain in MTP\'s a local scan of planar food (3 min). The rate of side effects and radiation exposure for the patients is very low (e.g., effective radiation absorbed dose lower than 1 mSv/30 MBq of erbium-169.\[4\] More important is the radiation exposure of the physician, especially in large number of treated patients. Erbium-169 with a low beta energy place not a role, the energy was absorbed by the syringe wall. Using rhenium-186 a 2.5 mm Perspex radiation protection of the syringe is sufficient. However, for using yttrium-90 with a maximum beta-energy of 2.1 MeV a 5 mm Perspex wall and a manipulator for fixation of the needle during the therapy is necessary.

**Conclusion:** The radiosynovectomy is a safe and effective treatment in rheumatoid arthritis, but also in other kinds of arthritis. The physician should be use sufficient radiation protection to reduce the radiation exposure, especially at the finger pulp.
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S6-03: Homogeneous Sn-117m Colloid - A Novel Radiosynovectomy Agent

**Nigel Stevenson, Jimmy Lattimer, Kimberly Selting, Gilbert Gonzales, Cynrhia Doerr, Alison Bendele, Jaime Simon, Suresh Srivastava**

R-NAV, LLC, Columbia, USA

Tin-117m (Sn-117m) has two significant energy emissions, a low energy gamma photon and low energy conversion electrons. The gamma photon energy of Sn-117m is 159 keV and can be imaged using standard gamma cameras found in all inpatient hospitals and outpatient imaging facilities. The conversion electrons (C.E.) from tin-117m are particle emissions with an average energy of 140 keV that interact therapeutically with tissue. However, unlike the beta rays found in most therapeutic radioisotopes, tin-117m C.E. are mono-energetic (principle emissions: 127, 129, and 152 keV; abundance 65, 12, and 26% respectively) and have a well-defined range in tissue of \~300 µm, limiting their therapeutic effect to the desired tissue without damage to adjacent healthy tissue. These C.E. have been shown to have a very strong anti-inflammatory effect and should be ideal for radiosynovectomy (RSV) applications. The characteristics of RSV isotopes are usually chosen to match the electron energies (i.e., range in tissue) to the size of the joint being treated. Sn-117m has a range similar to that of Eb-169 that is commonly used in smaller joints. However, the additional ability to image the Sn-117m adds a safety advantage to therapeutic treatment with this isotope. Adding to the advantageous characteristics of this new RSV isotope is our novel homogeneous colloid form in which the size distribution of the particles can be well controlled. Our standard colloid is produced with a particle size range of 2--20 µm (90% within 8--12 µm) which is too large to leak out of the joint yet is small enough to be phagocytized by the attending macrophages in the synovial cavity. Although this colloid is designed to replace Eb-169 in irradiating small joints the longer half-life and subsequent transport of phagocytized particles within the macrophages into the sub-synovial tissue may afford the opportunity to irradiate deeper into larger joints. Animal trials to evaluate the use of this novel isotope in RSV are underway. Osteoarthritis (OA) and rheumatoid arthritis (RA) inflammatory model rat trials have been performed. The colloid was tested in a collagen induced model of RA (*n* = 40), and an OA model induced by joint laxity and instability (*n* = 90). All rats were treated with a single injection of the Sn-Colloid (doses ranged from 2 to 50 µCi). Histopathology, autoradiography, blood and bio-distribution measurements were performed at 7, 28, 42 and 70 days after injection. Joint retention of the colloid was typically \>99.0% throughout the study.

Autoradiography indicated deposition of colloid in the synovium. The measured effects and safety of the microscopic evaluation of the cartilage and synovium will be reported. A study to evaluate the efficacy of the above Sn-Colloid in dogs with naturally occurring OA is underway. Sn-Colloid 1--3 mCi will first be injected into the elbow of 5 healthy purpose bred hounds to demonstrate retention and safety, with histopathology, autoradiography, joint fluid, radiographic and MRI imaging, gait analysis, blood and biodistribution measurements performed variously on day 0, 7, 14, 30 and 42 after injection. A further 48 client-owned dogs with naturally occurring elbow OA will randomly be enrolled into one of two groups to receive Sn-Colloid injections. These animals will be evaluated with blood work, PET/MRI and radiographic imaging, gait analysis, scintigraphy, joint fluid, and urine and feces analysis variously at 0, 1, 3, 6, 9, and 12 months. Initial results demonstrate that this unique Sn-Colloid delivered intra-articularly has exceptionally high retention in the joint space in OA and RA rat models. We will report various markers of efficacy and localization (such as biodistribution, autoradiography, pathology) in all the animal models. The initial data is supportive of our plans for the use of this isotope in animal OA and subsequently human inflammatory arthritides.
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S6-04: Radiosynoviorthesis of 17 Sacroiliac Joints with 186 Rhenium Colloid: 4-Years Outcomes

**Marika Vereb, Lucia Kaliska, Knut Liepe**

Klinikum Kassel, Nuklearmedizin, Kassel, Germany

**Purpose:** Radiosynoviorthesis (RSO) as a therapeutic procedure of rheumatoid arthritis, other inflammatory joint diseases, persistent synovial perfusion and other joint diseases is widely used in many countries in Europe. Is save, effective, accepted and good documented procedure. Using Y-90 for the knee joint, Re-186 for middle sized joints and Er-169 for small joints an improvement of symptoms and function may be observed in about 60-80% of patients, dependence on affected joint and type of arthropathy. On the present, in the literature they are not available data about application of RSO in the case of aseptic sacroiliitis, what is the meaning inflammation of one or both sacroiliac joints, most frequently by psoriatic arthritis, spondylopathy or HLA-B 27 positivity, most commonly occurred after 5--10 years existence of disease. Assessment of sacroiliitis is often not easy to diagnose, because sacroiliac joint pain is an often-overlooked cause of low back pain due, in part, to lack of specific findings on radiographs and symptoms mimicking other back-related disorders. Without adequate treatment, the disease often progresses and leads to degenerative changes, usually to the immobilization of the patient. We set the target to evaluate the effectiveness of RSO of sacroiliac joints outgoing from beneficial experience of RSO by persistent inflammatory joint diseases.

**Method:** A total of 7 patients (6 women, 1 men with 17 sacro-iliac joints), ranging from 33 to 80 years of age were treated as in-patients with RSO with known history of persistent unilateral or bilateral sacroiliitis (5 joints of them with psoriatic arthritis, 4 joints with polyarthritis, 4 joints with seronegative sacroiliitis and 4 joints with M. Bechterew). Everyone received 37--41 MBq 186Rhenium--colloid, average 37,4 MBq, strict intra-articular. Two patients were treated bilaterally and repeatedly, three patients were treated bilaterally; one patient was treated unilaterally and repeatedly and one patients were treated unilaterally. All patients have local pain and hyperperfusion of sacro-iliac joints on the two-phase bone scintigraphy. Five patients have undergone multiple RSO of extremity joints before, with excellent effect. We applied 2 ml of Lidocaine, followed by contrast media. After optimal contrast media distribution under C-Arm Fluoroscopy in prone position selected radionuclide in volume of 0.2--0.4 ml was injected. Finally was needle flushed by corticosteroid (Triamcinolon). Pelvis region was underlaid and elevated. After 186Rhenium application immobilization was recommended during 2 days hospitalization. Selection of radionuclide was empiric, according to physical properties.

**Preliminary Results:** Tolerance of RSO was excellent in all the patients. After injection of radionuclide was not observed any complications. The evaluation of positive effects of RSO was measured by subjective consideration of patient about pain relieve (according to 10 degree visual analogue scale \[VAS\] of pain). Acceptable result was considered as decrease of pain minimally in 2° of VAS. As objective measurement of good result was used control two-phase bone scintigraphy with improvement of hyperperfusion of sacro-iliac joint on follow-up scan.

**Conclusion:** Application of 186 Rhenium to sacroiliac joints in persistent sacroiliitis can provide pain relief, improve quality of life, and improve work status. No side effects were observed. Pre preliminary data are promising for future utilization of RSO in sacro-iliac joints. Our intention is to involve more patients into the study and confirm positive therapeutic effect of RSO in inflammatory sacroiliac joints. The assessment of the study is not finished yet. In near future, results will be supplemented with objective evaluation of disease stage by two-phase bone scintigraphy.
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S6-05: Management of Conjunctival Squamous Cell Carcinoma by Strontium-90 Irradiation - A 7-year Experience

**Raihan Hussain, Sadia Sultana, Rahima Perveen, Khokon Kumar Nath**

National Institute of Nuclear Medicine and Allied Sciences, BAEC, Dhaka, Bangladesh

**Objective:** A retrospective study of six consecutive years was done on patients with post-operative conjunctival squamous cell carcinoma (SCC) irradiated by strontium (Sr-90) to evaluate its efficacy and the risk of complications.

**Materials and Methods:** Study was done on 32 patients receiving post-operative beta irradiation from January 2008 to December 2014. There were 27 males and 5 females, age ranged from 25 to 85 years with a mean of 51 years. Study group includes 1 poorly differentiated, 16 well differentiated, 7 well differentiated with invasion, 1 moderately differentiated with infiltration, 1 verrucuous and 5 carcinoma-in situ SCC. All patients received 130 Gy (except one who received 60 Gy) to the post-operative sclera surface in five fractions by hand.held Sr-90 surface applicator. The patients were followed up at 1 week, 1 month, 6 month and 1 year interval after beta irradiation.

**Results:** Among the 32 cases, 26 had follow-ups for more than 1-year. Three had recurrence within one year. Short-term complications included conjunctivitis, photophobia, watering of eyes etc., As for long term complications, 2 cases developed cataract. The short.term complications were self limiting and had no serious effects. Two cases having cataract was over 60 years old, so it could not be clearly understood whether the normal ageing process or the radiation contributed more in the development of the cataract.

**Conclusion:** On the basis of our excellent results with minimal morbidity we would continue to advocate the use of strontium-90 surface application after surgical excision as a successful treatment modality for conjunctival squamous cell cancer. Sr-90 beta irradiation should be considered as a first-choice treatment option for post-operative conjunctival SCC.
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S6-06: Synovectomy with 153-Samarium Hydroxyapatite in Haemophilic Arthropathy

**Jose Ulisses Calegaro, Davi Hage, Mariana Sayago**

Hospital de Base and Grupo Nucleos, Brasilia, Brazil

**Introduction:** To present our retrospective experience in the treatment of knees, ankles and elbows in patients (pts) with haemophilic arthropathy using153-samarium hydroxyapatite (~153~Sm-HA), material produced in Brazil.

**Materials and Methods:** The treatment was made with an intra-articular injection of ~153~Sm-HA without corticosteroid of: 1--20 mCi in 20 knees of 18 pts, with median age = 21.4 ± 13.3 (ranging from 7 to 56 years) and Pettersson score of 5.3; 2--5 mCi in 166 joints of 62 pts, with median age = 20.6 ± 7.0 (ranging from 5 to 56), being 62 ankles (Pettersson score of 3.8) and 84 elbows (Pettersson score of 5.5). This protocol used particle size between 2 and 10 µm. Early (1--2 h) and later (3--7 days) scintigraphic studies were performed after the procedure. The activity in haemophilic arthropathy was characterized by recurrent joint bleeding (at least 1/month). The clinical evaluation before and 1 year after of synovectomy used the following criteria: reduction in haemarthrosis episodes and pain using a visual analogue scale, as well as improved joint mobility by goniometry. The occurrence of adverse events of the treatment was also considered. The statistical tests used *P* ≤ 0.05 as significant.

**Results:** The reduction in frequency of haemarthrosis (1) and intensity of pain (2) were: (1) 65.7%, 82% and 78%; (2) 42.5%, 61% and 37% for knees, ankles and elbows respectively, with statistical significance The improvement in motility has no significance for knees and elbows but have a little improvement in ankles. Two cases of mild synovitis were observed in knees, three in ankles and four in elbows. The scintigraphic scans showed the intra-articular distribution of the radioactive material, without leakage in all joints.

**Conclusions:** Synovectomy with ~153~Sm-HA showed very good results for median articulations, as ankles and elbows; knees may be treated with higher activities and this material has an excellent safety profile.
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S6-07: Bremsstrahlung Single-photon Emission Computed Tomography-Computed Tomography for Localization of Inadvertent Extra Articular Injection

**Qaisar Siraj, Al-Banna Anwar, Noora Bin Essa**

Farwania Hospital, Kuwait City, Kuwait

**Introduction:** Synovitis associated with different forms of arthritis present with joint pain and swelling as a result of accumulation of synovial fluid, which restricts the range of movement of the joint resulting in limitation of daily routine activities. Radiosynovectomy has now an established place in the management of patients with disabling synovitis. This involves intra articular introduction of colloidal preparation of radiotracer that will eventually lead to synovial membrane sclerosis.

**Case Report:** We present a case of a 45-year-old man with bilateral chronic synovitis of the knees with complaint of right knee pain associated with swelling and decreased range of motion. Radiosynovectomy was performed using 5 mCi of intraarticular Yttrium.90 (90Y) citrate into the right knee joint. For accurate confirmation of intra articular injection, static planar imaging was performed with open window of gamma camera 30 min post injection. A focal area of increased activity was seen without normal activity in the synovial cavity. SPECT-CT was next performed for precise localization of what seemed to be an extra articular injection radionuclide injection. Since ~90~Y emits beta particles, with an average of photo-peak of 0.935 MeK (Bremsstrahlung), we set our hybrid SPECT-CT camera to auto-detect the highest fundamental frequency, which in our study, corresponded to Xenon-133 window of 81 KeV. With the help of hybrid CT, the focal increased activity was seen to be at the infra patellar fat pad. **Conclusion:** This case study illustrates the benefit of Bremsstrahlung SPECT-CT in accurately localizing the radioactivity which helped reveal the non-intended extraarticular injection of the therapeutic agent. To our knowledge this is the first reported case of Bremsstrahlung SPECT-CT imaging in delineating the distribution of radioactivity following radiosynovectomy.
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S6-08: Response to Radiosynovectomy for Hemophilic Arthropathy (Medium-sized Joints) to Rhenium-86 Colloid and to Yttrium-90 for Larger Joints

**Emerita Andres-Barrenechea**

Department of Nuclear Medicine, St. Luke\'s Medical Center, Quezon City, Philippines

**Objective:** To determine the response of hemophiliacs with hemarthroses of medium sized joints to rhenium sulfide as compared to Yttrium-90 for larger joints.

**Materials and Methods:** M.B. R. is a 27-year-old male, Filipino; single, known diagnosis of Hemophilia A. He was referred because of left elbow and bilateral ankle hemarthroses. Aside from the persistent bleeding needing daily Factor Vlll replacement, he could hardly ambulate because of pain in the left ankle. Before injecting Rhenium-86 sulphide intrarticularly the required coagulation factor of at least 30--50% was ascertained. Radiosynovectomy was done after reviewing X-rays of the involved extremities and using the ultrasound guided procedure through the help of the rheumatologist. Around 10--15 cc of blood was aspirated from the 3 joints before we injected the isotope. Here are the doses given: 2.2 mCi for the right ankle; 2.34 mCi-left ankle and 3.42 mCi for left elbow. The total dose of which is 7.96 mCi or 294.52 Mbq. The allowable total dose in one sitting of Re-186 sulphide is 340 Mbq.

**Results:** Post RS scan was done showing successful intraarticular injection of the 3 joints involved by images with Brehmstrallung. In our previous study, 26 hemophilic patients with hemathroses of the knees or large joints were given Yttrium-90 intraarticularly. Forty-eight to 72 h immobilization was advised aside from ice packs over the local sites and splints were given. Patients were seen on 2 follow-ups with improved function, no longer requiring that much of Clotting Factor VIII and pain was resolved. These cases were seen after 1 year of follow-up and patient still has less bleeding episodes, needing almost no Factor Vlll.

**Discussion:** Hemophilia is a hereditary blood coagulation disorder that can occur in various forms. Hemorrhagic arthropathy occurs as a result of bleeding into the joint. Recurrent bleeding into a joint causes a gradual destruction of bone and cartilage, which can lead to the development of various joint alterations and eventually to ankylosis. RSO is indicated when a chronic state of synovitis has developed as a result of repeated articular hemorrhages and when hematological therapy has failed.

We are presenting this case of hemophilic arthroses, which is quite rare, and very seldom do we do multiple medium sized joints involvement at the same time. In this case there were several hemarthroses and the patient was in pain. It is important to know the limit of the total dose that should be given in one sitting. Likewise the ankles and the elbows are not the most frequent sites of bleeding but the knees. Also Rhenium- 86 sulphide is the indicated isotope for medium size joints as ankles and elbows having a penetrating power of 1--4 mm as compared to Ytrium-90 of 4--10 mm. Rhenium-86 colloid is an effective radiosynovectomy agent for medium sized joints. The recommended dose that should be instilled intraarticuarly is 2 mCi (74 Mbq) in the elbow and 2 mCi (74 Mbq) in the ankle joints. Multiple joints can be treated in one sitting. In the previous study we made all our patients (26 patients) underwent RS using Yttrium-90 as we injected intraarticularly the knees, the most commonly affected large joint among hemophiliacs and of which the recommended dose is 185 mCi or 5-6 Mbq.

**Conclusion:** Radiosynovectomy for hemophilic arthropathy is an efficacious form of therapy using Rhenium-86 colloid for medium sized joints as well as Ytrium-90 for large joints. With the overall improvement of this study, RS must be the procedure of choice for hemophiliacs with repeated bleeding and where surgery is not possible.

**Address for correspondence:**

Dr. Emerita Andres-Barrenechea, Department of Nuclear Medicine and PET, St. Luke\'s Medical Center, Quezon City, Philippines. E-mail: <emieab@yahoo.com>

Abstracts - Scientific Session 7: Liver Cancer/Metastases: S7-01 Re 188 Lipiodol Intra Arterial Treatment of Inoperable Hepatic Cancer and Liver Metastases

**Ajit S. Shinto**

Kovai Medical Centre and Hospital, Comprehensive Cancer Care Centre, Coimbatore, Tamil Nadu, India

**Introduction:** Studies have proven the safety and efficacy of trans-arterial rhenium-188 HDD conjugated lipiodol (radioconjugate) in the treatment of patients with inoperable hepatocellular carcinoma (HCC).

**Materials and Methods:** The radioconjugate was prepared by using an HDD (4-hexadecyl 1.2,9,9-tetramethyl-4,7-diaza-1,10-decanethiol) kit developed in Seoul National University Korea, and lipiodol. A WARMTH team headed by Dr. Ajit Padhy were in Coimbatore, India to help us set up the protocol and radiochemistry in the month of August 2013. Over a period of 18 months, 30 patients with inoperable HCC or metastatic liver lesions received at least one treatment of radioconjugate. Only 4 patients were re-treated for residual active lesion or new lesions. The level of radioconjugate administered was empiric with a range of doses between 60 to 200 mCi. Patients were followed for at least 12 weeks after therapy, until recovery from all toxicity. The clinical parameters evaluated included toxicity, response as determined by contrast-enhanced computed tomography, palliation of symptoms, overall survival, performance status (Karnofsky) and hepatic function (Child\'s classification). Liver function tests, serum alfa-fetoprotein (AFP) levels and complete blood counts were done at each follow-up visit.

**Results:** Of the 30 patients treated so far, 28 are still alive and do come for regular follow up. All of them report good quality of life. Median survival has not been reached. Side-effects were minimal and usually presented as loss of appetite, right hypochondrial discomfort and low-grade fever, even at high levels of administered radioactivity. The symptoms resolved with simple supportive therapy within 3 days of onset. Liver function tests at 24 and 72 h showed no significant changes and complete blood counts at 1 week, 4 weeks and 12 weeks showed no changes (no bone marrow suppression). Survival at 6 months was 100%. We could achieve biochemical or imaging stability of disease in almost 50% and partial or complete regression in another 35% patients approximately.

**Conclusion:** The results of this study show that ^188^Re-lipiodol is a safe and cost-effective method to treat primary HCC or metastatic liver lesions via the transarterial route. In terms of efficacy, it is potentially a new therapeutic approach for further evaluation by treatment of larger numbers of patients. In addition we have developed in house labelling procedures for Re 188 HEDP/V DMSA and SN colloid for radiosynovectomy to make the Re generator more commercially viable.We have also implemented endovascular brachytherapy with Re 188 filled balloons to prevent instent restenosis in patients undergoing femoral/iliac artery stenting. There are multiple centers in the country and in the developing countries who have requested us to impart knowledge as well as training to set up a similar facility and we are enthusiastic in serving as the nodal training centre in taking this modality forward. The 1~st~ world Rhenium congress to be held in Coimbatore, India in conjunction with WARMTH has been envisaged with a similar purpose in mind, i.e., to give a hands on experience to the delegates and engender confidence to explore the potential utility of Re 188.
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S7-02: Percutaneous Ablation Therapy - State of the Art

**Réto Bale**

University Clinic of Radiology, Microinvasive Therapy, Medical University of Innsbruck, Innsbruck, Austria

Percutaneous radiofrequency ablation (RFA) is a minimal invasive potentially curative local ablative tumour treatment with very low morbidity and mortality rates as compared to surgery. Recent studies have shown that patient long-term survival data after RFA of primary and secondary liver tumors approach the resection data despite inclusion of patients with a poorer prognosis due to comorbidities or disadvantageous tumour distribution.

However, since most of the data still favour resection conventional RFA is currently only considered the primary local tumour treatment in combination with surgery or in patients with unresectable colorectal liver metastases (CRLM). However, for hepatocellular carcinoma RFA is considered to be equally effective as compared to surgical resection. Recent improvements in ablation technology (probe design; simultaneous application of multiple probes; alternative ablation methods including microwave; electroporation and cryotherapy) and the application of stereotaxy for probe placement have led to local control rates approaching the rates of R0 resections. If stereotactic radiofrequency ablation (SRFA) achieves similar survival rates as compared to resection it may be the method of first choice in patients with potentially resectable primary and secondary liver tumors. Randomised controlled studies comparing resection and stereotactic ablation could finally answer the title question.
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S7-03: Selective Internal Radiation Therapy in Hepatic Metastases from Uveal Melanoma. Treatment Response in Comparison to Transarterial Chemoembolization with Fotemustin

**Heying Duan, Alexander Haug, Fredrik Waneck, Martin Funovics, Gundula Berzaczy, Christoph Holler, Martha Hoffmann**

Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria

**Aim:** Uveal melanoma is a rare tumor, which metastasizes primarily into the liver. The time from diagnosis to hepatic metastases varies strongly from 5 up to 240 months with a median of 36 months. The survival rate after detection of hepatic metastases is bad with a median 1-year survival of \<30%. Selective internal radiotherapy (SIRT) labelled with Yttrium-90 is used for several years in the treatment of primary or secondary liver tumors. This study aims to evaluate the therapy response of SIRT in hepatic metastases derived from uveal melanoma. We also aim to compare the results concerning time to progression and overall survival in patients with the same tumor entity, who received fotemustin mixed with iodinated poppy seed oil via transarterial chemoembolization (TACE).

**Materials and Methods:** Hitherto we included 20 patients (7 females and 13 males) aged 38--74 years (mean 59 years) who received SIRT for hepatic metastases from uveal melanoma. Imaging with CT or MRI was performed before SIRT and approximately 3 months after intervention to assess tumor response. Further imaging was performed in an interval of approximately 3 months. All patients underwent Tc-99m macroaggregated albumin (Tc-99m MAA) scintigraphy 1 week prior to SIRT for evaluation of potential extrahepatic uptake. Response to treatment and progression-free survival, as well as overall survival were calculated. The results were then compared with a cohort of patients suffering from the same disease in comparable conditions who were treated with Fotemustin via TACE.

**Results:** A mean treatment dose of 1.5 ± 0.5 GBq Y90-SIR-Spheres was applied. After 1 SIRT (only 2 patients, who initial showed partial response with progression were treated a second time), 7 patients showed partial response (PR) with a median time to progression of 7 ± 2.9 months (range: 3--25 months) and 6 patients showed stable disease with a median time to progression of 8 ± 1.9 months (range 3--14 months). 5 patients showed progressive disease (PD). 10 patients died of progressive disease within the observation period with a mean overall survival time of 8.5 ± 3.9 months (range: 1--32 months). Concerning TACE with Fotemustin, the included 21 patients required up to 6 interventions and showed a mean progression free survival of 7.3 months (3.3--11.3 months). Comparing to 1 intervention with SIRT, the results are quite similar, but concerning safety and adverse events, with SIRT, patients showed only minor symptoms like pain and nausea during the intervention while with TACE, patients had heavier and longer lasting symptoms like fever, pain and nausea, which required medication. Additionally, multiple interventions were required.

**Conclusion:** With these preliminary results we want to show the efficacy and safety of SIRT in isolated hepatic metastases derived from uveal melanoma and to compare the results with the previous in house standard approach with Fotemustin via TACE. Our preliminary results were promising by indicating a superiority of SIRT concerning adverse events and quality of life with equal efficacy compared to TACE.
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S7-04: Yttrium-90 Intra-Arterial Radioembolization Therapy of Unresectable Intrahepatic Cholangiocarcinoma: 5-Year Experience at a Single Center

**Hanna Svirydenka, Cinzia Pettinato, Fabio Monari, Francesco Ceci, Cristina Mosconi, Elena Tabacchi, Silvia Sanfilippo, Cristina Nanni, Eleonora Giampalma, Rita Golfieri, Aviral Singh, Stefano Fanti**

Department of Nuclear Medicine, Sant\'Orsola-Malpighi Hospital, Bologna, Italy

**Aim:** The aim of this study is to assess the safety and efficacy of intra-arterial radioembolization (IARE) of unresectable intrahepatic cholangiocarcinoma (ICC) with yttrium-90 (90Y) to promote its wider clinical application.

**Materials and Methods:** This retrospective study included 17 patients (age range 47--82 years, median age 66 years; 11 male, 6 female) diagnosed with ICC treated with ^90^Y IARE at a single institution during a 5-year period, from 2009 to 2014. Patient selection criteria included: histologically proven diagnosis of ICC, unresectable tumor, an EGOS (WHO) performance score of 0, 1 or 2, adequate baseline hematology and life expectancy of at least 3 months. The general tumor profile was observed and documented. Pre- and post-therapy the following criteria were assessed: (1) Biochemical and clinical toxicity according to CTCAE v3.0, (2) CT imaging at baseline and response according to mRECIST at 1, 3 and 12 months, and (3) median survival after the first treatment using Kaplan--Meier method. The baseline bilirubin level was \<1.3 mg/dL in 14 of 17 patients. The medium radioactivity given was 1.45 ± 0.43 GBq.

**Results:** The tumor profile demonstrated: Peripheral tumors = 1/17 (5.9%), infiltrative tumors = 16/17 (94.1%); solitary tumor = 1/17 (5.9%), multifocal disease = 16/17 (94.1%); tumor volume \<25% of liver volume = 16/17 (94.1%); liver-only disease = 16/17 (94.1%) patients. At the time of treatment, 6/17 patients had imaging findings indicative of portal venous thrombosis (PVT), and 10/17 patients presented with cirrhosis According to mRECIST criteria on imaging with CT, follow-up at 1 month demonstrated PR in 2/17 (11.8%), CR in 0/17 (0%), PD in 2/17 (11.8%), and SD in 13/17 (76.4%) patients. At 3 months of follow-up we observed PR in 1/15 (6.7%), SD in 9/15 (60%), CR in 2/15 (13.3%), PD in 2/15 (13.3%) patients, 2 patients died, and no information was available for 1/15 patient. At 12.month follow-up and we observed PR in 1/12 (8.3%), SD in 2/12 (16.7%), PD in 7/12 (58.3%) and CR in 0/12 (0%) patients, 5 patients were deceased, and no information was available for 2/12 patients. The median follow-up was 15.1 (range, 2--40) months, and the median survival after ^90^Y IARE was 15.9 months, except for 1 patient with only a 3-month follow-up which was excluded from this analysis - Post-treatment minor adverse effects were reported in 4 (23.5%) patients, which was associated with post-embolization syndrome (fatigue, transient abdominal pain, fever, and nausea/vomiting). We did not observe any hematological toxicity following IARE.

**Conclusions:** ^90^Y Intra-arterial radioembolization (IARE) promises to be a relatively safe and efficacious treatment for unresectable ICC. As demonstrated in this study IARE for ICC appears to confer a survival benefit of almost 16 months compared to systemic therapies. It demonstrates a favorable response by imaging criteria and has an acceptable post-procedural safety profile. Larger series and longer follow-up are needed to provide more reliable results and to further assess its impact on clinical management of unresectable ICC.
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S7-05:

In Situ

Vaccination: The Synergistic Roles of Immunotherapy and Radiobioconjugate Targetted Therapy

**Daya Hazra, Ajai Shukla, Nirmal Painuly, Praveen Tyagi, Padmamalika Hazra**

Innovative Cancer Therapy and Research Foundation, Agra, India

**Objectives:** To examine the evidence for the *in situ* vaccination phenomenon in Cancer Radiobioconjugate therapy, and suggest ways to maximise this.

**Methods:** Computation of the radiation doses delivered during radiobioconjugate targeting with special reference to hepatic metastases treated with 131 I labelled M3 antibody directed against the TPS tissue polypeptide specific antigen. Comparison with radiation doses delivered by external radiotherapy. Literature search regarding other evidence of synergy between immunotherapy and radiobioconjugate therapy. Measurement by immunoradiometric asssay of effects of external radiotherapy on circulating TPS levels during local irradiation of experimental animal tumours.

**Results:** Patients with hepatic metastases from colon carcinoma showed palliative effects with intravenous administration of 131 Iodine labelled anti TPS M3 antibody at doses of 25 Rads. Serial TPS estimations by immunoradiometric assay IRMA in experimental mice with xenografts of breast carcinoma created with MCF 7 cell lines injected subcutaneously showed rise in circulating TPS levels after external irradiation. Literature search supported the concept of *in situ* tumour vaccination inducing an anti tumour effect synergistic with the effect of radiobioconjugates. Such effects were possibly favoured by the repetitive continuous low dose rate radiation in radioimmunotherapy as contrasted to the mega doses in external radiotherapy.

**Conclusions:** In situ vaccination is a possible mechanism for the beneficial effects of radiobioconjugate Therapy although delivering radiation doses much less than the 60 rads used in external radiotherapy. The immune effects may be enhanced by external irradiation or cytokines or thermal warming of the tumour sites, or by the use of adjuvants locally, Toll like receptor agonists such as in recent trials combining local radiotherapy with intratumoral administration of toll like receptor (TLR) agonists or agents which recruit dendritic cells to the tumour.
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S7-06: Personalized Dosimetry with Intensification Using 90Y-Loaded Glass Microsphere Radioembolization Induces Prolonged Overall Survival in Hepatocellular Carcinoma Patients with Portal Vein Thrombosis

**Etienne Garin, Yan Rolland, Sophie Laffont, Julien Edeline, Eveline Boucher**

Cancer Institute Eugene Marquis, Rennes, France

**Aim:** To evaluate the response rate and survival of hepatocellular carcinoma (HCC) portal vein thrombosis (PVT) patients treated with ^90^Y-loaded glass microspheres (Therasphere^®^) using a personalized dosimetry and intensification concept.

**Material and Methods:** Therasphere^®^ was administered to 41 HCC PVT patients (main = 12; lobar/segmental = 29). 99mTc-Macroaggregated albumin (MAA) Single-photon emission computed tomography (SPECT)/computed tomography (CT) quantitative analysis was used to calculate the tumor dose (TD), healthy injected liver dose (HILD), and injected liver dose (ILD). Response was evaluated at 3 months using European Association for the Study of the Liver (EASL) criteria, with CT follow-up lasting until disease progression or death. Survival was assessed using the Kaplan--Meier method.

**Results:** The mean injected activity was 3.1 ± 1.5 GBq and mean ILD 143 ± 49 Gy. Applying a TD threshold of 205 Gy, MAA SPECT/CT achieved a 100% sensitivity and 90% overall accuracy (0 - false negatives; 4 - false positives) in response prediction. Based on TD and HILD values, 37% of patients received an intensification of the treatment (increased injected activity with the aim of achieving a TD ≥205 Gy and HILD \<120 Gy, applying an ILD \>150 Gy). This resulted in a high response rate (85%) without increased liver Grade ≥ III toxicity (6% vs. 12% in the non-boosted patients, ns). For the total 41 patients, median overall survival (OS) was 18 months (m) (range: 11--25). For patients with a TD \<205 Gy, median OS was 4.3 m (3.7--5 m) versus 18.2 m (8.5--28.7 m) for those with a TD ≥205 Gy (*P* = 0.005). Median OS was 20.9 m for patients with a TD ≥205 Gy and good PVT targeting (*n* = 36). OS was 12 m (3--∞) for patients with main PVT versus 21.5 m (12--28.7) for those with segmental or lobar PVT (ns). For the five patients with complete portal vein revascularization who underwent lobar hepatectomy, median OS was not reached, yet exceeded 24.5 m and was significantly higher than that of other patients (*P* = 0.0493).

**Conclusion:** Using a MAA SPECT/CT personalized dosimetry and intensification concept with ^90^Y-loaded glass microspheres induced prolonged OS for PVT patients as compared to the standard of care (sorafenib), without increasing liver toxicity. Prospective randomized studies are therefore warranted.
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S7-07: 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Detection of Local Recurrence in Patients of Hepatocellular Carcinoma Post Transarterial Chemoembolization

**Muhammad Numair Younis, Hamid Naseer, Khuram Shafiq Khan, Ahmad Qureshy,**

Irfan Ullah Khan, Abubaker Shahid Institute of Nuclear Medicine and Oncology, INMOL, Lahore, Pakistan

**Objective:** The study aimed at evaluation of patients of Hepatocellular carcinoma (HCC) post transarterial chemoembolization (TACE) using ^18^F-FDG PET.CT imaging (PET) for detection of local recurrence.

**Materials and Methods:** Post TACE patients of HCC underwent PET scan 45--60 min after intravenous administration of 7.10 mCi of ^18^F-FDG. 21 patients were imaged between 6 and 18 months after undergoing TACE. The contrast enhanced imaging was performed at GE PET Scanner hybrid with 16 slices CT. Scoring based on visual analysis combined with standardized uptake value (SUV) was done in each patient using mediastinal activity as standard. PET was compared with CT as well as serum α-Fetoprotein (AFP) where available. Management decision by the oncology team was done as repeat TACE, chemotherapy or follow up in these patients considering all available clinical data. Data was analyzed using software SPSS version 17.0.

**Results:** PET showed heterogeneous pattern of FDG uptake in HCC lesions ranging from low to high degree in reference to mediastinum activity. SUV ranged from 1.1 to 5.9 with a mean value of 3.5. Based on scoring, 47% patients were categorized as local recurrence, 38% as without local recurrence and 15% patients were borderline requiring further evaluation. PET detected recurrence in 47% as against 28% on CT. Correlation of scoring and AFP was in concordance significantly (*P* \< 0.014). Management groups were repeat TACE for 18%, chemotherapy for 53% and 29% follow up.

**Conclusions:** PET is efficient in detecting local recurrence of HCC after TACE, has better performance than CT and good correlation with AFP. PET may be considered for post TACE evaluation of all patients where AFP is rising even if CT is negative.
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S7-08: Personalized Dosimetry Techniques in Y-90 SIR-Spheres Radioembolization-Singapore General Hospital Experience

**Butch Magsombol**

Singapore General Hospital, Outram Park, Singapore Radioembolization is a novel technique for targeted treatment of inoperable primary as well as for metastastic liver tumors. Although an established procedure, it can be complex to extremely challenging as patients present with variations in the vascular anatomy. Blood flow to the tumors can be heteregenous from one patient to another or even in the same patient hence the need for personalized approach to treatment. In 2011 our institution have developed and adapted an imag-guided personalized predictive dosimetry technique by artery-specific Single-photon emission computed tomography-computed tomography (SPECT/CT) partition modeling. In essence, this combines or intergrates various techniques such as CT hepatic agiogram for a more selective or a superselective injection of Tc-99m MAA, SPECT/CT MAA and partition modeling for a unified approach to dosimetry. This in our opinion achieves a high clinical success for effective and safe Y-90 radioembolization.

**Address for correspondence:**

Dr. Butch Magsombol, Singapore General Hospital, Singapore. E-mail: <butchmagsombol@gmail.com>

Abstracts - Scientific Session 8: Peptide Receptor Radionuclide Therapy: S8-01 The LUPPET Study: 177Lu-DOTA-Peptide Radionuclide Therapy in Fluorodeoxyglucose Positron Emission Tomography Positive/Negative Patients. A Metabolism Guided Personalized Medicine for Gastroenteropancreatic Neuroendocrine Tumors

**Giovanni Paganelli**

IRST-IRCCS, Nuclear Medicine and Radiometabolic Therapy Union, Meldola, Italy

Peptide receptor radionuclide therapy with (PRRT) is one of the most active therapies in patients (Pts) with disseminated G1--G2-gastro-entero-pancreatic (GEP) neuroendocrine tumors (NETs). However, 25--30% of these patients do not respond to PRRT. An increased glucose metabolism is a characteristic of many tumors and this metabolic pathway correlates with a higher degree of malignancy. FDG PET--CT is a non invasive, whole body imaging procedure able to visualize *in vivo* the glycolytic activity of all tumor lesions. Fourty to 60% of GEP-NETs have increased glucose metabolism and a different grade of uptake may occur in different lesions (primary and metastases) within the same patient. Generally, PRRT-non responders Pts are FDG.positive. Our hypothesis is that, GEP-NET patients with FDG-avid lesions, would benefit more from a combination of PRRT plus a chemiotherapeutic agent. The scope of the LUPPET protocol is to select GEP-NETs Pts candidate for PRRT, not only based on a positive octreoscan/68 Ga-DOTA-Peptide scan and ki67 score, but also on the outcomes of the PET/FDG scan.

**Methods:** FDG-PET negative or positive GEP-NETs patients will be randomly assigned to two different protocols:

**LU-NET Study Design:** Patients with pancreatic NET (P-NET) or gastrointestinal NET (GI-NET) PET-FDG negative will be randomly assigned to two arm with two different dosages of PRRT with 177Lu Dotatate (Lu-tate): ARM 1: seven cycles of 3.7 GBq (total 25.9 GBq) - ARM 2: five cycles of 3.7 GBq (18.5 GBq total activity). In both groups PRRT will be followed by maintenance with SSA long acting (SS-LAR). Randomization will be stratified according to site of disease. The primary objective is to evaluate the disease control rate (DCR) at 12 months and safety at two different dosage levels. The secondary objectives are: progression free survival (PFS), late toxicity, quality of life (QOL) and overall survival (OS). LU-CA Study Design: FDG positive patients (P-NET or GI-NET) will be randomly assigned to two independent studies each with two different arms:

ARM1: oral low dose of capecitabine in association with 177Lu-Dotatate in seven cycles of 3.7 GBq (total 25.9 GBq) followed by SS.LAR and low dose of capecitabine. ARM2: 177Lu-Dotatate at 3.7 GBq/cycle for 7 cycles (total 25.9 GBq) followed by SS-LAR. The primary objective is to evaluate the progression free survival (PFS) in the two arms.

The secondary objectives are: the DCR, acute and late toxicity, quality of life, overall survival (OS) and the validation of prognostic role of FDG-PET for a precision medicine.

LU-NET end point is to determine the Minimal Effective Dosage still missing in PRRT.

LU-CA end point is to verify if the addition of capecitabine to PRRT increases the PFS and prolongs the OS.

**Expected Results:** Within each of the two protocols (LU-CA and Lu-NET), the random allocation of patients will answer to the pending clinical questions in PRRT: (i) Whether it is more effective in patients with FDG-PET positivity to receive a combined treatment with a chemotherapeutic and radiosensitizer agent. (ii) Whether it is sufficiently efficacious to receive a lower dosage (5 cycle vs. 7), in order to spare unnecessary irradiation to normal organs overcoming the "one fits al" concept of current PRRT.
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S8-02 From Molecular Imaging Using Positron Emission Tomography/ Computed Tomography to Personalized Therapy - 16 Years of Theranostics Experience in Neuroendocrine Tumors at the Bad Berka NET Center of Excellence?

**Harshad R. Kulkarni, Richard P. Baum**

Theranostics Center for Molecular Radiotherapy and Molecular Imaging (PET/CT), Bad Berka, Germany

The strong expression of somatostatin receptors (SSTR) by neuroendocrine tumors (NETs) enables diagnosis using Ga-68 SSTR PET/CT, as well as peptide receptor radionuclide therapy (PRRT), the molecular internal radiation therapy of NETs. Patient selection for PRRT is based on the Bad Berka Score (BBS), which takes into account clinical aspects and molecular features, including SSTR expression on the tumors, which is determined by Ga-68 SSTR PET/CT. Since 2004, almost 10,000 PET/CTs using Ga-68 have been performed. For kidney protection, patients are well hydrated and receive an amino acid infusion containing lysine and arginine given intravenously for 4 hours beginning 30 min before PRRT. Renal function is serially determined by Tc-99m MAG3 scan (TER) and by Tc-99m DTPA (GFR) measurements. After each 2 treatment cycles, restaging is performed by morphologic (CT/MRI) and molecular imaging (Ga-68 SSTR PET/CT), metabolic imaging (at least one F-18 FDG PET/CT before start of treatment), and in selected cases also F-18 fluoride PET/CT, blood chemistry and tumor markers. Another very important aspect is dosimetry. Estimation of tumor and normal organ doses performed after PRRT (using Lu-177 labeled somatostatin analogues DOTATATE or DOTATOC) is important to ensure that maximum dose is delivered to the metastases, therefore optimizing an individualized treatment protocol. Retrospective analysis was performed using our database (containing \>250 items per patient) in 1000 patients (age 4--85 years) with metastatic and/ or progressive NETs, undergoing 1.9 cycles of PRRT at our center using Lu-177 (*n* = 331), Y-90 (*n* = 170) or both (n = 499). Median total administered activity was 17.5 GBq. Patients were followed up for up to 132 months after the 1^st^ cycle of PRRT. Well.differentiated NETs (G1.2) accounted for 54%. Most patients (95.6%) had undergone at least 1 previous therapy (surgery 86.8%, medical therapy 55%, ablative therapy 14.2% and radiotherapy 3.4%). The median overall survival (OS) of all patients from the start of PRRT was 52 months (mo). Median OS according to radionuclide used: Y-90 24 mo, Lu-177 55 mo, both (TANDEM or DUO PRRT) 64 mo; according to the grade of tumor: G1 87 mo, G2 55 mo, G3 28 mo, unknown 50 mo; and according to origin of primary tumors: pancreas 45 mo, small intestine 77 mo, unknown primary 55 mo, lung 36 mo. Median progression.free survival (PFS) measured from the last therapy cycle was 22 mo, comparable for pancreatic (23 mo) and small intestinal (25 mo) NETs. We have also treated patients with progressive metastases of NETs and with a single functional kidney (24 patients). None of these patients showed grade 3 or 4 nephrotoxicity. PRRT resulted in partial remission in 36% and stable disease in 36% of the patients, 28% had PD. In 2009, we have given fractionated low dose PRRT to 2 patients on hemodialysis (to the best of our knowledge, this was the first ever worldwide experience). The Bad Berka neuroendocrine tumor center was the first also to use Y-90 DOTATATE. In a large patient group (\>350 patients), Lu-177 DOTATOC was administered for PRRT of progressive NETs, non-responsive to octreotide/ interferon treatment or chemotherapy. Historical comparison to established treatment modalities showed a significant benefit in progression free survival (PFS) or time to progression (TTP), e.g., compared to Octreotide LAR (PROMID study) PFS vs. TTP was 16 months longer, and compared to Sunitinib and Everolimus, respectively, PFS there was an improvement of PFS by 19 months.

In a particular patient, tumor lesions exhibit various sizes with inhomogeneous distribution of somatostatin receptors. The use of a combination of Lu-177 and Y-90 takes this heterogeneity into account. Sequential administration of Y-90 and Lu-177 labeled analogues is useful for the treatment of larger tumors, followed by treatment of smaller metastases, respectively in further treatment cycles. The BBNETC group pioneered the systematic use of Y-90 and Lu-177 DOTATATE (DUO PRRT) in sequence and concurrently, as well as the intra-arterial use of Y-90 DOTATATE and DOTATOC. Lu-177 DOTATATE or Lu-177 DOTATOC is predominantly used for small metastases or in patients with impaired renal or haematological function. Long term follow-up of up to 10 years after DUO PRRT showed no significant grade 3 or grade 4 nephrotoxicity attributed to concurrent or sequential DUO PRRT. The median fall in tubular extraction rate (TER) was lesser in patients undergoing DUO PRRT than in those undergoing PRRT with Y-90 alone.

**Conclusions:** PRRT lends a significant benefit in progression free survival as well as in overall survival in metastasized and/or progressive G1.2 NETs as compared to other treatment modalities and regardless of previous therapies. Combination of Lu-177 and Y-90 (DUO) based PRRT may be more effective than either radionuclide alone. Thus, in patients with progressive NETs, fractionated, personalized PRRT with lower doses of radioactivity given over a longer period of time (Bad Berka Protocol - "long term low dose, not short term high dose concept") is effective even in advanced cases and results in excellent therapeutic responses. More than 10 cycles of PRRT, given over several years were tolerated very well by most patients. Severe renal toxicity can be completely avoided or reduced by nephroprotection applying aminoacids; haematological toxicity is usually mild to moderate (except for some cases of MDS which occurs in 2--3%). Personalized PRRT according to the disease profile and patient condition yields better outcome and survival with improved quality of life. Though cure is rarely possible, excellent palliation with significant improvement of symptoms can be achieved by PRRT. In addition, neoadjuvant PRRT could be administered in cases of inoperable NET so as to render the tumor operable by inducing radiation induced necrosis and decrease in tumor size. Use of intra-arterial PRRT (\>100 treatments were already performed up to now at our center) is more effective for selectively targeting liver metastases and large, inoperable primary tumors. PRRT should only be performed at specialized centers as NET patients need highly individualized interdisciplinary treatment and long term care. PRRT can be effectively combined with transarterial chemoembolization (TACE), radiofrequency ablation (RFA), chemotherapy (e.g. using capecitabine/5.FU, temozolomide or doxorubicin), and kinase inhibitors (e.g. Everolimus). In future, systematic (randomized) prospective clinical trials (like the NETTER.1 study) are urgently needed to compare the results of PRRT with other treatment modalities in defined subset of patients (e.g. midgut NET, pancreatic NET, lung NET). The THERANOSTICS approach has recently been successfully applied also in metastatic, castrate resistant prostate cancer.
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S8-03: Results of Dosimetry.Based Peptide Receptor Radionuclide Therapy (DOTA-THER)

**Anibale Versari**

Department of Nuclear Medicine, PET Center, Reggio Emilia, Italy

Abstract not available.

S8-04: Control-Nets; An Evidence Base for Radiosensitizing Chemotherapeutic Peptide Receptor Radionuclide Therapy of Advanced Gastro-Entero-Pancreatic. Neuroendocrine Tumors

**Harvey Turner**

The University of Western Australia, Fiona Stanley Hospital, Murdoch, Australia Single centre prospective Phase 2 studies of combination of capecitabine and temozolomide with 4 cycles of 7.9 GBq Lutetium-177 octreotate PRRT at 8 week intervals have demonstrated favourable patient outcomes with enhanced quality of life, in a practical, affordable, safe outpatient treatment. Progressive advanced metastatic G1/2 GEP-NETS have been controlled and significant durable objective tumour response rates achieved; CR 16% PR 41% SD 37% PD 6% with median PFS 31 months.\[1\] Even better results were achieved with the same regimen in pancreatic NETS; ORR 80% CR 13% PR 70% SD 20% and no disease progression on study. Median PFS for this cohort of 30 pNET patients was 4 years. No dose-limiting toxicities were encountered and no grade 4 adverse events were seen.\[2\] A multi-centre Australasian randomized controlled trial CONTROL-NETS (Capecitabine ON Temozolomide Radionuclide therapy octreotate lutetium-177 Neuro.Endocrine Tumours Study) has commenced and is designed to provide a compelling evidence base to encourage the adoption by oncologists of radiosensitizing chemotherapeutic PRRT into mainstream practice in treatment of GEP-NETS.
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S8-05: A Retrospective Comparison Between 68Ga-DOTA-Tyr (3)-Octreotide Positron Emission Tomography/ Computed Tomography and 18F-DOPA Positron Emission Tomography/Computed Tomography in Patients with Extra-adrenal Paraganglioma for Planning Peptide Receptor Radionuclide Therapy

**Alexander Kroiss, Christian Uprimny, Clemens Decristoforo, Andreas Frech, Lydia Posch, Rudolf Wolfgang Gasser, Claudia Goetsch, Barry Lynn Shulkin, Georg Mathias Sprinzl, Christoph Url, Rupert Prommegger, Gustav Fraedrich, Irene J. Virgolini**

Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria

**Aim:** ^18^F-Fluoro-L-dihydroxyphenylalanine (^18^F-DOPA) PET offers high sensitivity and specificity in the imaging of nonmetastatic extra-adrenal paragangliomas (PGL) but lower sensitivity in metastatic or multifocal disease. These tumors are of neuroendocrine origin and can be detected by ^68^Ga-DOTA-Tyr (3)-octreotide (^68^Ga-DOTA-TOC) PET. Therefore, we compared ^68^Ga-DOTA-TOC and ^18^F-DOPA as radiolabels for PET/CT imaging for the diagnosis and staging of extra-adrenal PGL. Combined cross-sectional imaging was the reference standard.

**Methods:** A total of 5 men and 15 women (age range 22--73 years) with anatomical and/or histologically proven extra-adrenal PGL were included in this study. Of these patients, 5 had metastatic or multifocal lesions and 15 had single sites of disease. Comparative evaluation included morphological imaging with CT and functional imaging with ^68^Ga-DOTA-TOC PET and ^18^F-DOPA PET. The imaging results were analysed on a per-patient and a per-lesion basis. The maximum standardized uptake value (SUVmax) of each functional imaging modality in concordant tumor lesions was measured.

**Results:** Compared with anatomical imaging, 68Ga-DOTA-TOC PET and ^18^F-DOPA PET each had a per-patient and per-lesion detection rate of 100% in nonmetastatic extra-adrenal PGL. However, in metastatic or multifocal disease, the per-lesion detection rate of ^68^Ga-DOTA-TOC was 100% and that of ^18^F-DOPA PET was 56.0%. Overall, ^68^Ga-DOTA-TOC PET identified 45 lesions; anatomical imaging identified 43 lesions, and ^18^F-DOPA PET identified 32 lesions. The overall per-lesion detection rate of ^68^Ga-DOTA-TOC PET was 100% (McNemar, *P* \< 0.5), and that of ^18^FDOPA PET was 71.1% (McNemar, *P* \< 0.001). The SUVmax (mean ± SD) of all 32 concordant lesions was 67.9 ± 61.5 for ^68^Ga-DOTA-TOC PET and 11.8 ± 7.9 for ^18^F-DOPA PET (Mann--Whitney U-test, *P* \< 0.0001).

**Conclusion:** ^68^Ga-DOTA-TOC PET may be superior to ^18^F-DOPA PET and diagnostic CT in providing valuable information for pretherapeutic staging of extra-adrenal PGL, particularly in surgically inoperable tumours and metastatic or multifocal disease.
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S8-06: Severe Haematological Complications Associated with Peptide Receptor Radionuclide Therapy: 15 Years of Experience at Bad Berka

**Aviral Singh, Harshad Kulkarni, Karin Niepsch, Richard P. Baum**

Theranostics Center for Molecular Radiotherapy and Molecular Imaging, ENETS Center of Excellence, Zentralklinik Bad Berka, Bad Berka, Germany

**Aim:** Peptide receptor radionuclide therapy (PRRT) in NETs is known to be effective and relatively well.tolerated when conducted in accordance with a multi.disciplinary team approach, in large and well-equipped medical centers. Despite following an educated patient selection criteria and careful management planning, variable degrees of renal toxicity and haematotoxicity have been reported. We report the risk and incidence of severe haematological complications observed in 1276 patients treated at Zentralklinik Bad Berka GmbH (ZBB) with Y.90, Lu-177, and combined Y-90 and Lu-177 PRRT for NETs, and other SSR-expressing tumours.

**Materials and Methods:** From 1999 to 2014, a total of 1276 patients (719 males, 557 females; age range = 4--85 year; mean age = 59.5 year) diagnosed with histologically proven progressive NET or other SSR.positive tumour, were treated with 4429-cycles of PRRT with either Y-90 (N = 1584) or Lu-177 (N = 2845) labelled radiopeptides at ZBB. Patient selection for PRRT was performed according to the Bad Berka Protocol. In cases of severe and refractory haematotoxicty, bone marrow biopsy was performed. Severe haematotoxicity was graded according to CTCAE v3.0 criteria. A retrospective review and analysis of extensively recorded data was performed for this study. Patients with severe haematological complications were selected; follow-up with medical records and phone enquiry with patients\' family doctor was made to confirm the survival status of these patients. Two distinct groups were identified: Group A -- Patients with haematological malignancy, Group B -- patients with severe or life.threatening (Gr 3--4) haematotoxicity according to CTCAE v3.0. Tumour profile, grade and proliferation indices; patient functional performance status; survival status, radionuclide used, radioactivity administered, and possible risk factors were reviewed and analysed. Risk and Incidence of developing haematological complications in PRRT were analysed.

**Result:**

Group A: Patients with haematological malignancy 24/1276 patients (12 males, 12 females; age range 40--71 year, median age = 60 year) were found to have haematological malignancy during PRRT. 2/24 patients had previously diagnosed MDS/MPS (CML = 1; MPS (unclassified) = 1), and were excluded from this analysis. 22/1276 (1.72%) patients were diagnosed with haematological malignancy on bone marrow biopsy. Primary tumour profile of this group: NET 21/22 \[(GEP-NET = 19; of which Pancreas = 10, Ileum = 8, Duodenum = 1); and CUP.NET = 2\], and Paraganglioma = 1 patients. WHO disease stage ranged from IIIB-IV. Tumour proliferation Index (Ki-67): G1 = 6, G2 = 7, G3 = 1, and unknown = 9 patients. Karnofsky performance score varied form 70--100%. PRRT was performed with variable combinations and regimens of Y.90, Lu-177 along the principles of personalized medicine. At the time of analysis, 8/22 (36.36%) patients were alive, and 14/22 (63.63%) had been deceased. Reason for death: 9/22 = disease progression, 2/22 = Acute Leukemia, 1/22 = Neutropaenic septic shock secondary to LRTI, 1/22 = irreversible coma secondary to CVA/stroke, and information was not available for 1/22 patient. In this group, Myeloid neoplasms were observed in 18/22 (81.18%) patients: \[AML = 3, MDS = 15 (MDS-U = 13, t-MDS (RAEB Type 2) = 1, RAEB-Type-1 = 1)\]; MDS/MPS (CMML-Type-1) = 1/22 (4.54%) patient; Lymphoid neoplasms were noted in 2/22 (9.09%) patients: \[CLL (NHL) = 1; Lymphomatoid Granulomatosis = 1\]; and undifferentiated neoplasm represented by acute leukemia of ambiguous lineage, was observed in 1/22 (4.54%) patient.

Group B: Severe or life-threatening (G3-4) Haematotoxicity.

This group represented 15 patients (6 males, 9 females; age range 40--74 year, median age = 52 year). Primary tumour: GEP-NET 13/15 (pancreas = 9, ileum = 3, rectum = 1); and CUP.NET = 2 patients. WHO disease stage ranged from IIIB-IV. Tumour proliferation index (ki-67): G1 = 4, G2 = 7, G3 = 1, and unknown = 3 patients. Karnofsky performance score varied form 40--100%. At the time of analysis, 7/15 (46.66%) patients were alive, and 8/15 (53.33%) had been deceased. Reason for death was disease progression in all patients, and 1 patient died of septic shock secondary to LRTI in association with pancytopaenia. PRRT profile: Y-90 only = 3/15 (20%); Lu-177 only = 3/15 (20%); Y-90 and Lu-177 9/15 (60%) patients. 56 PRRT cycles were performed; with Y-90 in 22/56 (39.28%) patients (radioactivity range = 1.5.5.3 GBq, total = 83.7GBq, mean = 3.8 GBq); and with Lu-177 in 34/56 (60.71%) patients (radioactivity range = 3.9--9 GBq, total = 216.6 GBq, mean = 6.37 GBq). Grade 1--4 degree of uni-, bi- or tri- corpuscular haematotoxicities were observed: Thrombocytopaenia (G3--4) in 12/15 (80%), and Pancytopaenia (G3--4) in 9/15 (60%) patients. All cases of recoverable haematotoxicity were treated in accordance with national guidelines. Overall, the following co-existing risk factors for the development of haematological toxicity during PRRT were identified: previous history of myelosuppression, large bone marrow tumour burden, chemotherapy, radio.sensitising therapy (RST) agents, IMRT/EBRT, and TACE. In this cohort of patients, the risk and incidence of developing haematological malignancy during PRRT was 0.017 and 1.724 respectively; the risk and incidence of developing severe or life.threatening haematotoxicity during PRRT was 0.01 and 1.17 respectively. Combined risk and incidence of severe haematotoxicity during PRRT was 0.02 and 2.89 respectively.

**Conclusion:** Our results conclude that given the risk and incidence of PRRT.related refractory and severe haematological complications, it is mandatory to monitor the haematology profile of these patients and recognize this pathology adequately to guide treatment planning, and attempt to reduce the identified risk factors, in order to improve the efficacy and the overall outcome in such patients. Various possible risk factors for the development of haemototoxicty were identified, which require ongoing evaluation, whilst we await the results of genomic studies in similar cohort of patients to understand the genetic susceptibility of the development of haematotoxicity in PRRT.
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S8-07: Comparison of 68Ga-DOTATATE and 68Ga-DOTATOC Uptake in Primary Gastroenteropancreatic Neuroendocrine Tumor, Metastases and Normal Liver Tissue in the Same Patient

**Mila Todorovic-Tirnanic, Milan Gajic, Richard P. Baum**

Faculty of Medicine, University of Belgrade and Center of Nuclear Medicine, Clinical Center of Serbia, Belgrade, Serbia

**Objective:** ^68^Ga-DOTATATE and ^68^Ga-DOTATOC are two frequently used Ga-68 labeled somatostatin agonist analogues. DOTATATE binds to human somatostatin receptor (hsstr) subtype 2, while DOTATOC exhibits much higher affinity for hsstr subtype 3 and 5 but has lower binding to hsstr 2 compared to DOTATATE. As hsstr expression on tumor cells significantly correlates with the standardized uptake value (SUVmax) of ^68^Ga-DOTATATE and ^68^Ga-DOTATOC, the aim of this study was to compare *in vivo* distribution of two radiopharmaceuticals by determining their SUVmax in normal liver, primary tumors and metastases in patients with gastroenteropancreatic (GEP) neuroendocrine tumors (NET).

**Materials and Methods:** Thirty eight GEP NET patients with clinically, biochemically and morphologically stable diseases who had ^68^Ga-DOTATATE and ^68^Ga-DOTATOC PET/CT performed at consecutive controls, were included into this study. Time to acquisition after injection was the same for both studies (±10 min). Seventy six PET/CT studies were analyzed. SUVmax values for both radiopharmaceuticals in the primary tumor, metastases (in the liver, lymph node, soft tissue and bone), as well as in the normal liver tissue were determined and mean SUVmax values were compared.

**Results:** Overall 243 lesions: 225 metastases (98 hepatic, 67 lymph node, 43 bones, 17 soft tissues) and 18 primary NETs were analyzed on both ^68^Ga-DOTATOC and ^68^Ga-DOTATATE PET/CT study, as well as the normal liver tissue. The mean SUVmax in the TATE/ TOC group were: normal liver 6.8 ± 1.7/6.9 ± 1.8, liver metastases 15.4 ± 9.4/17.9 ± 11.4, lymph node metastases 12.0 ± 9.5/15.2 ± 13.3, bone metastases 7.5 ± 5.7/9.9 ± 8.0, soft tissue metastases 15.3 ± 16.4/17.3 ± 18.8, primary tumor 20.4 ± 13.7/24.23 ± 20.1. A highly significant difference (TOC higher when compared to TATE) was found for primary tumors (*P* = 0.008), liver (*P* = 0.000) and lymph node (*P* = 0.000) metastases, while uptake of ^68^Ga-DOTATOC was significantly higher in bone metastases (*P* = 0.011). In soft tissue metastases accumulation of ^68^Ga-DOTATOC was higher (mean difference in SUVmax values was 2.0), but it did not reach the level of significance. In normal liver the mean difference in average values of SUVmax was only 0.07 (not significant). Both radiopharmaceuticals accumulated higher in primary tumors compared to metastases. The highest mean SUVmax for metastases were seen in the liver and in soft tissue metastases (without significant difference compared to the primary tumor), intermediate in lymph nodes (significantly lower than in primary tumor) and the lowest in bone metastases. Normal liver tissue exhibited the lowest uptake of both radiopharmaceuticals (significantly less than in primary tumors and metastases in the liver, soft tissues and lymph nodes).

**Conclusion:** In primary GEP NET tumors and their metastases ^68^Ga-DOTATOC has remarkably higher uptake compared to ^68^Ga-DOTATATE. Both radiopharmaceuticals exhibited the highest uptake in primary tumors, which was 3 (^68^Ga-DOTATATE) to 3.5 fold (^68^Ga-DOTATOC) higher than in normal liver tissue. For both radiopharmaceuticals, liver and soft tissue metastases demonstrated the highest uptake among metastases, lymph node lesions were intermediate and bone metastases showed the lowest accumulation. There was no notable difference between DOTATOC and DOTATATE accumulation in the normal liver tissue. The higher uptake of ^68^Ga-DOTATOC in primaries and metastases could be beneficial when a theranostic approach is considered.
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S8-08: Future of Peptide Receptor Radionuclide Therapy

**Lisa Bodei**

Division of Nuclear Medicine, European Institute of Oncology, Milan, Italy Abstract not available.

Abstracts - Scientific Session 9: Quality of Life: S9-01 Current Status of Quality of Life Thinking - the Systematic Incorporation of the Patient Perspective into Research and Practice

**Eva Gamper**

Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria

Aside from prolonging survival a main aim of medical interventions in oncology is improving quality of life (QOL). Of course the very general concept of QOL is difficult to capture and thus, its assessment in health care for a long time was restricted to proxy ratings of functioning levels and symptom burden. With increasing recognition of the importance of incorporating the patient\'s perspective directly into research the field of patient-reported outcome (PRO) research evolved, of which QOL is the core concept. In the evaluation of therapies it has become the gold standard to complement traditional outcome parameters such as survival and response with PROs, the patients' subjective perspective on their health and QOL. During the past years there was increasing interest of implementing PROs also in clinical practice, where they already have proved beneficial for the timely and precise identification of symptoms and psychosocial distress. In addition they may allow for a more holistic perception of the individual patient, may improve physician.patient communication and support informed and shared decision making. The presentation will provide examples on what kind of additional information can be gained by assessing PROs and QOL in clinical studies and on how PRO assessment may be used to improve patient care in clinical practice. Current developments, including web.based home assessments and online platforms for using PROs for patient empowerment and self.management, will be presented.
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S9-02: Neuroendocrine Tumors Patient Journeys

**William Claxton**

Carcinoid and Neuroendocrine Tumor Society of Singapore, Singapore

Neuroendocrine tumors - what we now describe as "NET cancer" - is a relatively rare disease which is poorly understood and is often misdiagnosed. The term neuroendocrine is meant to suggest an interaction of SST (serotonin receptor) signal pathways and secretory hormones, primarily in the gut (not the brain). So we may act a bit crazy, but it is really just because the gross effects of this disease, combined with the novel therapies, need to travel for multidisciplinary care, costs, etc., can be very disruptive to our lives. As one patient has said, "we may be anxious, but we're not nuts"! From the patients' perspective, a diagnosis of NET cancer is no longer a terminal illness. Today one can view NET cancer as a chronic disease if it is well-managed using a combination of surgical debulking, regular monitoring with receptor.based imaging techniques and properly-staged peptide receptor radiotherapy. I will share highlights of the recent INCA/Novartis Global NET Patient Survey (<http://netcancerday.org>/results- from-first-globalsurvey-of-neuroendocrine-tumor-net-patients). This study provides context to the range of stress and psychological issues faced by patients with neuroendocrine cancer. For example: "The survey found that as many as 94% of US patients made lifestyle modifications as a result of their NET, including changes to their diet, physical activities, work and social life, which confirms the significant impact of this disease that we have long observed in the patient community." The "patient hierarchy of needs" is a diagram which is based on Maslow\'s hierarchy and seeks to explain how patient needs change throughout their medical journey. This is particularly relevant for NET Cancer, because the patients survive for years or decades, often moving from victim to advocate. The insights which flow from this diagram include appropriate points at which patients can participate in registries, trial treatments, support groups, health technology assessments and advocacy organisations. The NET patient journey is ideally one in which they seek coordinated multidisciplinary care, ideally from a centre of excellence, and work collaboratively with their specialist physicians to diagnose and treat the disease. Such patients can live long productive lives.
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S9-03: Patient Education for Those Seeking Peptide Receptor Radionuclide Therapy

**Josh Mailman**

NorCal CarciNet Community, Stanford, USA

**Background:** Neuroendocrine tumors (NETs) have an incidence of 5.25/100,000 in North America.\[1\] Diagnostic and treatment choices have evolved over the last two decades to include molecular imaging and therapies. In the last decade Peptide Receptor Radionuclide Therapy (PRRT) has become more commonplace in the management of NETs in Europe but its use is still in its infancy in North America. In 2011, PRRTInfo.org was launched in English that focused exclusively on PRRT. Visitors from around the world have made the site a destination for patient centered information on PRRT treatment and Gallium 68 (Ga68) imaging with over 1,500 unique visitors a month.

**Methods:** PRRTInfo.org collects de.identified data on article selection, external web search and in site searches. Using this dataset helps us better understand what patients are interested in regarding molecular therapies and imaging for NETs. 30,000 visits and 15,000 searches were analyzed to better understand the type of information patients are looking for when considering PRRT.

**Results:** Users from the United State made up over 55% of the site visits with India, United Kingdom, Canada and Germany each accounting for 5% of site visits. While on the site the most frequently searched term is Treatment followed by PRRT, Ga68, NETs, Imaging, Theranostics and Individualized. The most read articles are on "Restaging/Follow on Treatment", followed by "What is PRRT", "Centers that offer PRRT" and "PRRT Results"

**Conclusions:** With nearly 100,000 visits to PRRTinfo.org since launch in 2011, it is clear that patient, caregivers and other medical professionals are interested in PRRT. Centers providing this type of treatment should be offering their patient community detailed information about PRRT, how it is administered and its risks and side effects.
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S9-04: Tumor Response and Health-Related Quality of Life Predict Survival after Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumor Patients

**Margarida Rodrigues, Bernhard Nilica, Sabine Buxbaum, Eva Maria Gamper, Christian Uprimny, Irene Virgolini**

Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria

**Objective:** To evaluate whether tumor response and health-related quality of life are predictors of survival in patients with metastatic NETs after peptide receptor radionuclide therapy (PRRT).

**Materials and Methods:** 40 patients (age: 34--82 years) with metastatic NETs that were restaged at 6 weeks after first full treatment cycle with PRRT (monotherapy) were evaluated. Restaging included ^68^Ga-DOTA-TOC PET/CT, ^18^FDG-PET/CT, diagnostic CT and/or MRI. Primary tumor localization was foregut in 26 patients, midgut in 11 patients, other site in 1 patient and unknown in 2 patients. Full treatment cycle (4 to 5 applications at standard intervals of 10 weeks) was performed with ^90^Y-DOTA-TOC (mean activity: 9.7 ± 5.5 GBq) in 27 patients and ^177^Lu-DOTA-tate (mean activity: 18.8 ± 8.7 GBq) in the other 13 patients. According to RECIST criteria, partial/minor response at restaging was found in 3 patients, stable disease in 21 patients and progressive disease in 16 patients. Health-related quality of life was assessed with the EORTC quality of life questionnaire core.30. Patients\' scores were compared to the general population while adjusting for the effects of age and gender, using non-parametric and variance-analytic methods. Kaplan--Meier curve method and multivariate analysis were applied.

**Results:** Overall survival ranged 3--80 months. Mean survival in patients with partial/minor response was 40.3 months (28--66 months; time to progression: \>26 months), stable disease 31.4 months (14--80 months; time to progression: 7.7--36 months) and progressive disease 7.9 months (3--13 months). The pattern of health-related quality of life impairments was heterogeneous and correlated with survival. No correlation was observed between survival and age, gender or applied radionuclide for therapy.

**Conclusion:** Tumor response and health-related quality of life are predictors of survival after first full treatment cycle with PRRT in NET patients.
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S9-05: Quality of Life: Patient Response after First Treatment

**Ivy Mateo-Vito, Rebelidad Leshen, Helena McMeekin, Shaunak Navalkissoor**

Royal Free London NHS Foundation Trust, London, United Kingdom

**Background:** New therapies for cancer are often assessed primarily on the basis of increased survival, limiting us of valuable information about other benefits and drawbacks of the treatments. Adding years to life may extend survival, but adding life to years instead is an important task. NET tumours of gut origin may cause symptoms not only from the presence of tumour in the liver but also from overproduction of hormone.like substance called serotonin which causes characteristic symptoms called carcinoid syndrome: skin flushing, diarrhoea and wheezing.

**Aim:** To assess the symptom prevalence, intensity and their relation to quality of life in patient receiving PRRT (Lu177 and Y90 DOTATATE) after the first treatment.

**Method:** 32 patients receiving PRRT (30 Lu-177, 1.Y90, 1.Y90 + Lu177) filled in questionnaires before and after first session of administration. QLQ-GINET21 is a disease-specific module for patients with gut related carcinoid and NET that contains a total of 21 items: 4 single item assessments relating to muscle and/ or bone pain, body image, information, and sexual functioning and 17 items organised into five scales: endocrine symptoms (ED; 3 items), GI symptoms (GI; 5 items), treatment related symptoms (TR; 3 items), social functioning (SF21; 3 items), disease related worries (DRW; 3 items). The response format of the questionnaire is a 4-point Likert scale with higher scores reflecting more severe symptoms. Responses to the questionnaire are linearly transformed to a 0--100 scale using EORTC guidelines.

**Result:** Results analysed according to change in overall score and change in category score. Mean change in scores following PRRT: ED 28 to 17 (--39%), GI 27 to 22 (--19%), DRW 45 to 37 (--18%), SF21 42 to 36 (--14%), S 31 to 26 (--16%), TR 17 to 22 (29%) as expected due to patients do not have any treatment yet before the 1st session.

**Conclusion:** Overall improvement in quality of life is observed after the first treatment. Largest improvement was seen in endocrine symptoms. Inevitable worsening in treatment related symptoms.
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S9-06: Symptoms Referred by Patients with Differentiated Thyroid Carcinoma During Preparation for Radioiodine Treatment

**Sofia Vaz, Rita Sousa, Teresa C. Ferreira, Angelo Silva, Ines P. Carvalho, Pedro Ratao, Ana Daniel, Lucilia Salgado**

Department of Nuclear Medicine, Portuguese Institute of Oncology, Lisbon Center, Lisbon, Portugal

**Objective:** To analyze how patients (pts) with differentiated thyroid carcinoma (DTC) feel during preparation for radioiodine therapy (RAI), either after levothyroxine withdrawal (T4-off) or with recombinant human thyroid-stimulating hormone (rhTSH) injection.

**Materials and Methods:** A single-center, retrospective and descriptive study of adult DTC pts, who were planned to RAI between April and September 2013, was performed. The questionnaire was made orally by the same Nuclear Medicine doctor, during the clinical interview, immediately before treatment, either after 6 weeks of T4 withdrawal or 2 injections of rhTSH. A general question was asked: "How did you feel during the last week?" Other 9 more specific questions, based on clinical scoring scales in thyroidology, were asked to evaluate: edema, constipation, depression/ tiredness, slower movements/thoughts, concentration problems, mood changes, housekeeping, children caring and working difficulties. Finally the clinical impression was also registered, considering the patient answers and objective examination (namely edema and slower movements/speech/thoughts). Each topic was scored from 0 (absent/without interference on daily routine) to 3 (highly present/ high interference on daily routine). We obtained data from 206 pts, 167 were female, with a mean age of 53 years (19-84). Sixty six percent of pts were T4-off (135 T4-off vs. 71 rhTSH).

**Results:** The most prevalent symptom was depression/ tiredness (56%), followed by mood changes (32%), slower movements/thoughts (31%), difficulty concentrating (26%) and edema (24%), mainly periorbital. Aspects related to daily routine, namely, children care, routine work and housekeeping difficulties affected 4, 6 and 19% of the pts, respectively. Objective examination was in accordance with the subjective complaints in 11% of the pts. The symptoms were more frequent in T4-off pts. Edema was reported 12.4 times more in T4-off pts than in pts under rhTSH; the remaining symptoms were found 3.5 to 6.4 times more in T4-off than in rhTSH pts. Some pts used score 3 to classify depression/tiredness and slower movements/thoughts, and this was observed only in T4-off pts. The maximum score of the remaining complaints was 2.

**Conclusion:** There are clinical changes associated with the preparation for RAI. In spite of the fact that the perception of these changes is subjective, in our study most of the pts complained of depression/ tiredness (56%). Of course one can argue that this could also be related to the clinical situation. Nevertheless, it deserves proper attention and management, as it can have a negative impact in the daily life. In our study, 19% of the pts referred difficulties in performing daily tasks. The frequency and intensity of complaints were higher in T4-off pts.
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S9-07: Relation of Thyroid Hormone Status with Severity of Depressive Illness

**Mohammad Mizanul Hasan, Chaman Afrooz Chowdhury, Mohammad Sayadul Islam Mullick**

Bangladesh Atomic Energy Commission, Dhaka, Bangladesh

The relation between various hormones and depression has long been recognized. Among these thyroid hormones are widely studied. Research findings show controversial findings about its impact. The objectives of the present study were to find out the relation between severity of depressive illness and thyroid hormone. This was a cross sectional study that was conducted in the National Institute of Nuclear Medicine and Allied Sciences, Dhaka, Bangladesh from January 2013 to December 2013. Consecutive purposive sampling was done to include newly diagnosed patients of depressive illness of the age group 18 years and above. A total number of 100 patients (31 male and 69 female) were included in the study. Mean age was 32 years. The severities of depression in these patients were measured by using structured clinical interview for depression (SCID) and Hamilton rating scale for depression (HAMD). The status of thyroid hormones (FT3, FT4) and thyroid stimulating hormone (TSH) of these patients were assessed. Chi-square test, Pearson correlation test, regression analysis was done in 95% confidence interval using SPSS 16. The Hamilton Rating Scale Score was ranged from 13 to 31. 87% of patients had normal thyroid function, 12% had subclinical hypothyroidism and 1% had hypothyroidism. In Chi-square test FT4 and TSH were found statistically significant. However FT3 was not significant with HAMD score. Significant relation was present in both SCID and HAMD scale with TSH. FT3 and FT4 was not related to the severity. Statistically significant positive correlation was found TSH and HAMD score. FT4 and depression score was negatively related. The study concluded that the severity of depression increases with the increment of thyroid stimulating hormone.
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S9-08: Self-reported Bone Pain in Patients Treated with Radium 223: An Example of Web-based Home-Monitoring

**Sanja Kresic, Eva Maria Gamper, Sabine Buxbaum, Visnja Kenjic, Margarida Rodrigues, Bernhard Nilica, Bernhard Holzner, Irene Virgolini**

Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria

**Objectives:** Radium 223 has shown a survival benefit and a pain palliating effect in the treatment of prostate cancer patients with osseous metastases. However, there is evidence for other oncological therapies that the information on the prevalence and severity of symptoms may be biased as a result of assessment time points, which usually are during hospital visits. In addition, bone pain in these patients so far has not been assessed in detail using a bone pain specific questionnaire. Therefore, we aimed at assessing trajectories of self-reported bone pain as well as different aspects of physical, emotional, and social well-being over the course of treatment in patients treated with radium 223, including assessments at home.

**Methods:** The treatment schedule for patients treated with radium 223 is a monthly cycle over 6 months. Eligible for our study are all prostate cancer patients treated with radium 223 at Medical University of Innsbruck. For the web-based monitoring patients are invited to complete two questionnaires on bone pain and quality of life aspects (functional assessment of cancer therapy-bone pain and prostate) on a weekly basis using a tablet PC. The software CHES was used for conducting the web-survey. Patients were asked to provide their feedback on the web-based assessment of pain and QOL in a structured interview after completion of treatment. **Results:** So far, 5 of 7 eligible patients could be engaged for the home-monitoring program. The median age of patients was 73 years. Two patients agreed on completing the questionnaires at hospital visits but declined home-assessments. The patients participating in the web-assessment reported that the assessment modality was diversified and they appreciated the attention given to their QOL. Most patients completed the survey weekly. First results on the trajectory of bone pain and QOL in this patient group will be presented at the conference.

**Conclusion:** The web-based home-monitoring is feasible in elderly patients. Home-monitoring of bone pain and QOL between hospital visits in a larger sample will provide valuable insight in the well-being of these highly palliative patients.
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S9-09: Obesity and the Heart

**Carlos D. Libhaber**

University of the Witwatersrand, Johannesburg, South Africa

There is considerable evidence in the literature that shows that obesity is associated with the development of heart failure independent of traditional risk factors. What is the process involved in the transition from obesity-associated left ventricular hypertrophy (LVH) to LV dysfunction? I will discuss the extent to which central obesity explains variations in LV diastolic function at a community level independent of LV mass (LVM), LV remodelling or haemodynamic factors; whether obesity-related increases in LVM exceeding that predicted by workload (inappropriate LVM \[LVMinappr\] or alternative haemodynamic factors explains variations in LV ejection fraction (EF) at a community level; whether regression of LVMinappr is more closely associated with improvements in EF than LVM or LVM index (LVMI); and whether obesity-associated insulin resistance may explain decreases in LV diastolic function and variations in LVMinappr. In 626 randomly selected participants over 16 years of age from a community sample with a high prevalence of excess adiposity (\~24% overweight and \~43% obese) after adjustments for a number of confounders including age, sex, pulse rate, conventional diastolic (or systolic) blood pressure (BP), antihypertensive treatment, LVMI and the presence of diabetes mellitus or an HbA1c \>6.1%; waist circumference (*P* = 0.0012) was independently and inversely associated with a reduced early-to-late transmitral velocity (E/A), with similar findings noted for e'/a' in a subset of 212 participants with tissue Doppler measurements. In 478 randomly selected participants from a community sample, waist circumference, but not BMI was independently associated with the homeostasis model assessment of insulin resistance (HOMA-IR). HOMA-IR was inversely correlated with E/A (*P* \< 0.0001) and in a multivariate model with adjustments for waist circumference, age, sex, conventional diastolic or systolic BP, diabetes mellitus or an HbA1c \>6.1%, regular tobacco use, regular alcohol intake, pulse rate, treatment for hypertension and either LVMI or LV relative wall thickness in the model, the relationship between HOMA-IR and E/A persisted (partial *r* = −0.13 to 0.14, *P* \< 0.005). With further adjustments for either 24-h systolic or diastolic BP (partial *r* = −0.11, *P* \< 0.05, *n* = 351) or for aortic PWV (partial *r* = −0.11, *P* \< 0.02, *n* = 410), the independent relationship between HOMA-IR and E/A also remained. In 626 randomly selected adult participants from a community sample with a high prevalence of obesity, the strongest independent predictor of LVMinappr was BMI (*P* \< 0.0001). With adjustments for LV stress and other confounders there was a strong inverse relationship between LVMinappr and EF (partial *r* = −0.41, *P* \< 0.0001), whilst only modest inverse relations between LVM or LVMI and EF were noted (partial *r* = −0.07 to -- 0.09, *P* \< 0.05--0.09) (*P* \< 0.0001, comparison of partial r values). The independent relationship between LVMinappr and EF persisted with further adjustments for LVM or LVMI. In 168 mild-to-moderate hypertensives treated for 4 months, although in patients with an LVMI \>51 g/m 2.7 (*n* = 112) (change in LVMI = -13.7 ± 14.0 g/m 2.7, *P* \< 0.0001), but not in patients with an LVMI \<51 g/m 2.7 (*n* = 56) (change in LVMI = 1.3 ± 9.3 g/m 2.7) LVMI decreased with treatment; treatment failed to increase EF in either group (1.2% ± 10.8% and 2.7% ± 10.7% respectively). In contrast, in patients with inappropriate LVH (LVMinappr \>150%, *n* = 33) LVMinappr decreased (--32% ± 27%, *P* \< 0.0001) and EF increased (5.0% ± 10.3%, *P* \< 0.0001) after treatment, whilst in patients with a LVMinappr \<150% (*n* = 135), neither LVMinappr (--0.5% ± 23%), nor EF (0.9% ± 10.3%) changed with therapy. In 478 participants of a randomly selected community sample with adjustments for waist circumference, age, sex, conventional systolic BP, diabetes mellitus or an HbA1c \> 6.1%, regular tobacco use, regular alcohol intake, pulse rate, and treatment for hypertension, an independent relationship between HOMA-IR and LVMinappr was noted (partial *r* = 0.14, *P* \< 0.002). With further adjustments for either 24-h systolic BP (partial *r* = 0.11, *P* \< 0.05, *n* = 351), aortic PWV (partial *r* = 0.13, *P* \< 0.02, *n* = 410), or circumferential LV wall stress (partial *r* = 0.12, *P* \< 0.02, *n* = 478) the independent relationship between HOMA-IR and LVMinappr also remained. Thus, the relationship between indices of an excess adiposity and LVM beyond haemodynamic factors may be explained in-part by insulin resistance. In conclusion, these results provide clarity on the process involved in the transition from obesity-associated LVH to LV dysfunction. I show that an index of central obesity explains a considerable proportion of the variation in LV diastolic function at a community level independent of LVM, LV remodelling and haemodynamic factors; that obesity-related increases in LVM exceeding that predicted by workload (LVMinappr) or alternative haemodynamic factors explains a marked proportion of variations in EF at a community level; that regression of LVMinappr is more closely associated with improvements in EF than LVM or LVM index (LVMI); and that obesity-associated insulin resistance may explain decreases in LV diastolic function and variations in LVMinappr and hence EF. Therefore, studies are warranted to evaluate the impact of interventions that improve insulin sensitivity on obesity-related decreases in LV diastolic function and increases in LVMinappr.
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Abstracts - Scientific Session 10: Personalized Medicine/Theranostics: S10-01 Update 2015: Where We are Heading? The Beginnings, Evolution, and Current Status of "

Theragnostics

"

**Suresh C. Srivastava**

Brookhaven National Laboratory, Upton, New York, USA

**Introduction:** Recent advances in molecular biology have led to a better understanding of cancer and other disease states, and parallel research has shown promise for biological vehicles such as monoclonal antibodies, specific proteins and peptides, and a variety of other intelligently designed molecules, to serve as specific carriers to deliver cell killing radiation into tumors in a highly localized fashion. These developments have led to a renewed interest in the exciting possibility of treating human malignancies with the systemic administration of radionuclides. A number of other relatively new modalities such as the treatment of cancer, metastatic disease, metastatic bone pain, radiation synovectomy, bone marrow ablation, and others, have given additional impetus to need for research on therapeutic radionuclides tailored for specific applications. Certain of these dual-purpose ("theragnostic") radionuclides that seem to offer the exciting potential of pre-therapy low-dose imaging followed by higher-dose treatment in the same patient, thus possibly bringing us a major step closer to personalized medicine, are of great interest. This presentation will re-introduce and re-inforce our relatively novel paradigm conceived, developed, and promoted at Brookhaven National Laboratory (BNL) that involves individual theragnostic radionuclides or radionuclide pairs with emissions suitable for necessary pre-therapy information on biodistribution, dosimetry, the limiting or critical organ or tissue, and the maximum tolerated dose (MTD), etc., \[S.C. Srivastava. Paving the way to Personalized Medicine: Production of some Promising Theragnostic Radionuclides at Brookhaven National Laboratory. Seminars in Nuclear Medicine 42: 151-163, 2012\] Thus, when (selectively) targeted with appropriate carriers, theragnostic radioisotopes would enable pre-therapy low-dose imaging plus higher-dose therapy in the same patient, and thus potentially bring us closer to the age-long dream of personalized medicine. Beginning since the mid-1980's, our work with Sn-117m convinced us that it is arguably one of the most promising theragnostic radionuclides with unique nuclear, physical, and chemical properties. Results with this radionuclide will therefore be covered in greater detail. In contrast to most alpha/beta emitters, Sn-117m (tV2, 14.0 days; y 159 keV, 86%) decays via isomeric transition, with the emission of three major mono-energetic conversion electrons (127, 129, and 152 keV; abundance 65%, 12%, and 26%, respectively). These emissions with a very high LET have short discrete ranges of between 0.22 (127 keV) and 0.29 mm (152 keV) in water. Also, with the 159 keV Y-photon, Sn-117m is perfect for pre-therapy SPECT imaging. Therefore, Sn-117m when selectively targeted should be effective for imaging plus therapy of for a number of inflammatory conditions, including cancer, atherosclerotic disease, and for various other disorders such as arthrides (radiosynovectomy), etc., causing much reduced myelosuppression and greatly reduced dose to normal organs. This has been demonstrated in our various experimental work as described below, showing the expected effectiveness of high-LET low-energy conversion electrons to produce intense radiation dose within a very short distance without affecting normal tissues, in particular, the radiation-sensitive bone marrow.

**Bone cancer and Metastatic Bone Pain:** At BNL, we have completed and published work on palliation of metastatic bone pain in cancer patients using tin-117m-DTPA). This project (1985--2001) was the start of the "Theragnostics" paradigm.

**Cardiovascular Disease:** Cardiovascular diseases are a leading cause of death and, specifically, a ruptured vulnerable plaque (VP), also known as thin-cap fibroatheroma, (TCFA) accounts for \~ 70% of fatal acute myocardial infarctions and/or sudden death. The luminal calcified plaques are easily detected by existing diagnostics, and the patient has a number of treatment options. In contrast, VP develops and models positively outside the arterial lumen, and cannot at the moment be detected or treated by non-invasive techniques. In collaboration with Clear Vascular, Inc., however, our work shows that tin-117m, in addition to being a good therapeutic agent for cancer, also shows promise for the noninvasive molecular imaging and treatment of VP, in the coronary arteries and other areas of vasculature. Conversion electrons from Sn-117m have been shown to reduce inflammation, and thus, are ideal for treating VP's, as their range in tissue (\~300 \^m) is approximately the same as the VP thickness in human coronary arteries. We developed tin-117m-DOTA-annexin (TA) for VP imaging plus therapy, and showed that TA effectively targets and binds to macrophage cells undergoing apoptosis, which are present in abundance in VP's, and thus produces a therapeutic effect. This was demonstrated in a study in ApoE mice in doses equivalent to 3--5 mCi in humans, which also showed plaque stabilization, reduced inflammation, and therapeutic outcome. In addition, a preliminary Phase I and II clinical trial that involved human carotid endarterectomy patients who had carotid artery stenosis (CAS) and who were dosed and imaged for VP, with histology as the comparison, has also given promising results. The plaque composition showed significantly less expression of macrophages in the low, middle and high dose treatment groups as compared to the control group. In contrast, smooth muscle cell expression was greater in the middle and high dose groups as compared to the control, and in the low dose group, the difference was statistically significant between the low versus middle and high dose groups. At BNL, a novel radioactive stent stably electroplated with Sn-117m was also developed as a therapeutic tool for the treatment of atherosclerotic coronary arteries. Effects on vessel wall inflammation from various doses of electroplated Sn-117m were studied in hyperlipidemic rabbit aortas. Three days after stent implantation (4 doses: 0, \[cold tin\], 30, 60, and 150 \^Ci Sn-117m/15-mm stent), the rabbits were sacrificed. Immunohistochemical analysis of proliferating macrophages and smooth muscle cells demonstrated that inflammatory cells in the Sn-117m-stented segments were dramatically reduced in a dose-dependent manner.

**Radiosynovectomy:** Recently, in collaborative investigations with an R-Nav's novel tin-117m homogeneous colloid form, in which the size distribution of the particles is well controlled, it has been shown that the tin-117m conversion electrons, with their very strong anti-inflammatory effect may be ideal for theragnostic applications for radiosynovectomy (RSV) as well. The preliminary pre-clinical data in osteoarthritis (OA) and rheumatoid arthritis (RA) inflammatory model rat trials has given promising results.

**Conclusions:** Our previous clinical results with tin-117m-DTPA for palliation of metastatic bone pain were very successful\[3\] and are greatly promising for further applications and development. A recently developed novel inflammatory tracer, TA, specifically targets atherosclerotic disease. Its biological safety and theragnostic capability were demonstrated in ApoE mice and in preliminary studies in human patients with carotid vulnerable plaques. Recently begun pre-clinical studies with a tin-117m colloid in arthritic rat models show promise for the effectiveness of the use of tin-117m for radiosynovectomy.

**Acknowledgements:** This work in part was supported by the U.S. Department of Energy, under Contract \# DE-AC02-98CH10886, at Brookhaven National Laboratory. Additional research grant support by Clear Vascular Inc., including a Cooperative Research and Development Agreement (CRADA) with BNL, is gratefully acknowledged. The collaborative work on radiosynovectomy mentioned in this presentation was funded by R-Nav, LLC.

**Address for correspondence:**

Dr. Suresh C. Srivastava, Brookhaven National Laboratory, Upton, New York, United States. E-mail: <suresh@bnl.gov>

S10-02: From Preclinical Development to a Multicentre Clinical Trial: 111ln-CP04 Targeting CCK2-Receptors for Personalized Diagnosis and Therapy of Patients with Medullary Thyroid Carcinoma

**Clemens Decristoforo, Dariusz Pawlak, Christine Rangger, Piotr Garnuszek, Petra Kolec-Peitl, Katja Zaletel, Thea Maina-Nock, Helmut Maecke, Paola Erba, Renata Mikolajczak, Georg Gobel, Alicja Hubalewska-Dydejczyk**

Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria

**Introduction:** Diagnosis and treatment of metastatic medullary thyroid cancer (MTC) still remains a challenging clinical task. The cholecystokinin 2 (CCK-2) receptor is one of the most promising targets for personalized diagnosis and treatment being overexpressed with very high density and \>90% incidence. From a comparative evaluation DOTA-DGlu-DGlu-DGlu-DGlu-DGlu-DGlu-Ala-Tyr-Gly-Trp- Met- Asp-Phe-NH~2~ (CP04), labelled with trivalent radiometals including ^111^In and ^177^Lu, revealed excellent characteristics with high stability and receptor affinity, specific and persistent tumour uptake and low kidney retention. This analogue, labelled with ^111^In was selected for further clinical evaluation within the ERANET project GRAN-T-MTC. We here report on the pharmaceutical development and the study design for a first in human clinical trial.

**Methods:** A simple freeze dried kit formulation including ascorbic acid buffer and antioxidants for 111In labelling under mild heating conditions was developed. Three GMP batches of a 2 different kit formulations (10 and 50 \^g peptide content) were prepared, radiolabelled and analyzed by HPLC-analysis; stability assays were performed for both kits and the end radiolabelled product. Biodistribution of ^n1^In-CP04 in CCK2-receptor expressing tumour-mice and *in vitro* receptor binding experiments were conducted. Preclinical safety was determined in a preclinical extended single dose toxicity study. A clinical trial protocol was developed taking into account safety, dosimetry aspects and pharmacokinetics in patients with metastatic MTC.

**Results:** The final kits formulation contained 10 (low dose) or 50 \^g (high dose) CP04, 25 mg ascorbic acid, 0.5 mg gentisic acid and 5 mg Methionine. Radiolabelling performed with 200--250 MBq ^m^InCl3 resulted in reproducible RCY \>94%, remaining stable for \>4 h. A high receptor affinity (IC~50~ 1.2 nM) was found and tumour uptake in mice reached \>9%ID/g. No significant toxicity of the peptide in rats was found with \>100x the human dose. The clinical trial includes patients with progressive or metastatic nonoperable histologically proven MTC. To assess safety the first 4 pts will receive 2 doses of CP04: low-dose (diagnostic) and high-dose (therapeutic) of ^1n^In-CP04. If no SAE is present, the remaining pts receive high-dose of ^111^In-CP04 with and without gelofusine infusion (2 arms, randomized). Safety of ^111^In-CP04 i.v. administration, biodistribution, pharmacokinetics, dosimetry and diagnostic sensitivity/specificity will be assessed. All required documents for CT-application in the EU including CT-protocol. IMPD-file, Investigators brochure etc., were prepared and submitted.

**Conclusions:** In this project preclinical developments were successfully translated into a clinical formulation as a basis for a clinical trial that may become the first step to establish a new, more selective and efficient strategy for the diagnosis and therapy of MTC patients leading to reduction of mortality as well as improving quality of life.

**Acknowledgements:** GRAN-T-MTC is part of the ERA-NET on Translational Cancer Research (TRANSCAN) funded by the European Commission under the Seventh Framework Programme (FP7).
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S10-03: Production and Application of 44Sc towards Clinical Positron Emission Tomography Imaging of Cancer

**Christiaan Vermeulen, Cristina Muller, Katharina Domnanich, Aviral Singh, Richard P. Baum, Andreas Turler, Roger Schibli, Nicholas van der Meulen**

Center for Radiopharmaceutical Sciences, Paul Scherrer Institute, Villigen-PSI, Switzerland

**Objective:** ^44^Sc, a positron emitter with a half-life of 3.97 h and a high positron intensity of 94%, has attractive properties for positron emission tomography (PET) and could be used as an alternative to the currently-used ^68^Ga (t~1/2~ = 68.3 min). With chemistry similar to therapeutic ^90^Y and ^177^Lu, ^44^Sc can be used for diagnosis, as well as for planning and monitoring of therapy, before treatment with these radionuclides. The aim of this study was the optimum development of the ^44^Sc separation method and subsequent radiolabelling experiments, following which pre-clinical studies could be performed on mice. Finally, the produced DOTATOC-radiolabelled ^44^Sc could be applied to patients, enabling the recording of whole-body PET/CT scans.

**Materials and Methods:** ^44^Ca-targets were prepared by mixing 10 mg enriched ^44^CaCO~3~ with 150 mg graphite powder, pressed and encapsulated in aluminium. The targets were irradiated at PSI with 72 MeV protons, degraded to 11.5 MeV, at a beam current of 50 \^A for 90 min. 3 M HCl was used to dissolve the ^44^CaCO~3~ and the resultant solution loaded on to DGA extraction chromatographic resin, where ^44^Sc (III) was sorbed. ^44^Ca (II) was not retained and traces were eluted from the column with further addition of 3 M HCl. ^44^Sc (III) was eluted with 0.1M HCl from the column and sorbed on the second column consisting of SCX cation exchange resin. It was, subsequently, eluted with 700 \^L 5.0 M NaCl/0.13M HCl and directly used for labelling reactions. Whole-body PET/CT scans were performed on patients post injection of ^44^Sc-DOTATOC.

**Results:** Chemical separations following irradiation of the target material yielded up to 2.0 GBq ^44^Sc, the product of high radionuclidic purity. The separation was refined such that the enriched Ca could be recycled for use, and this method was fast and relatively uncomplicated. Pre-clinical studies proved successful, with excellent radiolabelling and imaging. Logistics was tested by shipping the product over a distance of 600 km, before it was labelled to DOTATOC. The radiolabelling purity was \> 99% and injection into patients produced scans showing excellent uptake, very high resolution and excellent contrast.

**Conclusions:** Sufficiently high quantities of ^44^Sc of a high nuclidic purity are accessible by irradiation of enriched calcium at a cyclotron. A fast and simple purification method has been reported which will potentially also allow using the resultant ^44^Sc product for the radiolabeling of peptides in an automated modular system according to good manufacturing practice (GMP). The excellent characteristics of ^44^Sc for PET imaging were demonstrated in preclinical experiments and by clinical application in patients. As a result, this work provides a promising basis for introducing ^44^Sc in clinical routine for nuclear imaging using PET/CT.
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S10-04: cGMP Conform Synthesis of \[68Ga\] NODAGA-RGD with a Remote Controlled Synthesis Unit and Initial Clinical Data

**Roland Haubner, Armin Finkenstedt, Armin Stegmayr, Christian Mair, Christine Rangger, Heinz Zoller, Irene Virgolini**

Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria

**Aim:** In preclinical studies it has been demonstrated that \[^68^Ga\] NODAGA-RGD is an alternative to \[18F\] Galacto-RGD in imaging integrin α~v~β~3~ expression. Here we present the fully automated synthesis under clean room conditions including all data (quality control, toxicological study, and dosimetry estimation) necessary to initialize clinical studies as well as preliminary data from first use in patients.

**Methods:** The labelling precursor NODAGA-RGD was prepared under GMP guidelines (piChem, Austria). ^68^Ga was produced via fractionated elution using 0.1N HCl and a ^68^Ga/^68^Ge generator IGG 100 from Eckert and Ziegler, Germany. Labelling was carried out in a remote controlled synthesis unit (Modular Lab, Eckert and Ziegler) under clean room conditions. Quality control included TLC, HPLC, GC, pH control, Ge-breakthrough, half-life, endotoxin content, and control of sterility. Additionally, storage stability after 4 h was studied and dose estimations based on animal data were carried out using the OLINDA program. An extended single dose toxicity study using Sprague-Dawley rats was carried out by CiToxLab, France. The initial clinical study included 4 patients with hepatocellular carcinoma (HCC). Static scans at 5, 35, and 70 min p.i. including 67 bed positions each were performed using the Discovery 690 PET/CT from GE, USA. Blood was sampled 30 and 60 min p.i. and urine 60 min p.i. to perform stability studies using HPLC.

**Results:** Under the employed conditions \[^68^Ga\] NODAGA-RGD could be produced in high radiochemical yield and radiochemical purity (HPLC and TLC \> 99%). For synthesis 2M NaOAc/HOAc puffer pH 5 was used. The pH in the final isotonic saline formulation was approximately 6. Ethanol content determined via GC was between 2.5 and 3.0% v/v. No detectable Ge was found. LAL test revealed 0.7 EU/ml. Sterility tests showed that all samples met the specifications according to Ph. Eur. 7^th^ ed.ition. No radiolysis of the tracer was found in the formulated solution during the 4 hour observation period. The calculated effective dose was comparable with the effective dose from a \|\^8F\] FDG scan. The single dose toxicity study showed that the compound is well tolerated. This was confirmed by the initial clinical study where no side effects were observed. High metabolic stability of \[^68^Ga\] NODAGA-RGD was found by analyzing the blood and urine samples. The static scans showed rapid tracer elimination from the body with low background activity in almost all organs. Unfortunately the investigated tumors did not show increased tracer accumulation indicating no or low integrin α~v~β~3~ expression.

**Conclusion:** Our study shows that \[^68^Ga\] NODAGA-RGD can easily be produced under GMP conditions meeting the requirements for clinical use. Initial clinical studies in patients with HCC did not allow identification of the tumor but demonstrated rapid elimination from the body, high metabolic stability of the tracer and low radiation burden. Low tracer accumulation in the tumor might be related to low receptor expression, thus further studies are needed to verify the integrin a~v~P3 imaging properties.
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S10-05: Clinical Usefulness of 18F-Sodium Fluoride and 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Cocktail in the Management of Oncology Patients

**Nozipho Nyakale, Andrei Iagaru, Sam Gambhir, Alfred Ankrah, Mike Sathekge**

Department of Nuclear Medicine, University of Pretoria, Pretoria, South Africa

**Introduction:** Combined 18F-NaFand 18F- fluorodeoxyglucose positron emission tomography/ computed tomography (18F-FDG PET/CT) scan for evaluation of malignancy may lead to improved patient care and reduction in health care costs in the management of oncology patients. This South African experience conducted as part of the Stanford trial evaluates the performance of 18F-NaF/18F-FDG (cocktail) PET/CT scan for detection of metastases.

**Methods:** Twenty three patients with histology proven malignancy at risk of bone metastases were included and underwent a 18F-NaF PET/CT scan, a 18F-FDG PET/ CT scan, and the cocktail scan. All scans were performed within a period of 2 weeks. We compared the results of the cocktail PET/CT with those of the 18F-NaF PET/ CT and the 18F-FDG PET/CT. The scans were reviewed by experienced Nuclear Medicine physicians. Lesions, denoted by areas of abnormally increased uptake, their location and pattern of distribution, were recorded separately for all 3 scans.

**Results:** 23 patients with a mean age 57.2 years (range; 33--79) with various cancers (breast, cervical, prostate and Kaposi sarcoma) were scanned. The performance of the cocktail PET/CT scan was superior to the separate 18F-NaF PET/CT and 18F-FDG PET/CT scans (169 lesions vs. 94 lesions vs. 106 lesions respectively). The sensitivity showed no statistically significant differences between 18F-FDG PET/CT and 18F-NaF PET/CT separately when compared to the cocktail. Of total number of lesions seen, the cocktail scan missed only 5 (2.87%) lesions which were located adjacent to areas of physiological FDG uptake (3 skull lesions) or noted to have low uptake in primary18F-FDG PET/CT scan (2 lung lesions).

**Conclusions:** The 18F-NaF/\[18F\]-FDG cocktail PET/ CT scans were equally accurate in detection of lesions as compared to individual 18F-NaF PET/CT and 18F-FDG PET/CT scans done separately. The complementary advantage of the cocktail may be clinically useful in staging of cancer patients with compliance difficulties.
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S10-06: Comparison of Estrogen Receptor, Progesterone Receptor and Human Epidermal Growth Factor Receptor 2/neu Receptor Positivity with the Incidence of Bone Metastasis and Treatment Response in Follow-up Bone Scans in Breast Cancer

**Soumendranath Ray, Jayanta Das, Subir Sinha**

Tata Medical Center, Newtown, Rajarhat, Kolkata, India

**Objective:** Bone metastasis is common in breast cancer. The aim of this study was to find out the correlation of incidence and treatment response in metastatic breast cancer with ER, PR and HER 2/neu receptor positivity.

**Materials and Methods:** Radionuclide bone scan of 537 female breast cancer patients were performed in our department from September 2011 to August 2013. The results of these baseline scans were correlated with T stages and ER, PR and HER2/neu receptor status of the disease. Follow-up bone scans of 120 patients were performed. The data was retrospectively analyzed. While analyzing the results of follow-up scans, identification of new lesions and extent and severity of the existing lesions were taken into consideration to evaluate treatment response.

**Results:** Out of 537 patients who underwent the baseline bone scan, one had carcinoma in situ, 23 of them had T1 lesion, 158 ladies had T2, 101 women had T3 and 158 ladies had T4 lesions .T staging was not known in 96 patients .Bone metastases were detected in 96 (18.24%) patients and bone scan was normal in rest 441 ladies. Majority of the patients who had a positive bone scan were asymptomatic. Incidence of positive scans was higher in locally advanced disease (31% in patients with T3 and T4 lesions against 16.4% for combined CIS, T1, T2 lesions). Multiple metastases were noticed in 73 patients and 25 patients had solitary lesion. Vertebrae were found to be the commonest site of metastases (76 out of 374 total bone lesions). 47 out of 96 patients had follow-up bone scan. Progressive disease was noticed in 23 patients (48.9%) and there was no progression in 24 (51%) patients. 73 out of 441 patients who had an initially normal bone scan underwent a follow-up bone scan. 18 out of 73 (24.6%) patients had metastases in the follow-up scan\-\-- 7 of them had solitary lesion and 11 women had multiple metastases. There was no statistically significant association between ER, PR and HER2/neu receptor status either with the incidence or with the progression of skeletal metastasis in our study group. In baseline studies, univariate and multivariate analysis of ER positivity with bone metastasis showed *P* values of 0.13 and \>0.4 respectively. For PR positivity the values were 0.06 and \>0.4 respectively and for HER 2/neu it was 0.76 and \>0.4 respectively. Univariate and multivariate analysis of ER, PR and HER 2/neu positivity and progression of disease showed *P* \> 0.4 in all subgroups. This statement holds true for both the group of patients- those with skeletal metastasis identified in preliminary bone scan as well as those without any bone metastasis in the first scan.

**Conclusion:** In this study the importance of 99mTc-MDP bone scan for follow-up and assessment of the treatment response in metastatic breast cancer has been reiterated. No correlation was found between the hormone receptor status and incidence as well as the treatment outcome in metastatic breast cancer.
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S10-07: Variable Computed Tomography Appearance and Ga-68 Prostate-Specific Membrane Antigen Uptake of Bone Metastases in Carcinoma Prostate

**Abhinav Singhal, Vineet Pant, Ishita Sen**

Fortis Memorial Research Institute, Gurgaon, Haryana, India

**Introduction and Objective of Study:** Bone is the most frequent site of prostate carcinoma metastasis with skeletal metastases identified at autopsy in up to 90% of patients dying from prostate carcinoma. Skeletal metastasis results in significant complications including bone pain, impaired mobility, pathological fracture, spinal cord compression, and symptomatic hypercalcemia. The bone metastases of prostate cancer are usually radiologically osteoblastic. Presentation with osteolytic bone metastases is not common and only a few case reports exist in the medical literature with this type of metastatic lesions. The objective of our study was to evaluate the CT appearance as well as PSMA uptake (SUVMax) of skeletal lesions in patients of carcinoma prostate undergoing Ga 68 PSMA PET CT scan.

**Materials and Methods:** 50 patients with biopsy proven Prostate cancer and rising prostate-specific antigen (PSA) levels were subjected to 68Ga-PSMA positron emission tomography (PET)/CT. Quantitative assessment of tracer uptake was performed 90 min post-injection by analysis of maximum standardized uptake values (SUVmax).

**Results:** 31 out 50 patients had metastatic skeletal lesions on Ga 68 PSMA PET CT scan. 18 patients had predominantly osteosclerotic lesions showing increased Ga 68 PSMA uptake (mean SUV Max: 32). 8 patients had predominantly osteosclerotic lesions not showing any significant Ga 68 PSMA uptake. 5 patients had predominantly osteolytic lesions which showed increased Ga 68 PSMA uptake (mean SUV max: 23). All of the patients with osteolytic bone metastases had higher baseline Gleason's score. There was no significant difference between the PSA doubling time, PSA level at baseline or presentation, and extrprostatic metastatic disease burden. Extrapelvic bone metastatic disease was more commonly seen in osteolytic group.

**Conclusion:** Metastatic presentation with osteolytic lesions is rare in prostate cancer. This type of presentation may lead to delayed diagnosis because patients may be investigated initially for other causes of osteolytic bone lesions especially multiple myeloma. Ga 68 PSMA PET CT can serve as a useful tool in evaluation of primary lesion as well as both sclerotic and lytic type of bone metastases.
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Abstracts - Scientific Session 11: Image-Guided Therapy: S11-01 Radionuclide Therapy: Image-Guided or - Unguided

**Cornelis A. Hoefnagel**

Department of Nuclear Medicine, The Netherlands Cancer Institute, Amsterdam, The Netherlands

As a treatment modality radionuclide therapy stands out by its specific targeting of tumors, either by systemic or locoregional application, its proven efficacy, cost-effectiveness and excellent palliative effects, as well as its limited toxicity and relative lack of longterm effects in comparison to other oncological therapies. Moreover, it is a truly nuclear medicine principle, that the feasibility of a radionuclide therapy is pre-assessed by a diagnostic tracer study and in this respect the availibility of suitable radiopharmaceuticals and the development of high quality technology for imaging are of the utmost importance, Nevertheless, when radionuclide therapies were introduced in the late 1930's, they were performed in the blind. Examples are treatments with strontium-89 and phosphorus-32 in bone and hematological diseases. And later, in the 1950's and 1960's, the indications for successful treatments like iodine-131 for thyroid disease and Gold-198 colloid for radiosynoviorthesis were supported by poor quality images with rectilinear scanners. This changed dramatically after the introduction of the gammacamera and in the 1970's the following nuclear medicine dogma's: (1) Never to administer a therapeutic dose without a proper imaging/tracer study, establishing the degree of uptake and retention in the target, and (2) not to perform radionuclide therapy in patients under 45 years of age, because of the risk of inducing second cancers and fertility disorders. Personally, I have always adhered to the first rule, but the second I had to give up soon, when confronted with 3 young female patients (aged 15--20 years) with disseminated thyroid cancer. All three were treated with I-131 and had a complete remission. And all three later had children. Optimal imaging is important as a proof of principle of the treatment per se, to assess if it is indicated and likely to be effective in the individual patient, to select the best suitable radiopharmaceutical and dose, to assess uptake and retention and to demonstrate its effect in follow up studies. New imaging technology, including SPECT/CT for single photon radiopharmaceuticals and PET/CT and PET/MR for relevant PET-tracers, is a major asset in this respect. They not only lead to the best possible assessment of the tracer's biodistribution and the tumor load and targeting, but may also be more convincing to clinicians to consider this treatment modality. Equally important is radiopharmacy, by producing similar or matching pairs of radiopharmaceuticals: preferably the combination of a PET tracer with a corresponding therapeutic agent. The best example of this in current practice is found in radionuclide therapy of neuroendocrine tumors by radiolabeled peptides (^68^Ga/^177^Lu pair). Examples of a variety of image-guided radionuclide therapies will be demonstrated, underlining the influence which imaging had on the choice of treatment and the understanding of its effect. These include ^131^I-therapy of thyroid cancer, radiosynoviorthesis, intra-arterial therapy, treatment of neuroendocrine tumors with radiolabeled peptides or meta-iodobenzylguanidine (MIBG), as well as treatment of bone metastases with ^153^Sm-EDTMP. In contrast, with the recent addition of alpha-emitting radiopharmaceuticals, that is, ^223^Ra-alpharadin or Xofigo, to our nuclear medicine arsenal, therapy is performed without post-therapy imaging. It is concluded, that the quality, understanding and promotion of radionuclide therapy as an oncological treatment modality is enhanced by optimal imaging, in particular hybrid imaging.
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S11-02: A Retrospective Comparison Between 68Ga-DOTA-Tyr3 Octreotide Positron Emission Tomography/Computed Tomography and 123I-Metaiodobenzylguanidine Single-Photon Emission Computed Tomography-Computed Tomography in Patients with Extra-adrenal Paraganglioma for Pretherapeutic Staging

**Alexander Kroiss, Christian Uprimny, Barry Lynn Shulkin, Andreas Frech, Rudolf Wolfgang Gasser, Christoph Url, Kurt Gautsch, Ruth Madleitner, Bernhard Nilica, Georg Mathias Sprinzl, Gustav Fraedrich, Irene Virgolini**

Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria

**Purpose:** Metaiodobenzylguanidine (MIBG), labeled with ^123^I, and somatostatin receptor (SST) imaging, labeled with ^111^Inpentetreotide, respectively, are functional imaging modalities, which achieve moderate sensitivity in localizing extra-adrenal paragangliomas (PGL). However both functional imaging modalities are limited in detecting localizing multifocal/malignant extra-adrenal PGL due to limited resolution of planar scintigraphy and of single photon emission computed tomography (SPECT) compared to positron emission tomography (PET), respectively. We compared functional imaging modalities in the diagnosis and staging of extra-adrenal PGL, using ^68^GaDOTATyr^3^octreotide (^68^GaDOTATOC) PET/ CT (diagnostic CT) and ^123^IMIBG scintigraphy, including SPECT/CT ("low-dose" CT). Functional and anatomical imaging (combined crosssectional imaging) referred as reference standard.

**Methods:** Three male and seven female patients (age range 26 to 73 years) with anatomical and/or histologically proven disease were included in this study. Three patients were either suffering from metastatic head and neck paragangliomas (HNPGL) or multifocal PGL and seven patients from nonmetastastic disease. Comparative evaluation included morphological imaging with CT, functional imaging with ^68^GaDOTATOC PET and ^123^IMIBG imaging. Imaging results were analyzed on a perpatient and on a perlesion basis.

**Results:** On a per-patient basis, ^68^GaDOTATOC PET showed a sensitivity of 100%, 10.0% for ^123^I-MIBG imaging and 20.0% for SPECT/CT, respectively, for both nonmetastatic and metastatic/multifocal PGL. In contrast, the overall sensitivity of ^68^GaDOTATOC PET on a perlesion basis was 100% (McNemar *P* \< 0.5) and that of ^123^IMIBG imaging was only 3.4% (McNemar *P* \< 0.0001) and of SPECT/CT was 6.9% (McNemar *P* \< 0.0001), respectively. Both, ^68^GaDOTATOC PET and anatomical imaging identified 27 lesions. ^123^I-MIBG imaging identified only 1 lesion and SPECT/CT 2 lesions. Two additional lesions were detected by ^68^GaDOTATOC PET, but negative in both, ^123^IMIBG and CT imaging.

**Conclusion:** Our analysis in this patient cohort indicates that ^68^GaDOTATOC PET/CT is superior to ^123^IMIBG imaging, including SPECT/CT, providing valuable information for pretherapeutic staging of paragangliomas, particularly in surgically inoperable tumors or multifocal/malignant disease.
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S11-03: 68Ga-DOTA-NOC Positron Emission Tomography/Computed Tomography for the Diagnosis of Adrenal Gland Neoplasms Compared to 131I-MIBG: Preliminary Study

**Xiao-Cheng Yao, Chun Zhang, Le-le Zhang, Guo-Qiang Shao, Feng Wang**

Nanjing First Hospital, Nanjing Medical University, Nanjing, China

**Objectives:** The aim of this study was to evaluate the clinical value of ^68^Ga-DOTA-NOC PET/CT in the diagnosis of adrenal gland neoplasms and compare to ^131^I-MIBG imaging.

**Methods:** Nine patients with clinically diagnosed or suspected pheochromocytoma were enrolled in this study. PET/CT were performed in all patents at 1h post-injection of 111-185MBq (3 \~ 5mCi) of 68Ga-DOTA-NOC, 131I-MIBG wholebody and SPECT/ CT was also performed in all patients, CGA level in blood and catecholamine in blood and urine was measured in all patients, final diagnosis was confirmed by histopathology and clinical follow-up. The imaging results were analyzed on a per-patient and on a per-lesion basis.

**Results:** Two patients with adrenal cortical adenocarcinoma, 2 patients with benign pheochromocytoma, 1 patient with the hereditary syndrome of multiple endocrine neoplasia type 2A (MEN 2a) who had RET mutation, 1 patient with malignant extraadrenal paragangliomas (PGL) were negative, whereas 2 patients with malignant pheochromocytoma and 1 patient with PGL were positive in 68Ga-DOTA-NOC PET/CT. In three positive patients, totally 16 lesions were visualized in 68Ga-DOTA-NOC image, the standard uptake value (SUVmax ) was 12.96 ± 5.98, whereas 39 lesions were found in 131I-MIBG imaging. In 131I-MIBG image, 7 patients with pheochoromocytoma were positive including MEN 2a patient , except 1 malignant pheochoromocytoma patient was negative, 2 adrenal cortical adenocarcinoma patients was negative.

**Conclusion:** This study indicated that 68Ga-DOTA-NOC PET/CT was valuable for the diagnosis of malignant pheochromocytoma, and provided additional information in staging and detection of extraadrenal lesion. 68Ga-DOTA-NOC PET/CT may serve as useful tools in guiding PRRT besides 131I-MIBG MIBG therapy, further study is needed.
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S11-04: Radionuclide Guided Surgery - Preliminary Experience

**Mairah Razi, Humayun Bashir, Abid Quddus Qazi, Amina Iqbal Khan, Asad Hayat, Aamna Hassan**
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**Objective:** Review of radionuclide guided surgical procedures done at a Tertiary Care Cancer Center.

**Materials and Methods:** Retrospective review of patient in whom radionuclide was injected preoperatively for localization of the target lesion intra-operatively with the help of a Gamma probe. Demographic data, pre-procedure diagnostic imaging and postoperative histological findings data was collected from the hospital information system. All patients underwent respective radionuclide scanning on the day of surgery and the surgery was carried out within 4 hours of intravenous radiopharmaceutical injection.

**Results:** In the 30 months period 4 patients under went surgical excision where hand-held probe, sensitive to Gamma as well as PET radiopharmaceuticals, was used intraoperatively to localize radionuclide avid abnormal tissue.

**Case 1:** A 50-year-old female. Diagnosis: Hyperparathyroidism. Pre-operative imaging showed a Right thyroid nodule along with a right sided parathyroid adenoma identified on diagnostic Tc99 Sestamibi scan. Radiopharmaceutical for radio-guided surgery: Tc99m Sestamibi. Histopathology: Parathyroid adenoma (right).

**Case 2:** A 34-year-old male. Diagnosis: Diffuse large B-cell lymphoma (stage IV). Site: Right axillary lymph which was hypermetabolic on diagnostic PET-CT but not clinically palpable on examination. Radiopharmaceutical for radio-guided surgery: F18-FDG (SUV max 5.2). Histopathology: Recurrent DLBCL.

**Case 3:** A 13-year-old male. Diagnosis: Grey zone lymphoma. Site: Right axillary mass (3 cm). Radiopharmaceutical for radio-guided surgery: F18-FDG (SUV max 1.5). Histopathology: Reactive changes with no evidence of lymphoma.

**Case 4:** A 15-year-old female. Diagnosis: Classic Hodgkin's disease. Site: Left axillary lymph node. Radiopharmaceutical for radio-guided surgery: F-18 FDG avid (SUV max 4.9). Histopathology: classical Hodgkin's disease recurrence. Case 3 and 4 had had unsuccessful axillary dissections earlier without probe guidance.

**Conclusion:** The use of hand-held Gamma/PET probe improves the success of surgical excisions in well selected cases.
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S11-05: First Human Diagnostic Application of Scandium-44 Highlights a Path Towards Theranostics with Scandium-47 in Somatostatin Receptor Expressing Tumors

**Aviral Singh, Richard P. Baum, Ingo Klette, Nick van der Meulen, Cristina Müller, Andreas Türler, Roger Schibli**

Theranostics Center for Molecular Radiotherapy and Molecular Imaging, ENETS Center of Excellence, Zentralklinik Bad Berka, Bad Berka, Germany

**Aim:** Scandium-44 (^44^Sc) is a novel β^+^ -emitting radionuclide for PET imaging. Owing to its physical properties, it may provide an alternative to the short-lived (t~1/2~ = 68 min) Galium-68 (^68^Ga) for molecular imaging of somatostatin expressing tumours. Sc^3+^ behaves chemically similar to lanthanides and rare earth elements (^90^Y^3+^, ^177^Lu^3+^) in forming DOTA complexes. We report first human data using ^44^Sc-DOTATOC for PET/CT imaging in metastatic NET patients being treated at Zentralklinik Bad Berka (ZBB), Germany.

**Methods:** ^44^Sc (t^1/2^ = 3.97 h, Eβ^+^ 1475.4 keV, 94.34%) was cyclotron-produced at PSI-Villigen (Switzerland), transported over 600 km by road to ZBB (Germany), and radiolabeled with somatostatin analogue DOTATOC (DOTA0, with a specificity of 10 MBq ^44^Sc/nmol DOTATOC, and a high yield of radiolabeled compound (99% ± 1.6; pH range = 3--4.5). ^44^Sc-DOTATOC (78--130 MBq) was administered to 5 male patients (age range 44--70 years) with GEP-NETs who presented for re-staging of their disease. Whole-body PET/CT (Biograph mCT Flow 64) scans were performed at variable time intervals from 10 min to 24 h p.i. Total number of SSR-positive target lesions was counted and SUVs determined. Imaging results were compared to US, MRI, and ^68^Ga-DOTATOC PET/CT.

**Results:** PET/CT imaging after injection of ^44^Sc-DOTATOC demonstrated a high specific uptake in liver and lymph node metastases, with best target-to-non-target ratios seen at 2 to 4 h p.i.

Two patients were diagnosed with progressive disease (PD): Five additional metastases were detected in one patient, and one new metastasis was revealed in the other patient, compared to previous respective ^68^Ga-DOTATOC studies. Three patients were diagnosed with stable disease (SD) in one patient, a single new small metastasis was detected with overall regressive tumor load; a few variably distributed metastases were detected in another patient, while in the third patient no new metastases were detected. No adverse effects were observed in any of the patients.

**Conclusions:** ^44^Sc with commendable properties is a highly promising positron-emitter for molecular imaging of somatostatin receptor expressing tumours. It can be produced centrally and multiple patient doses can be delivered to other remote PET centers over \>1,000 km distances. In our patient group, ^44^Sc-DOTATOC was safe for human use, exhibited very high target-to-non-target ratios, and late imaging (up to 24 h p.i.) was possible. ^44^Sc-DOTATOC is a highly sensitive tracer and at least equal to ^68^Ga-DOTATOC for PET imaging, and may even prove be more useful with regular application. It demonstrates significant promise as an optimum THERANOSTIC radionuclide, given that pre-therapeutic imaging and dosimetry for PRRT can be performed, in order to plan an possibly provide radionuclide therapy by using the β-emitting Scandium-47 (47Sc).
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S11-06: Characterisation of Neuroendocrine Tumors with 68Ga-DOTANOC Positron Emission Tomography/ Computed Tomography and 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography: A Comparison with Histopathology

**Rakesh Kumar, Punit Sharma, Niraj Naswa, C. S. Bal**

Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India

**Introduction:** Neuroendocrine tumors (NETs) are a diverse group of malignancies derived from the diffuse neuroendocrine cell system. Somatostatin receptor imaging of NET using ^68^Ga labeled radiopharmaceuticals has demonstrated excellent results in the management of NET. However, many patients with histopathological diagnosis of NETs do not show any ^68^Ga-labeled radiopharmaceuticals uptake. In such patients ^18^F-FDG PET/CT may be useful as FDG is considered as marker for differentiation of malignant tissues.

**Objectives:** The present study was aimed to characterise NETs with ^68^Ga-DOTANOC PET/CT and ^18^F-FDG PET/ CT and compare results with histopathology.

**Methods:** A total of 21 patients (age 49 ± 16.5 year), diagnosed with NET underwent both ^68^Ga-DOTANOC PET/CT and ^18^F-FDG PET/CT scans. All patients had atleast 1-year clinical and imaging follow-up.

**Results:** ^68^Ga-DOTANOC PET/CT demonstrated sensitivity of 96% while similar value for ^18^FDG PET/ CT was 68%. Patients with NET-G1 and G2 had positive ^68^Ga-DOTANOC PET/CT and negative ^18^FDG PET/ CT in 6 cases whereas both testes were positive in 11. In the remaining 5 cases with NET-G3, ^18^FDG PET/CT was positive in all 5 while ^68^Ga-DOTANOC PET/ CT was positive in only 2. The mean Ki67 was 12% for ^68^Ga-DOTANOC PET/CT positive tumors and 18% for tumors with both ^68^Ga-DOTANOC PET/CT and ^18^FDG PET/CT positive. Clinical and imaging follow-up demonstrated stable disease in patients who were positive on ^68^Ga-DOTANOC PET/CT while progression of disease was reported in all 3 patients who ^18^FDG PET/CT positive.

**Conclusion:** A combined dual tracer 68Ga-DOTANOC PET/CT and 18F- FDG PET/CT can characterise NETs and correlate well with histopathology. Patients of NET with positive on 68Ga-DOTANOC PET/CT has better prognosis than those who are 18FDG PET/CT positive and 68Ga-DOTANOC PET/CT negative studies. 68Ga-DOTANOC PET/CT is useful in selecting patients for somatostatin analogues therapy.
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S11-07: Role of 18F-Fluorodeoxyglucose Positron Emission Tomography/ Computed Tomography in Predicting Pathologic Response to Neoadjuvant Chemo Radiotherapy and Survival in Patients of Non Metastatic Esophageal and Gastro-Esophageal Junction Carcinoma

**Ankur Pruthi, Sameer Taywade, Partha Sarathi Choudhury**

Department of Nuclear Medicine, Rajiv Gandhi Cancer Institute and Research Centre, Rohini, New Delhi, India

**Objective:** To assess the role of 18-F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) in predicting the pathologic response and survival of patients with non metastatic esophageal carcinoma treated with neoadjuvant chemoradiation (CRT) and esophagectomy.

**Methods:** 32 patients (18 males, 14 females; mean age 56.7 years, median age 58 years) with locally advanced (stage II/III) esophageal carcinoma who underwent neoadjuvant chemo-radiation (CRT) followed by total esophagectomy at our institute during 2010-13 were analysed. Their staging and post neoadjuvant chemo-radiation 18F-FDG PET/CT studies were re-evaluated by an experienced nuclear medicine physician. Response to neoadjuvant chemo-radiation on PET/CT images was compared to pathologic response. Follow up information was obtained after careful evaluation of patient's electronic medical records. Disease free survival was calculated from the day of surgery till the first evidence of recurrence. Various PET/CT findings like SUV max, presence of lymph nodal abnormalities were correlated with pathologic response, incidence of recurrence and disease free survival using appropriate statistical tests.

**Results:** Most tumours were squamous cell carcinomas (29 out of 32; 90.6%) and involved mid thoracic esophagus (17 out of 32; 53.1%). Post-CRT ^18^F-FDG PET/CT study identified pathologic response with 76.2% sensitivity, 70% specificity and 74.2% accuracy. However, negative predictive value was only 41.7%. Patients were followed up for median duration of 10.8 months (interquartile range 6.3- 17.7 months). PET/CT parameters like SUVmax and presence of lymph nodal abnormalities in pre-treatment scan didn't show significant correlation with disease free survival. Pathologic response was found to correlate with the post-CRT FDG PET/CT maximal standardized uptake value (SUVmax) (*P* \< 0.05) and a post-CRT FDG PET SUVmax of ≥4 was found to be the only factor which correlated with reduced disease free survival (1 year survival rate of 25% vs. 68.1%; *P* = 0.026).

**Conclusion:** Post chemo-radiation PET/CT was found to be predictive of pathologic response and disease free survival. In view of low negative predictive value, surgery should still be considered even if the post-CRT FDG-PET/CT scan is normal because microscopic residual disease cannot be ruled out.
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S11-08: Lu-177 Labeled DOTAGA- Prostate-Specific Membrane Antigen Small Molecules for Theranostics of Metastasized Castrate-Resistant Prostate Cancer: Initial Clinical Results

**Harshad Kulkarni, Martina Weineisen, Christiane Schuchardt, Ingo Klette, Hans-Jürgen Wester, Richard P. Baum**
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**Aim:** The aim of our study was to determine the feasibility, safety and efficacy of peptide radioligand therapy (PRLT) using Lu-177 labeled DOTAGA-PSMA small molecules (Lu-177 PSMA) in patients (pts) with metastasized castrate-resistant prostate cancer (mCRPC).

**Methods:** We established a prospective database (338 items per patient) of mCRPC pts, undergoing PRLT at our center. 43 pts (mean age 71 ± 7 years, mean Gleason score 8 ± 1, median PSA 41.6, range 0.05 -- 324 ng/ml) underwent 1-5 cycles (in all 78) of Lu-177 PSMA PRLT. Mean administered activity per cycle was 5.5 ± 0.7 GBq (range 3.6--8.6). Post-therapy response after at least 2 therapy cycles could be assessed until now in 24 patients.

**Results:** Lu-177 PSMA demonstrated a high and specific uptake on post-therapy planar and SPECT/CT images, correlating with the high uptake noticed on pre-therapy Ga-68 PSMA PET/CT, and thereby with the PSMA expression. Response (partial remission) according to molecular response criteria on Ga-68 PSMA PET/CT was observed in 10 patients, correlating with the fall in PSA after therapy and 6 patients exhibited partial remission according to morphological response criteria. Stable disease was noted in 9 and 13 patients, according to molecular and morphological response criteria, respectively. There was rapid clearance of tracer from the kidneys (effective half-life 19--57 h) and whole body (12--91 h). Tumor lesions exhibited a high mean absorbed dose, up to 300 Gy. No adverse effects, especially salivary toxicity (dry mouth), were observed There was also no significant alteration in blood counts or other laboratory parameters, especially renal function (creatinine, calculated GFR and tubular extraction rate as determined by Tc-99m MAG3) remained unchanged.

**Conclusions:** Peptide radioligand therapy using Lu-177 labeled DOTAGA-based PSMA small molecules is feasible, safe and effective in the treatment of metastasized castrate-resistant prostate cancer in combination with Ga-68 PSMA PET/CT, which is useful for patient selection as well as follow-up (Theranostics concept).

**Address for correspondence:**

Dr. Harshad Kulkarni, THERANOSTICS Center for Molecular Radiotherapy and Molecular Imaging (PET/CT), Bad Berka, Germany. E-mail: <harshad_r_k@yahoo.co.in>
